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ABSTRACT 
Kimberly Williams: Neurotrophin-chemokine receptor interactions on macrophages regulate 
HIV neuropathogenesis 
(Under the direction of Rick Meeker) 
 
Invading perivascular macrophages and microglial cells play a pivotal role in the 
neuropathogenesis of Human Immunodeficiency Virus (HIV) associated neurological 
disorders.  As with many neurodegenerative diseases, the activation of macrophages and 
microglia cells in the central nervous system (CNS) leads to the secretion of unknown 
neurotoxins and is thought to contribute heavily to neuronal damage.  However, these cells 
are very dynamic with a wide range of functions including neuroprotection and repair.  It has 
become increasingly clear that strategies to modulate specific phenotypes of these cells have 
substantial therapeutic potential. This thesis has identified a novel neurotoxic phenotype in 
human macrophages that extends beyond the classical M1 inflammatory or M2 anti-
inflammatory activation categories often seen in the literature. Macrophage phenotypes that 
correlated with the secretion of neurotoxins assessed by measuring calcium dysregulation in 
neurons consisted of suppressed calcium spiking and the formation of polarized podosomes.  
We found that macrophages not possessing this neurotoxic phenotype showed increased 
ruffling of the membrane and increased calcium spikes. In neurodegenerative diseases, an 
imbalance in pro-neurotrophins versus mature neurotrophins have been observed, however 
the actions of pro-neurotrophins on macrophages have never been studied. We have shown 
that, similar to their opposing roles in neurons, proNGF signaling in macrophages stimulated 
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the neurotoxic phenotype while mature NGF created a more neuroprotective phenotype 
which was dependent on TrkA. The neurotoxic phenotype was also driven by HIV in a 
p75NTR and CXCR4 dependent manner.  Neurotrophin signaling was able to modulate the 
HIV neurotoxic phenotype by exacerbating neurotoxin production (proNGF) or partially 
restoring the non-toxic phenotype (NGF). This thesis for the first time identified an 
interaction between the neurotrophin receptors p75NTR and TrkA and the HIV co-receptor 
CXCR4 through the use of co-immunoprecipitation techniques, which may be involved in 
the regulation of neurotoxic phenotypes. NGF co-stimulation with HIV increased CXCR4 
phosphorylation and association with G-protein receptor kinase 2 (GRK2). This contrasted 
with the decrease in GRK2/CXCR4 complexes seen with HIV stimulation alone. 
Phosphorylated CXCR4 (pCXCR4) was found in overlapping domains with p75NTR and 
TrkA, which was downregulated by HIV.  NGF was able to restore the p75NTR/pCXCR4 co-
localization and partially restored pCXCR4/TrkA co-localization. This data indicated that 
NGF suppressed the HIV neurotoxic phenotype by facilitating phosphorylation of the HIV 
co-receptor CXCR4 while proNGF enhanced HIV effects. Overall, these studies have 
identified novel effects of the neurotrophins on macrophages that may provide new 
therapeutic avenues for the control of toxic macrophage phenotypes seen in HIV associated 
neurocognitive disorders and other neuroinflammatory diseases.  
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CHAPTER 1: INTRODUCTION 
Inflammation in the Central Nervous System 
The central nervous system (CNS), consisting of the brain and spinal cord, was once 
thought to be an immune privileged environment protected from debris and systemic immune 
cell infiltration by the blood brain and blood cerebrospinal fluid barriers. However, we now 
know that there is constant communication between the immune system and the central 
nervous system to ensure proper homeostasis and signaling in the brain.  The introduction of 
external stressors such as injury and infection can lead to inflammation in the brain known as 
neuroinflammation [1]. Short periods of neuroinflammation can be beneficial in the central 
nervous system, however, prolonged and excessive activation of these immune responses can 
cause chronic inflammation that leads to neuronal damage and loss[2].  Excessive 
inflammation can take many forms and is often seen in neurodegenerative diseases[3].  This 
thesis will focus on inflammation resulting from HIV infection that underlies the 
development of HIV Associated Neurocognitive Disorders (HAND). Understanding how to 
control inflammation in the central nervous system is important in creating new therapeutic 
avenues for HIV neuropathogenesis, and a better understanding of these processes is a major 
goal of this dissertation. The following section reviews the normal composition and functions 
of immune cells in the central nervous system, the major immune cells in the brain, 
microglia, and how they are activated to create chronic neuroinflammation.   
 
2 
Normal composition of Immune cells in the Central Nervous System  
  Under normal conditions, immune cell infiltration into the brain is highly restricted 
by the blood brain barrier resulting in a vastly different composition of immune cells inside 
the brain compared to other organs. For example, the population of T cells in the brain 
parenchyma is one tenth of its appearance in other organs. Immune surveillance in the brain 
is mediated primarily by microglial cells, also known as the resident macrophage of the 
brain. Microglia/macrophages are a part of the mononuclear phagocyte group and are among 
the first cells to respond to injury and infection during innate immunity [2,4]. Microglia 
represent 0.5%-16.6% of cells present in the brain and are found in higher quantities in white 
matter regions compared to grey matter regions [5]. Microglia cells are normally tightly 
controlled quiescent cells in the central nervous system with distinct roles in maintaining a 
healthy environment. These roles include surveillance of the microdomain, removal of debris 
and noxious agents through phagocytosis, modulation of synaptic connections and plasticity, 
communication with other brain cells and responding to infectious and toxic agents[6].  
Astrocytes, the most abundant glial cells in the CNS, also contribute to innate 
immunity, though to a much lesser extent. Astrocytes are found throughout the brain in both 
white and grey matter regions. Under normal conditions astrocytes support neuronal 
function, secrete neurotrophic factors and aid in neural activity and homeostasis. Physically, 
astrocytes influence the formation and maintenance of the blood brain barrier by contributing 
to its structural and functional integrity[7]. While they are not classical immune cells, 
astrocytes respond to insult and injury by changing cell morphology resulting in cell 
hypertrophy and scar formation referred to as astrogliosis. Astrocytes are also able to secrete 
pro-inflammatory cytokines and complement proteins. Though astrogliosis has been 
associated with neurodegenerative diseases such as Alzheimer and Parkinson disease and 
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HIV associated cognitive disorders, it will not be a focus of this dissertation.  
 Immune surveillance in the CSF  
Though immune cell populations are low within the parenchyma of the brain, 
constant surveillance and communication of the central nervous system is always occurring 
by systemic immune cells located in cerebrospinal fluid (CSF) and specialized structures just 
outside the CNS proper. Studies have shown that approximately 450,000 white blood cells 
are normally found within the CSF of healthy adults [8,9]. The composition of these cells is 
quite different from blood indicating that these cells are highly selected for entry into the 
brain compartment. Though there are reduced numbers of T cells in the brain, T cells can 
traffic into the CSF to survey and elicit signals to the central nervous system through 
interactions with ependymal and epithelial cells that line the ventricles and choroid plexus 
respectively[10]. Flow cytometry studies have shown that the T cells found in human and 
mouse CSF were CD4+, activated central memory (CD45RA-/CD27/28+) T cells, suggesting 
that they were recruited into the central nervous system, possibly through the choroid plexus 
or meninges[11]. T cells are thought to make the greatest contribution to HIV in the CSF, 
although the interactions of virus with cells in the parenchyma and the contributions to 
associated cognitive disorders are unclear.   
The central nervous system is also surveyed by subsets of monocyte-derived 
macrophages, which include perivascular macrophages, choroid plexus macrophages and 
meningeal dendritic cells. These specialized macrophages usually remain in their respective 
locations under normal conditions relaying systemic information to the CNS and receiving 
messages from the brain[12]. However, it is controversial whether these macrophages enter 
the brain parenchyma under special conditions such as to replenish the long lived microglia 
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during aging and in response to adverse conditions like infection. Varvel et al. has shown that 
after experimental depletion of microglia from mice, the microglia were replenished by 
engrafted peripheral blood derived monocytes entering the brain from small blood vessels 
and capillaries[13]. Similarly in a Simian Immunodeficiency Virus (SIV) animal model for 
neuroAIDS, labeled monocytes in bone marrow were able to travel into brain tissues more 
readily than in uninfected macaques [14]. Other studies, however, have tried to determine if 
the expansion of microglia in the parenchyma of the brain during chronic and 
neurodegenerative disease were from infiltrating perivascular macrophages resembling 
microglia or proliferating microglial cells [15,16] and determined that the populations 
represented a microglia expansion.   
 
Macrophage/Microglia activation and its role in Neuroinflammation  
Neuroinflammation has been widely implicated as a pivotal event contributing to 
neurodegeneration. Though many neurodegenerative diseases have different causative 
etiologies, there are common pathologies seen among these diseases. Of importance, 
macrophage activation, permeability of the blood brain barrier, infiltration of systemic 
macrophages and secretion of neurotoxins have been noted in neurodegenerative diseases 
such as Alzheimer disease and HIV associated dementia (HAD)[17-20]. Though the 
mechanisms for these common pathologies are not fully understood, it is well accepted that 
macrophage activation is a key step.  
 Macrophages/Microglia cells are highly dynamic and can express a wide range of 
phenotypes driven by their ability to respond to a wide range of external cues. Activation by 
these environmental stimuli occurs through interactions with many cell surface receptors that 
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mediate functional changes in macrophages including morphology, migration, phagocytosis, 
cytokine secretion and antigen presentation. Though it was thought that macrophages were 
only able to produce pro-inflammatory factors, being one of the most secretory cells in the 
body, macrophages are capable of releasing factors needed in homeostasis, inflammation and 
host defense responses under the control of multiple mediators. Macrophage activation 
phenotypes are transient and reversible depending on cues received from the 
microenvironment and range from strong inflammatory responses designed for elimination of 
invading pathogens to anti-inflammatory, protective and wound healing activities essential 
for tissue repair. This versatility in functions has led to the characterization of two polarized 
activation states, classical activation or M1 and alternative activation or M2 [21-23]. Reports 
have suggested that macrophages may require at least two signals to achieve polarization 
[24].  
 Classically activated inflammatory macrophages have been shown to arise from type 
1 cytokines such as interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and 
lipopolysaccharide (LPS) stimulation. M1 induction can also occur after recognition of 
pathogen-associated molecular patterns (PAMPS) and Damage- associated molecular 
patterns (DAMPS) on foreign or damaged agents such as viruses, bacteria and dead cells. M1 
macrophages also express increased MHC class I and II receptors and secrete complement 
factors necessary for complement-mediated phagocytosis[25]. Activation of M1 
macrophages leads to secretion of pro-inflammatory cytokines and chemokines such as IL-
12, IL-23, TNF-α, IL-1, and IL-6 and production of reactive oxygen species which damage 
proteins.  
 Alternative M2 activation of macrophages is the balancing anti-inflammatory 
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activation state of macrophages leading to the secretion of anti-inflammatory cytokines, 
chemokines, growth factors and other reparative factors[26]. M2 has been sub-divided by 
some into 3 groups M2a, M2b and M2c [23]. M2a is induced by IL-4 and IL-13, while M2b 
is induced by immune complexes in combination with IL-1β or LPS and M2c is induced by 
IL-10, TGF-β or glucocorticoids. These activation categories however are overly simplistic 
and often a hurdle to understanding the wide range of phenotypes of macrophages, as many 
studies fail to go beyond a characterization of the classical cytokines. Hyperresponsiveness 
of classically activated macrophages can lead to tissue damage while exaggerated wound 
healing properties have been shown to increase infections in severe burn patients indicating 
that a balance of activities must be maintained.  Understanding how these activation states 
may intertwine to create the proper balance in macrophage function is important for the 
development of precisely targeted macrophage therapies in the future.  
In the normal CNS, microglia are in a resting homeostatic state and activation is 
tightly controlled to avoid potential indirect damage to neurons, which cannot readily 
regenerate and repair. To achieve this, neurons aid in controlling the resting state of 
microglial cells through constant communication carried out by specialized cell surface 
receptors and their ligands on both cells. Specifically, signaling partners, CD200/CD200 
receptor and fractalkine /CX3CR1 have been implicated in controlling the resting state of 
microglia[27]. Loss or deficits in these receptors has resulted in increased microglial 
activation in animal models and have been implicated in neurodegenerative diseases[28].  
The resting state can also be compromised from external stressors such as HIV infection of 
the brain, leading to chronic activation of microglial cells and subsequent neurodegeneration.  
The activated cells responding to HIV infiltration into the brain portray many of the classical 
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M1 phenotypes such as increased secretion of proinflammatory factors and upregulation of 
the cell surface marker, CD16[8,17,29-31]. This inflammatory activation is associated with 
neuronal damage and a gradual progressive degeneration of the CNS without appreciable cell 
death. This suggests that damage caused by microglial/macrophage activation may be 
reversible and interventions that restore the balance of microglia activation states may be 
fruitful therapeutic options for HIV associated disorders. This thesis aims to identify novel 
signaling interactions capable of establishing favorable macrophage phenotypes that prevent 
HIV neuropathogenesis.  
 
General overview of HIV infection  
In order to understand how to control the HIV-associated inflammatory cascade 
responsible for HIV associated cognitive disorders, it is important to understand the general 
nature of the virus and how it infects and interacts with its host cells.      
History of HIV: a public health problem  
Human immunodeficiency virus (HIV) is an epidemic affecting an estimated 1.2 
million Americans in the United States and is predicted to have 50,000 new cases each year 
(http://www.cdc.gov/hiv/statistics/basics/ataglance.html ). HIV is transmitted through bodily 
fluids such as mucosal barriers and blood. The most common form of transmission is through 
sexual transmission, and HIV is the number one deadliest sexually transmitted disease. The 
first cases of HIV described in the 1980’s were 5 homosexual men presenting with 
Pneumocystis carinii pneumonia (PCP). HIV was originally thought to be a disease affecting 
only this population as more reports of homosexual men diagnosed with Kaposi Sarcoma 
followed. However, non-homosexual, intravenous drug users and blood transfusion recipients 
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began to surface, negating these theories [32,33]. HIV quickly became an epidemic because 
we now know the early stages of disease present with mild symptoms, resulting in the 
transmission of virus from patients unaware that they were infected. To this day, 1 in 7 
people infected with HIV are unaware of their status, which contributes to the continuous rise 
in infection. Though patients presented with various opportunistic infections, they all shared 
one common hallmark, depletion in CD4+ T cell counts that led to a decline in the patient’s 
immune system. In 1983 HIV was discovered as the virus that caused Acquired Immune 
Deficiency Syndrome or AIDS [34,35].  
HIV Infection  
HIV infection can be broken down into four stages: primary acute infection, a 
clinically asymptomatic stage, symptomatic HIV infection and progression from HIV to 
AIDS. After transmission, primary infection typically lasts 2 weeks, allowing virus to 
establish itself in the host body. During acute infection viral replication takes off, reaching 
peaks of millions of virus copies per millimeter of plasma just 21-28 days after infection, and 
CD4+T cell numbers begin to decline. Like in the blood, viral loads in the CSF can peak 
around week three, though found at ~1% of the quantities in the blood. Patients have flu-like 
symptoms 90% of the time during acute infection, and signs of meningoencephalitis may 
occur. Clinical symptoms at this point do not warrant suspicion of infection unless a history 
of HIV risk is known as antibodies against HIV cannot be detected in the host blood until 6-
12 weeks post infection. Before the second phase of infection, there is a rapid drop in viral 
production and slight recovery of T cells. In the second phase known as the asymptomatic 
phase, HIV continues to replicate and a gradual decline of T cells occurs leading to 
symptomatic HIV infection and AIDS. Neurological deficits are the first signs of 
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symptomatic infection in 10-20% of patients. With severe HIV infection this increases to 
60% of patients with clinically relevant CNS manifestation.  Approximately 30-40% showed 
signs of dementia. Once CD4+ T cell counts fall below 200 cells per milliliter, patients are 
diagnosed with AIDS. During the AIDS stage, patients are more likely to suffer from 
opportunistic infections and severe dementia, which leads to their demise. 
Currently there is no cure for HIV and the current treatments include several classes 
of antiviral drugs used to block the main steps in replication: entry, fusion, reverse 
transcription, proteolytic processing and integration.  The first antiretroviral treatment was 
approved by the FDA in 1987, a nucleoside reverse transcriptase inhibitor, azidothymidine 
(AZT, Zidovudine). This drug was ineffective in suppressing long term viral replication. 
Since then it has been discovered that a combination of at least three antiretroviral therapies 
used to block different phases of HIV replication is needed to manage infection.  This 
strategy became known as highly active antiretroviral therapy (HAART), currently known as 
combination antiretroviral therapy (CART)[36]. The use of these drugs has led to longer life 
expectancy as patients have suppressed viral loads systemically and increased CD4+ T cell 
counts. However these drugs cannot effectively cross into the brain, where virus can persist. 
This poses a need for neuroprotective therapies in conjunction with standard CARTs. In 
order to achieve this we must first understand the nature of the virus and its interaction with 
the central nervous system.  
Structure of the HIV Virion  
HIV, a member of the lentivirus subgroup of retroviruses, is a round virion (100nm in 
diameter) containing a double stranded RNA genome in its core.  HIV has an outer 
membrane known as the viral envelope consisting of a lipid bilayer containing viral proteins 
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necessary for fusion and entry into the host cell.  The envelope protein which mediates 
infection is a 160 kDa glycoprotein known as gp160.  The gp160 protein is cleaved and 
further glycosylation occurs in the Golgi to produce a 41 kDa transmembrane protein, gp41, 
and a 120 kDa surface envelope protein, gp120.  Gp41 serves as the stalk for gp120. The 
gp41/gp120 complex forms oligomers of three molecules in the membrane and is necessary 
for virus entry into the host cell[37].  
The viral core contains the double stranded RNA and proteins necessary for 
replication and integration into the host genome. The HIV genome consists of 9 genes: the 
structural genes that encode cell surface proteins: Gag, Pol, and Env; the regulatory genes 
that control replication: Tat and Rev; and the accessory genes involved in virus replication 
and continued infection: Vpu, Vpr, Vif, and Nef. The core also contains reverse transcriptase, 
integrases, and proteases which are encoded by the pol gene and are necessary for viral 
integration into the host genome[38].  
HIV binding and entry into host cell  
Viral fusion and entry into the host cell is dependent on the interaction of the viral 
surface glycoproteins with two classes of surface receptors on the host cell, the primary 
receptor CD4 and the co-receptors, CXCR4 and CCR5. CD4 is a transmembrane protein 
consisting of 4 glycoprotein domains (D1-D4) that are in high abundance on T cells. 
Macrophages also express CD4 though in much lower quantities. CD4 expression is 
necessary for proper infection of the host cell though it has no known functions under normal 
conditions.  The co-receptors CXCR4 and CCR5 are chemokine, G protein coupled receptors 
(gpcr) that respond not only to HIV but also their natural ligands SDF (CXCR4), MIP-1 
and Rantes (CCR5) to orchestrate migration under normal conditions. HIV virions have 
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tropism preferences for the co-receptors, which explain the ability of some viral strains to 
infect T cells (CXCR4 preferring) whereas other strains infect cells of monocyte lineage 
(CCR5 preferring). Although the strong infection preferences under some circumstances 
suggested that the preferences might be mutually exclusive, it is now recognized that both 
chemokine receptors are expressed on each cell type and viral infection by T cell tropic or 
macrophage tropic strains is not exclusive to their preferred receptors.  In addition, there are 
also dual tropic viruses, CXCR4/CCR5 that can infect through both receptors.  The 
efficiency of entry is determined to a large degree by the abundance of CD4 in conjunction 
with either co-receptor[39].   
HIV entry is achieved when the HIV surface protein, gp120 binds to CD4 causing a 
conformational change in the gp120 trimer allowing interactions with co-receptors CCR5 or 
CXCR4. Once gp120 binds to the co-receptor, a second conformational change occurs in 
gp41, exposing a fusion domain that embeds itself into the cell membrane resulting in fusion 
and the formation of a pore for viral entry into the host cell.  Since most infection involves 
transmission at mucosal and cellular barriers, initial infection is typically mediated via the 
infection of CCR5 expressing macrophages that are abundant at these sites.  The importance 
of CCR5 for entry and infection is evident in a select group of individuals who are resistant 
to infection (approximately 10% of Caucasians) due to a deletion mutation in the CCR5 gene 
on allele 32 (CCR5∆32) that restricts the binding of CCR5 preferring HIV virions[40,41].  
Integration into the genome and viral replication  
After fusion occurs, the virion releases its material into the host cell during a process 
referred to as uncoating which releases the viral genome and proteins necessary for reverse 
transcription and integration. The initial replication steps occur in the cytoplasm of the host 
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cell and begin with reverse transcription of the viral double stranded RNA into double 
stranded DNA and formation of the replication complex. The replication complex also 
known as the pre-integration complex consists of the viral DNA/RNA, reverse transcriptase, 
integrase, viral matrix protein p17, viral proteases Vpr, histones and non-histone proteins. 
This complex is transported to the nucleus to begin integration. Once into the nucleus, the 
viral and host DNA is prepped for viral DNA insertion, catalyzed by integrases followed by 
ligation. Once integrated into the host genome the provirus begins to multiply, making viral 
RNA and mRNA that are later translated into viral proteins. After transcription of the viral 
copies, the RNA is transported out of the nucleus and the viral proteins and genomic RNA 
are then packaged in the cytoplasm of the host cell. Budding of the viral RNA and protein 
package is the final stage of virus production and occurs through exocytosis[42].   
Replication and mutations  
During heterosexual transmission, 80% of infection is initiated with a single 
variant[43]. On average, an infected individual will produce 1010 virions in a day[44].  Unlike 
mammalian cells, viral DNA repair is inefficient.  This leads to a high mutation rate of 3 X 
105 nucleotide bases per cycle of replication leading to the generation of many 
variants[45,46]. Over time the viral populations in a patient becomes increasingly more 
diverse contributing to the genetic variability of virions. This evolution of the virus aids in its 
long-term survival within the host and leads to resistance of HIV drug treatments causing the 
need for constant changes in a patient’s therapy[47].  
In the central nervous system, HIV replication is slow and the amount of virus 
synthesized within the CNS is still controversial.  Phylogenetic analysis of viral envelope 
sequences in blood and CSF has shown that most virions match sequences from blood[48].  
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However, these analyses have also identified small groups of unique variants suggesting an 
evolution of viral sequences unique to the CNS[49].  This has led to the idea that strains of 
HIV compartmentalized in the CNS may have unique properties that encourage 
neurodegeneration[50,51] although this is still controversial.  Understanding the interactions 
of HIV with cells in the CNS is essential for the development of strategies that control 
replication and disease progression.  
HIV in the CNS 
HIV infection in the CNS is a persistent problem that has evolved with the 
introduction and evolution of antiretroviral therapy.  In this section we will review how HIV 
infection is thought to cause neuropathogenesis.  
HIV in the CNS before the era of HAART  
Before the introduction of HAART, a large proportion of patients presented with 
opportunistic central nervous system infections and neurological deficits ranging from mild 
cognitive-motor impairment to severe dementia. In 1987, patients with severe sub-acute 
encephalitis were identified as having AIDS dementia complex (ADC), currently termed HIV 
associated dementia or HAD[52-54]. HAD was characterized as subcortical damage causing 
severe cognitive impairment, altered psychomotor movements and severe disturbance in day 
to day activities [55]. Before the HAART era, 20-30% of patients were diagnosed with HAD 
[56,57] and it is unclear why only a subset of patients have clinically significant CNS 
impairment.  
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After the era of HAART  
After the initiation of HAART treatment, the prevalence of HAD decreased 
drastically[58-60].  However 18-50% of HIV patients still present with milder neurocognitive 
disorders, now designated HIV associated neurocognitive disorders (HAND)[61]. HAND 
encompasses HAD, asymptomatic neurocognitive impairment (ANI) and minor 
neurocognitive disorder (MND). ANI affects 24% of HIV patients with abnormal 
neuropsychological performance but no change in life activities while MND affects 52% of 
patients and also results in abnormal neuropsychological testing with mild interference in 
daily activities[62]. This reduction in clinical neurological symptoms suggested that neuronal 
damage created by HIV infection may be fully reversible and highly amenable to therapeutic 
intervention.  
Target cells in the central nervous system  
Though neuronal damage is responsible for the clinical symptoms, HIV does not 
infect neurons.  Unlike systemic infection, the role of CD4+ T cells in the spread of HIV in 
the central nervous system is not clear. HIV infection of astrocytes has been reported in 1-3% 
of astrocytes [63] although this is not a common observation.  Astrocytes lack expression of 
the primary HIV receptor CD4 and are unable to transcribe viral material[64] and thus do not 
produce infectious virions. Full length HIV genomes have not been detected in these cells, 
but multiple fragments of HIV RNA and proteins have been identified within astrocytes 
which may be released and have indirect neurotoxic effects[65].  The best supported 
contribution of astrocytes to HIV neuropathogenesis is via a loss of glutamate transporter 
function which is thought to facilitate excitotoxic damage [66].  Another potential indirect 
contribution of astrocytes to neuropathogenesis is through interactions with HIV soluble 
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proteins, nef and gp120, that lead to disruptions in the blood brain barrier increasing its 
permeability[67,68].   
The main cellular targets that carry the HIV burden in the central nervous system are 
the perivascular macrophages and microglial cells. These long lived cells are able to harbor 
virus and produce a slow steady viral replication once virus enters the brain[69].   
HIV entry into the central nervous system  
HIV enters and infects the central nervous system shortly after the initiation of 
primary infection.  Once infection is established the brain acts as a protective reservoir for 
HIV [70]. In human studies, HIV RNA has been measured in the CSF prior to treatment and 
during HAART treatment even when systemic infection is suppressed[71]. This phenomenon 
has been termed CNS escape. Though HIV entry into the CNS has been accepted since the 
1980’s, the mode of entry is still controversial today. The most accepted theory of HIV entry 
is the Trojan Horse hypothesis: Activated monocytes expressing CD14+/CD16+ cell surface 
markers, some of which are infected with HIV, are able to cross the blood brain barrier[29]. 
Once in the brain, monocytes are differentiated into perivascular macrophages. These 
activated macrophages are then able to produce more HIV, which then infects resident 
microglial cells.  
Other theories suggest that cell free virus may diffuse across a disrupted blood brain 
barrier. However, these studies are largely based on findings from late stage, infection and it 
is not clear if there is disruption of the BBB during the initial stages of infection when the 
CNS reservoir is thought to be established.  Soluble HIV surface protein gp120 has been 
implicated in disrupting the integrity of the blood brain barrier and enhancing monocyte 
migration[72]. Also it has been postulated that virus can interact with the endothelial cells 
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that line the blood brain barrier and modify proteins that are essential for maintaining tight 
junctions in the blood brain barrier[68,73].  
Another mode of entry involves HIV entry via the choroid plexus.  The choroid 
plexus is a unique organ with specialized functions including the production of cerebrospinal 
fluid (CSF). This intricate structure extends from the ependymal of the lateral, third and 
fourth ventricles of the brain and is the home of many immune cells including a large 
population of macrophages that survey the central nervous system, providing immune 
surveillance within the cerebral ventricles.  HIV titers within the CSF can reach levels of 106-
107virions /ml yet no study has shown that HIV or infected macrophages can enter into the 
parenchyma of the brain via the choroid plexus and ventricular system.   
 
Mechanisms of Neuropathogenesis  
The first clinical reports of neurological disorders during HIV infection showed 
remarkable neuronal damage and loss in post mortem analysis of patients with HAD 
symptoms compared to HIV patients with no signs of cognitive deficits[74,75] . The basal 
ganglia and hippocampus, regions that mediate cognitive motor processing and cognition, 
respectively typically show the most pathology leading to the description of HAD as a 
subcortical dementia. Other pathological features of CNS infection with HIV included 
infiltration of macrophages into the perivascular regions often presenting as multinucleated 
giant cells, clusters of activated microglia (microglial nodules), and a relatively diffuse 
microgliosis, and reactive astrogliosis [76-78]. Of all the pathology seen, activated 
macrophages are the best correlate for neurocognitive disease severity [79]. 
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   To date there has been no good indication of HIV infection of neurons although they 
do express co-receptors CXCR4 and CCR5 [80,81].  Some early studies showed that the 
neuronal damage was caused by the HIV surface protein gp120 which is cleaved from 
macrophages after engagement with the CD4 receptor [82,83]. Others have linked damage to 
cytokines such as TNF, arachidonic acid, quinolinic acid and other HIV proteins including 
Tat and Nef [84,85]. Of all of these factors the greatest support for a pathogenic role has been 
for gp120 and Tat.  Various direct and indirect neurotoxic mechanisms have been 
hypothesized but a common theme has been the ability of the proteins to induce an 
inflammatory response.  This, in turn, has led to many studies showing that soluble proteins 
secreted by stimulated macrophages produced neural damage.  Lynn Pulliam and Dana 
Giulian were the first to show that HIV infected macrophages secreted neurotoxic factors 
leading to neuronal damage [17,18]. Lipton showed subsequently that the secretion of 
neurotoxins from microglia does not require infection and that the gp120 surface protein was 
sufficient to induce the secretion of these factors[86]. In a feline immunodeficiency virus 
(FIV) model, both infectious FIV and its envelope protein FIV-PPR produce comparable 
levels of neurotoxicity [87]. Similar to human pathology, gp120 transgenic mouse brains 
have increased appearance of vacuolizations in dendrites, decrease in synapto-dendritic 
complexity and increased activation of macrophages. With this appreciation that macrophage 
secretion of neurotoxins is the culprit for neuronal damage, the search for the neurotoxic 
factors has been an ongoing struggle[88] yet to be resolved. 
These initial studies and observations have led to the ability to study 
neuropathogenesis in culture. Cultured neurons in the presence of challenged 
macrophages/microglia or their conditioned medium can allow cellular analysis of neuronal 
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damage as it evolves during early stages of pathogenesis. Hallmarks of early neuronal 
damage include swelling of the soma, calcium dysregulation, and beading along dendritic 
processes [89,90]. Although neuronal death and apoptosis have been documented and has 
been highly investigated as a mechanism of neuronal death, it represents a very small number 
of cells seen in the late stages of infection.  Indeed the cognitive symptoms in HAD can be 
dramatically reversed by antiretroviral therapy[60].  Thus, there is little evidence that 
neuronal death plays a significant role in the development of dementia except perhaps at very 
late stages of disease.   
Alteration in calcium homeostasis has been implicated in neurodegenerative diseases 
such as Alzheimer, Parkinson disease and HAD and is known as the “calcium hypothesis for 
neuronal disease”[91]. Although many different definitions of neuronal calcium 
dysregulation have been used in different studies, studies in this thesis focus on the influx of 
calcium that occurs in two phases leading to neuronal damage and in extreme cases death. 
This bi-phasic calcium deregulation was originally worked out in cultured embryonic spinal 
neurons challenged with glutamate during excitotoxicity [92]. Neurons responding to 
macrophage derived factors show a similar calcium profile.  The first phase is an acute influx 
in calcium initiated by the conditioned medium from activated macrophages. This acute 
influx in calcium lasts no more than two minute before returning to baseline calcium levels 
with a plateau developing at variable intermediate levels. In the second phase known as the 
delayed or pathologic phase, calcium influx rises and is sustained until the death of the cell or 
cells are returned to favorable conditions. Once neurons are returned to favorable conditions 
such as normal culture conditions or addition of neurotrophin ligands, neuronal integrity is 
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returned suggesting the potential role to reverse neurological dysfunction during HIV 
infection with proper therapeutic avenues.  
During the delayed calcium rise, another hallmark of neuronal damage appears: the 
formation of beading along the dendritic processes. This beading can also be seen in post 
mortem tissue from HIV patients with HAD. Beading is dependent on calcium, [93] and in 
an FIV model it has been shown to follow the delayed calcium influx in neurons [89].  
 
Neuroprotection  
Mechanisms of neuroprotection and animal models  
Though the initiation of HAART has reduced the prevalence of HIV associated 
dementia in patients, there is still a need for neuroprotection as many patients still present 
with mild to moderate cases of neurocognitive impairment[94] . It is also predicted that as 
patients age, HIV cognitive disorders will continue to increase in prevalence and severity. 
When assessing how to therapeutically target HIV in the central nervous system three general 
strategies have been followed:  1) complete eradication of the virus from the central nervous 
system, 2) blockade of neuronal damage and 3) suppression of macrophage inflammatory 
activation.  
 
Eradication:  
Eradication of the virus from the central nervous system is a hard task because the 
brain is a protected reservoir that harbors virus that is unique to this compartment. Strategies 
for viral eradication of systemic latent T cells are currently ongoing [95] but are more 
difficult to apply to macrophages and microglia.  Because HIV is integrated into the cell 
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genome, eradication strategies would have to reactivate viral replication in order to identify 
and kill infected cells. It is unclear if there is latent virus in the CNS or a low persistent level 
of replication.  In either case difficulties in identifying and eradicating latent virus or 
destroying the resident immune cells hosting virus would be technically very challenging and 
potentially more damaging to the CNS than the infection. A better understanding of HIV in 
the central nervous system and how virus is harbored will be necessary in order to make 
complete eradication of virus from the brain a possibility[96].   
 
Inhibiting Neuronal Damage:  
Though the mechanisms of neuronal damage are not fully understood, calcium 
dysregulation via suppressed clearance processes in conjunction with activity of NMDA 
glutamate receptors or voltage gated calcium channels, oxidative stress and structural damage 
have been implicated as primary underlying causes. Neuroprotective therapies that cross the 
blood brain barrier and target these processes have been explored.  Some have gone to 
clinical trials but none have yet proven to be effective.   
One potential therapy that has been tested in animal models of HIV infection and in 
clinical trials was a non-competitive NDMA antagonist, memantine.  A severe combined 
immunodeficiency (SCID) mouse injected with HIV infected human monocyte-derived 
macrophages into the caudate and putamen was used to produce HIV encephalitis (HIVE) 
and resulted in impaired synaptic transmission and long term potentiation in the CA1 region 
of hippocampus slices. Treatment with memantine significantly improved synaptic 
transmission in these mice. Simian immunodeficiency virus (SIV) infected macaques 
presented with a cocktail of viruses, showing accelerated signs of HIV neurocognitive 
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impairments and allowing researchers the ability to study progression of CNS degeneration 
over a few months. Greater than 90% of macaques develop SIV encephalitis when infected 
with two different viruses, a biological viral strain and a neurovirulent recombinant 
clone[97]. Memantine treatment administered to SIV infected rhesus macaques 2 weeks post 
infection, at peak viremia, prevented dopamine deficits often seen in this animal model. 
Memantine also upregulated mRNA and protein expression of brain derived neurotrophic 
factor (BDNF), suggesting a potential role in neurotrophic support [98]. Based on the 
beneficial effects seen in animal studies, memantine was tried in a phase 2 clinical trial to 
treat HIV neurocognitive disorders; however, subjects showed no significant improvement in 
neuropsychological performance[99]. One promising neuroprotective modulator that is 
currently in clinical trials to treat Alzheimer disease, LM11A-31, has been a focus in our lab 
for the treatment of HIV associated dementia.  In these studies, a naturally occurring feline 
immunodeficiency virus (FIV) animal model recapitulates disease progression in HIV 
infected patients. FIV rapidly penetrates the CNS and leads to neuropathogenesis.  Neuronal 
damage in this model is similar to what is seen in HIV infected patients albeit less severe.  In 
mixed neural cultures (neurons, astrocytes and microglia), FIV induced calcium 
dysregulation followed by the formation of varicosities along processes. Pretreatment of 
feline neurons with LM11A-31 blocked neuronal damage normally seen after treatment with 
conditioned medium from FIV-infected choroid plexus macrophages.  This provided strong 
in vitro evidence that neurotrophic support may be a new potential therapeutic avenue for 
neuroprotection in HAND and other neuroinflammatory disorders [89].    
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Suppression of macrophage activation:   
Much attention has begun to surface around the regulation of macrophage and 
microglial activation during disease. Though there is much that still needs to be understood 
about HIV induced macrophage activation, it has been shown that much of the toxic activity 
can be attributed to non-infectious interactions. HIV surface glycoprotein, gp120, can 
activate macrophages through the G-protein coupled co-receptors CXCR4 and CCR5, 
independently of binding to the primary HIV receptor CD4[86,100]. The relative role of 
CCR5 or CXCR4 tropic viruses in the generation of neural damage has been actively debated 
in attempts to determine if particular HIV strains have greater neurovirulence.  HIV virions 
in the central nervous system are typically CCR5 tropic, however, macrophages also contain 
CXCR4 receptors. Studies have shown that both CCR5 and CXCR4 tropic virions result in 
the secretion of toxins by macrophages however the exact mechanism is not clear [101]. HIV 
engagement with these receptors activates downstream MAPK signaling (Erk1/2, JNK, p38) 
and phosphorylation of pyk2 and FAK which have been implicated in morphological changes 
of the cell leading to migration and secretion of cytokines and other neurotoxic 
factors[102,103].  
Studies have reported that HIV gp120 increases macrophage secretion of M1 markers 
such as TNF-α [104-106] whereas others have shown that HIV infection increases the M2 
marker IL-10[107-109]. These seeming discrepancies in the polarization of macrophage 
activation are difficult to reconcile unless one assumes that macrophage activation states 
reflect much more complex phenotypes.  
While anti-inflammatory agents are routinely used for a wide variety of diseases, they 
typically suppress all activity globally or act through mechanisms that are not known.  These 
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have failed to provide significant long-term neural protection in clinical trials for many 
neurodegenerative diseases.  One in particular that was assessed for the treatment of HAND 
is minocycline.  Minocycline, a tetracycline antibody, has been shown to suppress the 
expression of M1 markers with no transient effect on M2 markers [110] through mechanisms 
that are unclear. In culture minocycline inhibits microglial activation and reduces excessive 
matrix metalloproteinase activity and nitric oxide synthesis in neuron/microglial co-cultures 
from human fetal brain. Also, minocycline treated SIV infected macaques showed a 
reduction in perivascular macrophage infiltration and an overall reduction of CD68 and MHC 
class II expressing cells in the brain compared to untreated SIV infected animals. 
Minocycline decreased SIV encephalitis by reducing HIV viral loads in brain tissue and CSF, 
the inflammatory chemokine MCP-1 in CSF and axonal degeneration in this animal model. 
[111-113].  Infected macrophages in culture treated with minocycline showed reduced viral 
production and prevented reactivation of virus in latent infected cells[113]. A Phase II 
clinical trial was conducted for treatment of HIV associated cognitive impairments. Though 
hopeful, no improvement in neuropsychological test was seen at the end of this 
study[114,115].  
Macrophages respond to many external cues depending on which tissues they are 
located in and the health of their environment. In the central nervous system neurotrophic 
support is necessary for neuronal health and stability.  In the FIV model, increased microglial 
expansion and activation was seen in co-cultures with neurons.  LM11A-31, the 
neuroprotective modulator that blocked neuronal damage induced by macrophage 
conditioned medium was also able to reduce the number of microglia seen in these cultures. 
In unpublished data LM11A-31 also blocked neurotoxin production from macrophages.  This 
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raised the possibility that the neuroprotective effects of LM11A-31 could be linked to actions 
of the drug on macrophages as well as neurons[89]. However, very limited information on 
expression and function was available to determine if neurotrophin receptors were likely 
targets.  Understanding how neurotrophic support in the central nervous system may alter 
macrophage activation during normal and pathologic conditions such as HAND is important 
for future therapeutic development, and is a primary goal of this dissertation.  
Neurotrophin Signaling 
As early as 1996 Levi-Montalcini [116] introduced the idea that neurotrophins may 
regulate the immune response. Since this early observation, a handful of studies have 
explored neurotrophin receptor gene transcript expression and immunoreactivity in immune 
cells in blood and various pathologic tissues[117]. These studies have shown that 
neurotrophin receptors are expressed on many types of immune cells. However few details 
were available to indicate the level of expression, localization and functions of the receptors.  
The presence of neurotrophin receptors on macrophages and microglia would provide 
considerable opportunity for neurotrophin regulation of immune cell function, particularly in 
the nervous system where neurotrophins are abundant. However, this aspect of neuroimmune 
interactions has received little attention and much of what we know regarding neurotrophin 
signaling comes from neuronal studies. 
In the nervous system, neurotrophins and their receptors play a fundamental role in 
the development and maintenance of neurons.  They have a wide range of well documented 
functions within both the central nervous system and peripheral nervous system (PNS) 
including established roles in neuronal differentiation, regulation of neurite outgrowth, 
synaptic regulation, cell survival and death [118].  Many of the functions are context and 
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tissue specific providing a highly versatile system for the development and maintenance of 
proper brain function[119-122].  The neurotrophin family is comprised of nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and 
neurotrophin-4 (NT-4).  Each neurotrophin exerts unique actions via interactions with 
specific high affinity tropomyosin regulated kinase (Trk) receptors.  NGF interacts with 
TrkA, BDNF with TrkB, NT-3 with TrkC and to a lesser extent with TrkA and TrkB and 
NT-4 with TrkB.  In addition to the Trk receptors, both the mature neurotrophins and their 
pro-neurotrophin precursors can bind to the p75 neurotrophin receptor (p75NTR) with low and 
high affinity, respectively[123]. Trk receptors and their ligands are involved in neuronal 
survival, differentiation, proliferation, migration and synapse formation. Binding of 
neurotrophins causes dimerization of Trk receptors and activation through auto 
phosphorylation. The p75NTR is a member of the tumor necrosis factor (TNF) receptor family 
and contains a death domain. Unlike the Trk receptors, p75NTR lacks a catalytic domain and 
exerts its functions by interacting with other receptors[118].   
Neurotrophins are synthesized by glial cells and neurons [124,125{Huang, 2001 
#11152]}  as a pro-neurotrophin which is then proteolytically processed to the mature 
neurotrophin[126]. Initially, the pro-neurotrophins were thought to be inactive precursors of 
the active mature peptides.  With the later recognition that the pro-neurotrophins are 
physiologically active came numerous studies showing that the pro-neurotrophins are ligands 
for the p75NTR.  It is now well recognized that neurotrophin signaling is dependent on the 
balance between mature vs. pro-neurotrophins as well as the nature of the target receptor 
complex. The p75NTR plays a pivotal role in the regulation of various pro-neurotrophin and 
mature neurotrophin functions and the potential significance of this role has been elevated by 
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recent recognition of upregulated p75NTR expression in response to injury and disease[117] .  
The availability of high affinity targets for pro versus mature neurotrophins is highly 
regulated by the interactions of p75NTR with its receptor partner.  Heteromeric association of 
p75NTR with Trks enhances mature neurotrophin signaling by increasing the affinity of the 
neurotrophin for the receptor by as much as 100-fold to a KD of approximately 10 pM, [127-
129] thereby increasing cell survival, differentiation and growth.  In contrast, the p75NTR -
sortilin complex binds pro-neurotrophins with high affinity and activates pathways that lead 
to apoptotic cell death.  The best studied of the pro-neurotrophins is proNGF.  ProNGF is 
synthesized and secreted by a variety of different cell types providing a rich source of cell-
cell interactions[130-133].  Cleavage of proNGF can take place intracellularly by convertases 
or extracellularly by the enzymes furin, plasmin and matrix metalloprotease-7 (MMP-7) 
[134,135].  ProNGF and proBDNF have both been shown to trigger a p75NTR-dependent 
apoptotic cascade[136-140].  Confirmation of the role of each pro-neurotrophin was provided 
by demonstrating protection using specific antibodies to proNGF[137,141] or proBDNF 
[142].  The apoptotic cascade induced by proNGF and proBDNF was dependent on the 
interaction of p75NTR with the co-receptor sortilin since addition of a fusion molecule 
containing the extracellular domain of sortilin prevented the apoptotic effects of proBDNF.  
In p75NTR deficient mice, less cell death is seen after axotomy [143,144], seizures[141] or 
ligation by proNGF[136].  Similar effects are seen after sortilin knockout[145].  Activation 
of the p75NTR/sortilin complex is thought to induce cell death through extended activation of 
c-Jun N-terminal protein kinase-3 (JNK-3) which in turn induces the synthesis of pro-
apoptotic factors while also phosphorylating and inactivating anti-apoptotic factors[119].   
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The dichotomy between the actions of mature neurotrophins versus pro-neurotrophins 
has led to the hypothesis that an imbalance may facilitate the progression of many 
neurodegenerative diseases and contribute to natural decline in aging.  The potential 
significance of proNGF signaling was further elevated by the observation that proNGF was 
the predominant form in human brain and was increased by two-fold in the parietal cortex of 
patients with Alzheimer disease [146].  A corresponding loss of TrkA in patients with 
Alzheimer disease[147,148]  and preservation of p75NTR and sortilin expression [147,149] 
provided further support for a shift in pro versus mature neurotrophin signaling[150,151].  
Excess pro-neurotrophin signaling has also been implicated in the pathology associated with 
other neurodegenerative conditions.  BDNF expression has also been shown to be down 
regulated in the hippocampus of a gp120 transgenic mouse model with impaired 
neurogenesis and neurite outgrowth. The pro form of this neurotrophin proBDNF was 
increased in gp120 transgenic mice compared to control [152]. Direct administration of 
BDNF was shown to be neuroprotective and block gp120 mediated neurotoxicity [153-155]. 
Also the loss of proper neurotrophin processing has been seen during brain injury. For 
example, the loss of MMP-7 activity in response to kainic acid induced seizures[156] and in 
diabetic retinopathy[157] is thought to contribute to the disease pathology by reducing the 
conversion of proNGF to NGF. However, other studies in HIV infected patients have shown 
that increases in MMP-7 activity are associated with a decline in neurological function[158].  
These studies indicate that interventions designed to restore a more favorable balance of 
mature neurotrophin-Trk protective signaling have the potential to slow neurodegenerative 
processes.  No studies have yet looked at potential interactions of pro-neurotrophins with 
immune cells; particularly microglia and macrophages within the neurotrophin rich CNS.  
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Neurotrophin Receptors Expressed on Immune Cells     
Though much of neurotrophin signaling has focused on neurons, a few studies have 
explored the expression of these neurotrophin receptors on immune cells. Much of the work 
has occurred in pathologic tissues where it was hard to distinguish which cells contained 
neurotrophin expression.  Other studies examined gene transcripts but not protein. The 
following section reviews what is known regarding neurotrophin signaling in immune cells 
with a focus on the expression and function of neurotrophin receptors on 
macrophages/microglia.  
Studies have shown that CD3+ T cells from blood, tonsil, thymus and inflamed 
muscle do not express the p75NTR [159-162] although they do express small amounts of TrkA 
and TrkB. In involuted thymus from myasthenia gravis patients 15% of T cells expressed 
TrkB receptors. This expression was reduced in hyperplastic and neoplastic tissues. 
Conflicting data suggests the expression of TrkB and p75NTR at negligible to moderate levels 
in CD20+ B cells[163,164]. Natural killer (NK) cells isolated from human blood also 
expressed p75NTR, TrkA and sortilin intracellularly [160,165]. Stimulation of the NK cells 
with IL-2 or IL-12 increased p75NTR but not TrkA or sortilin expression by up to 10-fold. 
Stimulation of NK cells with proNGF induced cell death similar to what has been seen in 
neurons[160]. Also, p75NTR and TrkB have been documented in eosinophils isolated from 
blood of atopic dermatitis patients [166]. TrkB and P75NTR expression in eosinophils was 
increased about 5-fold and 2-fold, respectively, in lesional mast cells of atopic dermatitis 
patients compared to control patients. Stimulation of eosinophils from atopic dermatitis with 
BDNF inhibited apoptosis in a dose dependent manner[166]. Similarly, increased p75NTR 
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expression was found in human mast cells isolated from skin lesions of atopic dermatitis 
patients [167]. These results suggest varying expression of neurotrophin receptors on 
immune cells.  
 
Macrophages/microglia 
Neurotrophin expression has been identified in cells of the monocytic lineage in 
various tissues and at varying levels.  Nakajima et al. reported that 99% of microglia 
expressed all neurotrophin receptors although the amount of expression varied among cells. 
This abundance in neurotrophin expression has not been seen in other studies although 
almost all studies show positive expression of neurotrophin receptors. Low to moderate 
p75NTR expression was seen in macrophages in inflamed muscle tissue[162]. P75NTR 
expression was absent in macrophages in the thymus and tonsils but moderately positive in 
the red pulp of the spleen in normal lymphoid tissue. Conversely, TrkA was expressed 
weakly in tonsils, lymph nodes and thymus and absent in spleen tissue [168] suggesting that 
expression may be tissue or context specific. Microglia, the resident macrophages of the 
brain, showed weak p75NTR expression in white matter regions of normal brain but 
expression was increased in glial cell bodies and large patches of macrophages/microglia in 
white matter MS plaques, as well as in glioblastoma, ALS and HIV encephalopathy [169]. 
TrkA and p75NTR have also been detected in monocyte derived macrophages isolated from 
human peripheral blood mononuclear cells. In cultures of human monocyte-derived 
macrophages (hMDM) stimulation with LPS increased TrkA expression by four fold but had 
no effect on p75NTR expression. NGF deprivation reduced this induction of TrkA expression 
yet increased p75NTR expression.  LPS stimulated macrophages induced apoptosis in only 6% 
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of cells. However the addition of NGF neutralizing antibody in the presence of LPS induced 
a five-fold increases in apoptosis [170]. Garaci et al. also found that HIV infected 
macrophages expressed 30% more TrkA compared to control cells[171]. This HIV induced 
increase in TrkA expression was significantly reduced during NGF starvation. Conversely, 
15 % of HIV-infected macrophages were immunoreactive for p75NTR in culture. P75NTR 
expression was increased to 35 % with NGF starvation and was accompanied by an initiation 
of apoptosis in approximately 45 % of HIV- infected cultured macrophages [171]. In a 
similar fashion, p75NTR expression was moderate to strong in microglial-like cells positive 
for tal1b5 and CD68 surrounding blood vessels and neurons in frontal cortical dysplasia, 
glioneuronal tumors and dysplastic neuronal tissue[172]. There were no Trk receptors found 
in these samples suggesting a primary role for p75NTR in these disease states. Moderate to 
strong p75NTR expression was also found in microglia in hippocampal sclerosis samples from 
temporal lobe epilepsy patients[173].  Taken together, there is strong support for the presence 
of neurotrophin receptors on immune cells but the results of expression have been 
inconsistent and the functional role of these receptors rarely addressed.  
Functional studies of neurotrophin receptors on macrophages 
There is limited functional data available for the role of neurotrophins on 
macrophages.  Conflicting data has suggested a role for NGF in HIV replication[171,174]. 
One of the few studies that explored the effects of NGF on macrophages reported that NGF 
stimulation increased CXCR4 expression on the cell surface of monocytes and macrophages 
in culture but did not alter CCR5 or CD4 expression. This regulation of CXCR4 was specific 
to NGF as other mature neurotrophins did not affect CXCR4 expression. Samah et. al. 
concluded that NGF stimulation increased CXCR4 expression to enhance macrophage 
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chemotaxis to its endogenous ligand SDF-1[175,176]. However understanding how NGF 
may be regulating CXCR4 expression has not been explored. While these studies provide a 
glimpse of the possible role of neurotrophin receptors on microglia and macrophages, a 
greater appreciation of macrophage-neurotrophin receptor involvement in normal and 
pathologic conditions is needed. [113] 
In this thesis I compare, for the first time, the involvement of mature NGF and 
proNGF in determining the functional activation state of human monocyte derived 
macrophages (hMDM) under normal conditions and in the context of HIV stimulation. I 
hypothesize that the activation state of hMDM is differentially regulated by neurotrophin 
receptors p75NTR and TrkA via interactions with CXCR4. ProNGF signaling through p75 
synergistically signals with CXCR4 resulting in increased phosphorylation of CXCR4 
leading to an active state associated with the generation of neurotoxins. Conversely, NGF 
signaling through TrkA is hypothesized to induce a more protective macrophage phenotype 
largely by interfering with the phosphorylation of CXCR4.  
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CHAPTER 2: DIFFERENTIAL REGULATION OF MACROPHAGE PHENOTYPE 
BY MATURE AND PRO-NERVE GROWTH FACTOR 
 
Introduction 
Macrophages are dynamic cells that can express a wide range of phenotypes driven 
by external cues.  The phenotypes range from strong inflammatory responses designed for 
elimination of invading pathogens to anti-inflammatory, protective and wound healing 
activities essential for tissue repair.  To highlight the different functional states, many studies 
have focused on characterizing the phenotypes of macrophages as classically or alternatively 
activated based on their receptor composition, secretion profiles, morphology and response to 
external cues. Classically activated inflammatory macrophages have been shown to arise 
from interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and lipopolysaccharide 
(LPS) stimulation leading to secretion of pro-inflammatory cytokines and chemokines, often 
with accompanying tissue damage. Alternative activation of macrophages is stimulated by 
interleukin-4 (IL-4), IL-10, transforming growth factor-β (TGF-β), or IL-13 and leads to the 
secretion of anti-inflammatory cytokines, chemokines, growth factors and other reparative 
factors[26].  In addition to these well characterized stimuli, macrophages in various tissues 
can be regulated by a wide array of external cues causing phenotypes that may intertwine 
these subgroups through mechanisms that are not fully understood.   
A potentially important but poorly explored set of cues may be neurotrophic factors.  
Although it has been over two decades since the first studies identified neurotrophin 
interactions within the immune system,[177] our knowledge of their functions is limited.  
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Multiple studies have documented expression of various neurotrophins and their receptors in 
macrophages suggesting that they may play a role in control of the innate immune system 
[169,172,178-184]. Relatively few studies have looked closely at the functions of these 
receptors on macrophages.  Most information regarding the functions of the neurotrophin 
receptors comes from studies in the nervous system where neurotrophins are important 
factors for development, maintenance, survival and differentiation of neurons[121].  The 
neurotrophin family includes nerve growth factor (NGF), brain derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4).  Neurotrophins bind to tyrosine 
protein kinases known as tropomyosin related kinase (Trk) receptors, TrkA (NGF), TrkB 
(BDNF and NT-4), and TrkC (NT-3) with high affinity.  An additional member of the 
neurotrophin receptor family, the p75 neurotrophin receptor (p75NTR) is a member of the 
tumor necrosis receptor family and binds all neurotrophins with low affinity.  The 
neurotrophin receptors function as homomeric or heteromeric complexes, providing 
opportunities for various signaling actions. The p75NTR in particular can interact with any of 
the Trk receptors where it facilitates receptor activation by increasing the affinity of mature 
neurotrophin binding.  
The neurotrophins are synthesized as precursors (pro-neurotrophins) that must be 
processed by proteolysis to form the mature protein. All pro-neurotrophins (proNGF, 
proBDNF, proNT3, proNT4) bind the p75NTR when it associates with alternative co-receptors 
such as sortilin.  Signaling of mature and pro-neurotrophins through their respective 
receptors often have opposing effects in target cells. Mature neurotrophin signaling has been 
associated with neuronal survival, growth and differentiation while proNGF signaling often 
leads to neuronal degeneration and apoptosis [185,186].  These differences have led to the 
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hypothesis that the balance of pro-neurotrophins versus mature neurotrophins may regulate 
the course of neurodegenerative diseases [185].  Regulation of macrophage and microglial 
functions by neurotrophins may be particularly important in the nervous system where 
neurotrophin expression is high.  In addition to neurons, macrophages also secrete 
neurotrophins.  Neurotrophin mRNA expression has been documented in 
microglial/macrophages in multiple sclerosis plaques [169] as well as HIV-infected 
macrophages [187]. NGF has been shown to increase CXCR4 mediated migration of 
macrophage precursor cells, monocytes [183] and to induce the secretion of plasminogen and 
urokinase-type plasminogen activator from microglia [178].  No studies have yet compared 
the functional activation of these receptors by pro- versus mature neurotrophins.  The 
following studies were designed to further characterize the expression of neurotrophin 
receptors on human monocytes and monocyte-derived macrophages (hMDM) and determine 
the functional role of mature versus pro-neurotrophins.  We show that monocytes and 
macrophages express both p75NTR and TrkA within the same membrane domains and exhibit 
very different phenotypes in response to mature NGF and proNGF.   
 
Materials and Methods 
Isolation and culture of human monocyte-derived macrophages 
Human buffy coat leukocytes were purchased and shipped within 24 hours after blood 
draw from healthy donors at the New York Blood Center (http://nybloodcenter.org/), a non-
profit organization for the collection and distribution of blood for clinical and research 
purposes. All research use was screened by the center and no personal identifiers were sent 
with the shipment.  Blood was diluted 1:1 with phosphate buffered saline (PBS) and was 
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layered on top of Ficoll-Paque (GE Healthcare 17-1440-03). Blood/Ficoll-plaque was 
centrifuged at 500 X g for 25 min and the peripheral blood mononuclear cells (PBMCs) were 
collected from the PBS/Ficoll-Paque interface.  PBMCs were washed in red blood cell lysis 
buffer (Sigma R7757) to remove any red blood cell contamination. PBMCs were centrifuged 
at 450 X g, the supernatant aspirated and the pellet re-suspended in Dulbecco’s modified 
eagle medium (DMEM) with high glucose, 10% fetal bovine serum (Gibco 160000-044) and 
20 µg/ml gentamicin (Gibco 15750-60).  Cells were aliquoted into low adhesion 6 well plates 
(Corning 3471) at a density of approximately 107 cells/well. PBMCs were cultured for 5-7 
days to allow monocyte attachment. Remaining white blood cells were washed from the plate 
yielding a pure monocyte/macrophage culture.  The adherent cells were differentiated into 
monocyte-derived macrophages (hMDM) using human GM-CSF (15 ng/ml) in complete 
DMEM for one week.  Monocyte experiments were carried out within 1 hour of PBMC 
isolation to prevent cell attachment.   
Primary cultures of rat forebrain 
All animal work was done in accordance with NIH animal welfare guidelines and was 
approved by the University of North Carolina- Chapel Hill Institutional Animal Care and Use 
Committee (approval number 14-147.0). Timed gestational embryonic day 9 (E9) pregnant 
female Long-Evans rats were delivered from Charles Rivers and allowed to rest in UNC 
animal husbandry until the time of experiments. At gestational day E17, rats were sacrificed 
by anesthetizing with isoflurane until breathing and heart stopped.  The uterus was removed, 
rinsed briefly in 70% ethanol and placed in HEPES-buffered Hank's balanced salt solution 
(HBSS) on ice. The brain was removed from each fetus, extensively washed, and the 
cortex/hippocampus was dissected from each brain and cleaned of Dura-arachnoid membrane 
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and visible vessels. The tissue was transferred to a 15 ml tube containing 5 ml calcium-
magnesium free-HBSS + 2.4 U/ml dispase + 2 U/ml DNase I and incubated for 25-30 min at 
36° C.  Tissue was triturated and allowed to settle for 2 min.  The suspended cells were 
transferred to a 50 ml culture tube containing 25 ml of minimum essential medium (MEM) 
with glutamine + 10% fetal bovine serum + 20 µg/ml gentamicin.  After several rounds of 
trituration in 2-3 ml fresh calcium-magnesium free HBSS, dissociated cells were seeded at a 
density 20,000 cells/cm
2
 on poly-D-lysine-treated coverslips for imaging and staining or 
50,000-100,000 cells/cm2 in 100 mm plastic dishes for Western blots.  After 24 hours, 
cultures were transferred to Neurobasal medium with B27 supplement.  The resulting 
cultures were >95% neurons at day 4 after seeding.  
 
Immunostaining 
Differentiated hMDM grown on poly-D-lysine coated coverslips were transferred to 
DMEM containing 1% FBS and stimulated for 1 or 24 hours using three different conditions: 
NGF human recombinant protein (100 ng/mL, Sigma N1408), proNGF human recombinant 
protein targeted to high affinity sites (1 ng/ml, Alamone N-280), or vehicle.  The cells were 
gently washed and fixed in 2% paraformaldehyde in PBS.  Cells were washed 3X in PBS and 
incubated in 3% normal goat serum for one hour. Incubation of primary antibodies was 
carried out overnight at 4o C. Cells were stained using antibodies to: p75NTR (Millipore cat 
#07-476, 1:500), TrkA (Santa Cruz cat #SC-80961, 1:500), TrkB (Millipore 07-225, 1:500), 
TrkC (Santa Cruz SC14025, 1:500) and sortilin (Millipore AB9712, 1:500). Cells were 
washed in PBS and incubated with species specific secondary antibodies conjugated to Alexa 
488, 568 or 593 (Molecular Probes) in the dark for 1 hour at room temperature.  Coverslips 
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were then mounted using Fluoromount (Southern Biotech 0100-01) and digitally imaged on 
an Olympus XI71 microscope.   
Analysis of stain intensity and morphology for individual cells or regions of interest 
within the cells was accomplished using Metamorph software.  Co-localization of p75NTR 
foci with TrkA or sortilin staining was analyzed by staining one receptor red and the other 
green followed by thresholding by intensity of stain, computer identification of stained 
objects and then documentation of each object’s central X/Y coordinate for each wavelength.   
Objects with X/Y coordinates that overlapped within 0.46 microns were scored as co-
localized. 
 
F-actin and live-dead stains  
F-actin was stained using Alexa488 phalloidin (1:50, Molecular Probes) to show 
structural changes.  Podosomes were visible in the hMDM as small, intensely fluorescent 
puncta whereas ruffles appeared as moderate to brightly stained extensions of the membrane.  
Cell viability was assessed by incubating cells with the live cell stain, calcein AM (1 µM, 
Invitrogen/Molecular Probes) and the dead cell nuclear stain, ethidium homodimer (1 µM, 
Invitrogen/Molecular Probes), for 30 min at 36o.  Cells were washed with aCSF and imaged 
live.  Healthy macrophages with bright green fluorescence were counted.  The unstained 
“ghosts” of dead cells were often visible and were counted separately.  The number of 
ethidium stained nuclei was counted to quantify dead cells with multinucleated cells counted 
as a single cell.  Some ethidium stained cells were observed floating on the surface which 
were difficult to quantify.  Thus, the count of live cells was preferentially used as the best 
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index of cell survival.  Some cultures were fixed with 2% paraformaldehyde and stained with 
100 nM bisbenzimide to assess total and condensed, fragmented, apoptotic nuclei.    
   
Western blots 
Human monocyte-derived macrophages were stimulated with NGF or proNGF for 
time periods of 0, 10, 30, 60 min and 1 day.  At the appropriate time, cells from two 60 mm 
or one 100 mm dish were harvested using 1.5 ml lysis buffer (1X Ripa buffer (Thermo 
Scientific 89900), 1 mM phenylmethylsulfonyl fluoride (PMSF, Pierce Chemicals PI 36978), 
1:100 Halt® protease inhibitor cocktail (Thermo scientific cat# 1861228).  Protein 
concentration was measured by BCA assay (Thermo Scientific 23225). Protein lysate was 
resolved on SDS-Page gels (Biorad cat# 456-1034) and transferred to a nitrocellulose 
membrane (Biorad 162-0112). The membranes were blocked in 2% Bovine Serum Albumin 
(BSA, Sigma BP1605-100), Odyssey Blocking Buffer (1:1 dilution, Licor 927-40000 for 
Odyssey) and PBS or milk plus 0.01%Tween (for film) for one hour at room temperature. 
The primary antibodies were incubated overnight at four degrees. The membranes were then 
washed in PBS+1% Tween and incubated in secondary antibody for one hour at room 
temperature. The membranes were washed again and imaged using the Odyssey or film 
imaging system. The primary antibodies used were 1:500 p75NTR (Millipore 07-476), 1:500 
TrkA (Santa Cruz SC80961), 1:1000 Akt (Cell Signaling 9272S), 1:1000 pAkt (Millipore 05-
1003). Secondary Antibodies were goat anti-rabbit 680RD (Licor 926-68071) and donkey 
anti-mouse 800CW (Licor 926-32212), for Odyssey.  Film was processed using hoseradish 
peroxidase (HRP) conjugated secondary antibody and SuperSignal West Pico detection 
(Thermo Scientific, #34080).   .   
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Phagocytosis of fluorescent beads 
Human MDMs were stimulated overnight in 1% DMEM with NGF or proNGF.  
Fluorescent 1 micron beads (Molecular Probes/Invitrogen F-8887) were placed into each 
well for 4 hours at a concentration of 4.3 x 105 beads/ml. Excess beads not phagocytosed by 
hMDMs were washed from the plate. The hMDMs were stained with the live cell stain 
calcein AM (1 µM, 20 min) and digital images of the live cells were captured at a 
magnification of 674X.  Some cells were then fixed in 2% paraformaldehyde and stained 
with phalloidin-Alexa488 (1:50).  Cells were individually traced and Metamorph software 
was used to measure the number of beads in each cell for each condition.  The bead density 
was calculated by dividing the number of beads by the area of the cell.  The average bead 
density was then calculated and compared between the treatment conditions.   
 
RT-PCR 
The hMDM were stimulated in DMEM with 1% FBS plus NGF or proNGF 
overnight.  Cells were lysed using Trizol Reagent (Invitrogen 15596-026) and RNA was 
purified according to RNeasy protocol (Qiagen cat# 74104). Reverse transcription was 
carried out according to SuperScript III First-strand Synthesis Kit (Invitrogen cat# 18080-
051). The reaction was performed using an ABI 7500 system (Applied Biosystems) and 
Absolute SYBR Green Rox mix (AB-1163/A). mRNA levels were determined by the cycle 
threshold. The results were normalized to GADPH. Primers used were TrkA (Forward: 
5’ATG CTG CGA GGC CAG CGG CA 3’ Reverse:5’ CCT GAC AGG GTC AAG TCC TG 
3’), TrkB (Forward: 5’ CTG GAC CAC GCC AAC TGA CAT 3’ Reverse: 5’ GCA TCG 
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GGC CCG CCC TCC GAA 3’), p75NTR (Forward: 5’ ATC TTG GCT GCT GTG GTT G 3’ 
Reverse: 5’ TGT AGA GGT TGC CAT CAC CC 3’),  GADPH (Forward: 5’ CCC ATC 
ACC ATC TTC CAG GA 3’ Reverse: 5’ TTG TCA TAC CAG GAA ATG AGC 3’).   
 
Transmigration Assay 
Following an overnight stimulation of hMDMs with NGF or proNGF in DMEM with 
1% FBS, cells were harvested by incubating in ice-cold calcium-, magnesium-free HBSS for 
approximately 20-30 minutes to facilitate release of the hMDM from the low adhesion plate.  
Cells were washed from the plate with a 1 ml Rainin pipette using the flow of medium from 
the tip of the pipette to dislodge any remaining cells.  The hMDM were centrifuged at 80 x g 
for 5 min, the supernatant carefully aspirated and the soft pellet was re-suspended in DMEM 
containing 1% FBS.  The cells were counted and seeded into 8.0 micron Matrigel invasion 
chambers (BD Biocoat cat# 354480) at a density of105 cells/chamber.  Migratory behavior 
was measured by the number of cells entering the bottom chamber which also contained 
DMEM with 1% FBS.  Cells in the bottom chamber were labeled with the fluorescent live 
cell marker calcein AM (Life Technologies, C3100MP, 1 µM 20 minutes) and counted at 1 
and 3 days after seeding.    
 
Flow Cytometry 
PBMCs and hMDMs were stimulated with NGF or proNGF in 1% DMEM for 1 hour 
(PBMCs) or overnight (hMDM).  Cells were removed from low adhesion wells and 
centrifuged for 5 minutes at 450 x g. Cellular pellets were re-suspended and fixed in a 
Fluorfix solution (Biolegend 420801) for 20 minutes at room temperature. Fixed cells were 
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then treated with permeabilization buffer (EBioscience 020-8333-56) and centrifuged for five 
minutes at 450 x g at 4o C. The wash step was repeated followed by re-suspension in 100 µl 
of permeabilization buffer plus antibody (1.5 μl p75; Alomone Labs ANT-007-F and 20μl; 
TrkA R&D Systems FAB1715P; 5μl CD 206 Biolegend 321114; 5μl CD16 Biolegend 
302008 and 5μl CD 163 Biolegend 333607) at room temperature for twenty minutes.  The 
stained cells were washed three times in cell staining buffer (Biolegend 420201). Flow 
cytometry was performed on a FACS Calibur (Becton Dickinson, San Jose, CA) using direct 
immunofluorescence with at least 100,000 events. Monocytes were determined by 
populations of cells with high forward scatter and low side scatter. All cells were gated to 
remove debris. Three color staining analysis was utilized. Cells were analyzed according to 
side scatter and receptor bound fluorescence, and data was collected with logarithmic 
amplifiers. Fluorescence spillover compensation was estimated using single-stained and 
unstained samples with the Cell Quest software (BD). After collection, data was further 
analyzed with FlowJo software (TreeStar Inc., Ashland, OR). 
 
Protein profiles of macrophage conditioned medium 
The hMDMs were chronically stimulated for 3 days in 1% DMEM with NGF or 
proNGF.  Medium was collected and centrifuged at 400 X g for 5 minutes to remove any 
floating cells in the medium. The cell free medium was added to a RayBiotech human 
antibody array L-507 and processed according to the RayBiotech Biotin Label-based human 
antibody array protocol. Slide arrays were scanned using an Agilent technologies DNA 
microarray scanner and the analysis was carried out using MetaMorph® software.  Internal 
negative controls were used to establish basal fluorescence and variation across the array.  
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The minimum detectable fluorescence signal was set at 3.2 standard deviation units above the 
average background to give a probability of 0.001 that a protein signal would be identified as 
positive by chance.  The linearity of signal detection was verified from internal positive 
standards.  Since signal intensity varied between different arrays, protein expression was 
normalized to the total signal for all proteins on the array and expressed as a relative optical 
density value to indicate the strength of each signal.  Expression of each protein was 
compared for NGF or proNGF versus matched untreated controls.  A comparison of NGF 
versus proNGF was then run to determine if the pro and mature peptides activate different 
secretory pathways. Proteins on the array that met the cutoff for a significant change were 
clustered into functional groups using DAVID software [188,189] and the relative 
enrichment of various functional classes determined taking into account the focused nature of 
the array.  Based in part on this information, specific functional subgroups were analyzed in 
greater detail to determine which classes of proteins were preferentially modified by NGF or 
proNGF.      
 
Neurotoxicity of macrophage-conditioned medium 
Pilot studies indicated that a 30 minute stimulation of hMDM was sufficient to induce 
secretion of toxic factors which persisted for several hours after removal of the stimulus.  
Thus, the cells could be primed with neurotrophin, washed and the neurotrophin free medium 
subsequently tested for activity.  Macrophages were stimulated with NGF or proNGF in 
serum free DMEM for 30 minutes. The medium was then replaced with serum free DMEM 
and the medium collected after 1 hour or 24 hours.  The macrophage-conditioned medium 
(MCM) was centrifuged at 2500 rpm for 10 minutes to remove any cells and then frozen in 
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aliquots at -80o C.  The neurotoxic activity of the medium was tested on primary rat neurons 
cultured on coverslips.   Neurons at 6-12 days in vitro were loaded with the calcium 
indicator, Fluo-4 AM (2 µM, Molecular Probes, Inc., Eugene, OR) in aCSF (aCSF: NaCl 137 
mM, KCl 5.0 mM, CaCl
2
 2.3 mM, MgCl
2
 1.3 mM, glucose 20 mM).  After 30 minutes, the 
coverslip was transferred to a specialized stage for imaging.  Cells were maintained in aCSF 
and time lapse digital images were captured automatically by the MetaMorph® System.  
Images were captured every 6 seconds for 6 minutes to assess acute effects and every min for 
60 minutes to assess delayed effects.   Three pre-stimulation measurements were taken to 
establish basal levels of fluorescence at the beginning of each experiment.  Neurons were 
stimulated with MCM at a 1:5 dilution. The increase in fluorescence intensity within each 
cell was then measured relative to the baseline fluorescence to correct for cell to cell 
differences in dye loading and intrinsic fluorescence.  For most studies, cellular responses 
were averaged across all cells from at least triplicate runs to provide an indication of the 
“typical” response.  In some cases individual cell response patterns are shown where the 
average masked important cell-specific profiles.    
 
Macrophage calcium responses to NGF and proNGF  
Macrophages cultured on coverslips were incubated with NGF or proNGF and the 
calcium indicator, Fluo-4 AM in aCSF for 30 minutes. Time lapse digital images were 
captured automatically and changes in fluorescence intensity within each cell measured as 
described above.   
Statistical analyses 
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Graphpad Prism software was used for data summaries and graphics.  Parametric 
statistics were used to evaluate most changes induced by NGF or proNGF relative to matched 
or unmatched control samples depending on the experiment.  In cases where the data were 
not normally distributed non-parametric statistics were used.  Means + standard error of the 
mean were calculated for at least three replicate experiments.  T-tests were used for paired 
comparisons, analysis of variance with repeated measures for temporal data and Chi-square 
for the analysis of cell populations as indicated.  Unless otherwise indicated, a probability of 
<0.05 for rejection of the null hypothesis was considered significant.    
Results 
Macrophages display distinctly different morphological phenotypes in culture 
 
In culture, hMDM exhibited different morphologies which were, in part, dependent 
on the culture and stimulation conditions.  Examples of prevalent morphological features are 
summarized in Figure 1.1.  Three major structural features were identified which were found 
to correlate with macrophage phenotype:  1) ruffled membranes on the surface and edges of 
the cell and cellular processes (Fig 1.1A, arrows), 2) “fried egg” morphology with finger-like 
projections along the outer edges of the membrane (Fig 1.1B, arrow) and 3) flat amoeboid 
cells with few readily visible membrane specializations (Fig 1.1C).  The full range of 
morphologies could often be seen in the same culture although under particular stimulus 
conditions a single morphological type typically predominated.  Occasionally, individual 
cells would display a combination of the above features although a single feature would 
usually dominate.  To provide insight into the potential functional role of these 
specializations, each morphological feature was related to particular macrophage phenotypes 
described below. 
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Figure 1.1.  Varied appearance of human monocyte-derived macrophages (hMDM) in 
culture.  A-C. Bright field images of hMDMs in culture illustrating ruffled membranes (A, 
arrows),  flat, fried egg-like morphology with finger like folds in the outer membrane (B, 
arrow) and flat amoeboid appearance with few membrane specializations (C).   Scale bar = 
20 µm in all images.   
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TrkA and p75NTR are co-localized to discrete domains on macrophages 
 
To investigate the expression and localization of neurotrophin receptors, we stained 
hMDMs for each class of neurotrophin receptor. Strong focal expression of p75NTR (Fig 
1.2A) and TrkA (Fig 1.2B) was seen in regions of the macrophages containing ruffles (Fig 
1.2C, arrow) or finger-like membrane specializations (see Fig 1.6).  Although both receptors 
were expressed within the same structural domain, p75NTR expression was typically more 
focal and surrounded by a more diffuse TrkA stain (Fig 1.2D).  TrkA and p75NTR staining 
were also seen in small endosome-like structures throughout the cell (Fig 1.2D, arrowhead).  
TrkB immunoreactivity was low with little or no expression localized to ruffles (Fig 1.2E, 
arrow) and occasional staining in endosomal-like structures (Fig 1.2E, arrowhead). Staining 
for TrkC was consistently negative as were control hMDM stained with secondary antibody 
in the absence of primary antibody (Fig 1.2F). It is notable that the structural specializations 
were highly dynamic.  Even washing the cells too aggressively could trigger changes in 
shape and morphology as well as the ability to detect foci of both p75NTR and TrkA.  It was 
difficult to unambiguously identify staining in large flat cells that had no clear membrane 
specializations (Fig 1.2G, outline of cell marked with dashed lines).  Overall, the percentage 
of macrophages with readily identifiable staining was 47.4% p75NTR-positive and 44.3% 
TrkA-positive.  Macrophage expression of p75NTR and TrkA was confirmed by Western blot 
(Fig 1.2H). RT-PCR also verified mRNA transcript for p75NTR and TrkA with comparable 
delta cycle thresholds for each receptor (11.54 + 0.54 and 11.95 + 0.84, respectively).  
Consistent with the staining results, weak or no significant mRNA expression was detected 
for TrkB or TrkC.   
47 
Since p75NTR and TrkA are potential signaling partners, the extent of co-localization of 
p75NTR and TrkA was determined in double-stained macrophages.  At the whole cell level, 
56.3 + 8.0% of the hMDM expressed both TrkA and p75NTR.  However, to determine if TrkA 
and p75NTR were co-localized to the same microdomains, the overlap of the stained foci was 
determined with a resolution of + 0.46 µm using MetaMorph® software. TrkA was co-
localized to 15.7 + 4.8% of the p75NTR foci (range 4.9 to 33.6%). Some of the co-localization 
of p75NTR and TrkA was seen in small endosome-like structures.  Thus, while p75NTR and 
TrkA were expressed in the same general location in most cells (e.g. Fig 1.2C) only a subset 
of the receptors overlapped.   
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Figure 1.2.  Neurotrophin receptors p75NTR and TrkA were concentrated in discrete domains 
on human macrophages. A-C. A single macrophage stained for p75NTR (A, red), TrkA (B, 
green) illustrating the localization of immunoreactivity to ruffled areas . C. DIC image 
overlay showing the merged receptor stain for p75NTR (red) and TrkA (green) associated with 
membrane ruffles on the surface of the macrophage. D. Highly magnified view of the outer 
membrane of a macrophage showing p75NTR (red) immunoreactivity surrounded by more 
diffuse labeling of TrkA (green). Immunoreactivity for p75NTR and/or TrkA (arrowhead) was 
seen in endosome like structures at these foci as well as throughout the cell. E. 
Immunoreactivity for TrkB was typically weak with little expression at membrane 
specializations (arrow).  However, a few cells showed immunoreactivity in endosome-like 
structures within the cell (arrowhead). F. hMDMs stained with secondary antibody in the 
absence of specific primary antibody showed no significant immunoreactivity. G. hMDM 
with no expression of p75NTR or TrkA within the cell or along the outer membrane 
(membrane border identified with dotted lines).  The cell is adjacent to a stained cell 
illustrating the variable nature of the expression of p75NTR and TrkA. H. Western blots of 
hMDM lysate confirming immunoreactive bands at 75 kDa and 140 kDa for p75NTR and 
TrkA, respectively.   
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p75NTR and TrkA are expressed on monocytes 
 
Expression of p75NTR and TrkA on hMDM was confirmed with flow cytometry using 
a different set of antibodies.  By flow cytometry, 53.0 + 8.5% of the macrophages were p75+ 
and 14.1 + 1.7% was TrkA+.  To explore whether p75NTR and TrkA were also present on 
monocytes, the precursors of mature macrophages, we used flow cytometry to measure the 
expression on freshly isolated PBMCs from healthy donors.  Cells were stained and analyzed 
from seven separate donors with similar results. On average, 59.2 + 14.9% of the gated 
monocyte subset was p75+ and 29.5 + 12.6% was TrkA+.  The p75NTR expression was similar 
to the expression seen on the macrophages whereas TrkA expression was higher on the 
monocytes. The cellular co-localization of p75NTR and TrkA by flow indicated that, on 
average, 88.8% of the TrkA+ monocytes were also positive for p75NTR.  This was slightly 
higher than the 56.3% cellular co-expression seen in the immunostained hMDM.     
   The above results established the expression of p75NTR and TrkA under normal 
culture conditions.  The presence of both p75NTR and TrkA suggested that macrophages may 
be subject to the differential actions of NGF and proNGF as suggested for neurons.  
Therefore, we assessed responses to stimulation with NGF or proNGF to determine how 
these neurotrophins influence the phenotype and functions of the macrophages.  
 
Survival versus death in human monocyte derived macrophages 
 
To determine if neurotrophins support survival of macrophages as they do for 
neurons, hMDM were cultured in serum free medium in the presence or absence of various 
concentrations of NGF (0, 3, 10, 30 or 100 ng/ml).   After 28-32 hours, hMDM  were stained 
with the live cell marker, calcein AM, imaged, and normalized to control hMDM  maintained 
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in medium containing 10% FBS. The percentage of live, healthy hMDMs stimulated with 
NGF in culture medium lacking serum increased in a dose dependent manner from 38.1 + 
10.7% at 0 ng/ml NGF to 101.2 + 6.0% at 100 ng/ml NGF (Fig 1.3A) with an estimated EC50 
of 14.0 ng/ml.  A separate set of hMDM maintained in medium containing 10% FBS and 
stimulated with each concentration of NGF showed no changes at any concentration with a 
mean survival of 100.6 + 2.2% (relative to control hMDMs).  In parallel with the survival 
data, a dose-dependent decrease in ethidium homodimer staining was seen with maximal 
protection at 100 ng/ml NGF (not shown).   
The pro-survival actions of NGF were consistent with the phosphorylation of Akt, a 
known pathway for NGF mediated survival in neurons.  However, as illustrated in Fig 1.3B, 
stimulation with NGF or proNGF both resulted in a time-dependent increase in 
phosphorylation of Akt (33.2 + 7.0% and 69.0 + 31.2%, maximal increase respectively,  
p=0.032) relative to controls, followed by recovery (Fig 1.3B). This suggested that 
neurotrophin receptors p75NTR and TrkA both mediate pro-survival functions on hMDMs.  
 Since signaling of pro-neurotrophins through the p75NTR receptor can promote cell 
death in neurons, we stained hMDMs stimulated with neurotrophins overnight  with the dead 
cell marker ethidium homodimer and then fixed the cells in 2% paraformaldehyde before 
staining with the nuclear stain bisbenzimide to identify all nuclei as well as apoptotic nuclei.  
On average, 10.1 + 1.4% of the untreated hMDM nuclei stained positive for ethidium 
homodimer.  This value did not change significantly after overnight treatment with 1 ng/ml 
proNGF (9.6 + 1.2%) or 100 ng/ml NGF (12.2 + 2.2%) (Fig 1.3C). Condensed and/or 
fragmented nuclei represented 7.2 + 1.1% of the total population in the vehicle-treated cells 
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and also did not change with proNGF or NGF treatment (6.5 + 1.0% and 7.3 + 1.2%, 
respectively; Fig 1.3D).  
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Figure 1.3.  Neurotrophins promote cell survival in hMDMs. A.  NGF increases survival of 
hMDMs in a dose response (0ng/ml,3ng/ml,10ng/ml,30ng/ml and 100ng/ml) manner. 
EC50=14.0ng/ml (n=9). B. Time course (0,10, 30, 60, 240 min) of changes in the ratio of 
pAKT: total AKT levels after addition of 100ng/ml NGF or 1ng/ml proNGF.  
Phosphorylation (activation) of AKT determined from quantification of bands in western 
blots was increased with NGF or proNGF in each of five different runs followed by recovery.  
NGF stimulation resulted in a longer lasting phosphorylation of AKT.  Results are expressed 
as mean + sem. p=0.032 treatment effect over time (n=4). C. Live cultures of treated or 
untreated hMDM were stained with the dead cell marker, ethidium homodimer. The total 
number of dead cell nuclei stained with ethidium was low and was not changed after 1 day 
stimulation with 100ng/ml NGF or 1ng/ml proNGF (n=12).  D. The same cultures of 
hMDMs were fixed and counterstained with the nuclear stain bis-benzamide to reveal 
apoptotic nuclei.  The number of condensed, fragmented apoptotic nuclei was very low and 
did not change after stimulation with 100ng/ml NGF or 1ng/ml proNGF (n=12).  
 
 
Expression of the p75NTR and TrkA in monocytes and macrophages stimulated with NGF or 
proNGF 
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53 
 
To investigate whether neurotrophin stimulation of human monocytes or 
macrophages would alter neurotrophin receptor expression, we stimulated hMDM with 100 
ng/ml NGF or 1 ng/ml proNGF for 24 hours and analyzed receptor expression by flow 
cytometry (Figure1. 4A).  Untreated cells were 53.0 + 8.5% p75+ and 14.1 + 1.7% TrkA+.  
NGF stimulation of hMDMs resulted in a small but significant decrease in p75NTR expression 
relative to both controls (-20.4 + 7.3%, p=0.046) and proNGF (-22.5%, p=0.053). Expression 
of TrkA was not significantly affected (-11.2 + 16.8%).  Treatment with proNGF did not 
have a significant effect on p75NTR or TrkA expression (+2.6 +.08% and +0.6 +13.6%, 
respectively). 
Freshly isolated PBMCs were also stimulated with NGF or proNGF for 1 hour and 
total gated monocytes were analyzed.  Untreated cells were 59.2 + 14.9% p75+ and 29.5 + 
12.6% TrkA+.  NGF and proNGF did not affect p75NTR or TrkA total expression (Figure1. 
4B).  However, as illustrated in Figure 5, monocytes positive for p75NTR (Fig. 1.5A) or TrkA 
(Fig. 1.5B) could be subdivided into two subpopulations expressing low and high receptor 
content.  NGF stimulation slightly increased the proportion of TrkAhigh expressing monocytes 
(Fig 1.5C) compared to both matched controls (+14.1 + 21.6% p=0.021) and proNGF (21.6% 
p=0.02). ProNGF stimulation did not affect the p75high or TrkAhigh populations (Fig 1.5C).   
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 Figure 1.4.  Neurotrophin receptor expression on hMDMs and monocytes quantified by flow 
cytometry. Receptor expression of TrkA and p75NTR was assessed by flow cytometry 
analysis  on cultured hMDMs (A) and freshly prepared human PBMCs (B). A. hMDMs 
stimulated with 1ng/ml proNGF or 100ng/ml NGF for 1 day had no effect on TrkA 
expression. NGF stimulation reduced p75NTR expression (n=7). B. Human monocytes 
stimulated with 100ng/ml NGF or 1ng/ml proNGF for 1 hr showed no significant change in 
total receptor content of p75NTR or TrkA. (n=6).  
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Figure 1.5.  Monocytes expressed high and low levels of p75NTR and TrkA.  Two populations 
of positively labeled neurotrophin receptors were seen by flow cytometry. A. Representative 
histogram of p75NTR low and high populations seen in monocytes relative to unstained cells. 
B. Representative histogram of TrkA low and high populations (dashed lines) seen in 
monocytes relative to unstained cells (solid lines). C. Monocytes stimulated with 100ng/ml 
NGF or 1ng/ml proNGF for 1 hr had no effect on the proportion of p75high expressing 
monocytes. NGF stimulation induced a small but significant increase in monocytes with high 
expression of TrkA. (n=7).     
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 Co-localization of the p75NTR and TrkA on hMDM is influenced by NGF and proNGF 
At the cellular level by flow cytometry we did not see a significant difference in 
p75NTR/TrkA co-expressing cells; however, we sought to understand whether regional co-
localization of p75NTR and TrkA immunoreactivity within individual hMDM was sensitive to 
neurotrophin stimulation.  Cultured hMDMs were double stained for p75NTR and TrkA, and 
the overlap of the staining (Figure 1.6A) was analyzed at a resolution of 0.46 µm (Merged 
inset).  In the absence of stimulation, an average of 15.7 + 4.8% of p75NTR staining co-
localized to TrkA foci (Fig 1.6B).  When the hMDM were exposed to NGF or proNGF, co-
localization of TrkA with p75NTR increased significantly to 60.0 + 2.4% and 30.4 + 5.1%, 
respectively, (p<0.001 for both). The co-localization of p75NTR and TrkA induced by NGF 
was twice that of proNGF, (p<0.001) indicating a preferred mobilization of these receptors to 
the same domain by NGF. The double-labeled profiles were typically seen in ruffled regions 
and small endosome-like structures as described above (Figure 1.2).   
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Figure 1.6.  Neurotrophin receptors p75NTR and TrkA are co-localized to the same 
microdomains on hMDMs.  A. Immunoreactivity of TrkA (green), p75NTR(red) and 
colocalized foci of p75NTR and TrkA ( yellow) found on finger-like membrane specializations 
of hMDMs.  At higher magnification (inset) the partial overlap of p75NTR and TrkA can be 
seen indicating that the two receptors are closely associated but only occasionally within the 
same microdomain.  B. The ratio of TrkA labeling co-localized with p75NTR at a resolution of 
0.46 µm was quantified. 100ng/ml NGF significantly increased co-localization compared to 
control and 1ng/ml proNGF after 1 day.   A smaller yet significant increase in co-localization 
of TrkA and p75NTR was seen with proNGF(n=12).  
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Sortilin receptor expression on hMDM 
A well-recognized action of proNGF in some cell types is fostered by the interaction 
between p75NTR and the sortilin receptor. To determine if sortilin receptors were also present 
on human macrophages, we evaluated its expression by immunostaining.  Sortilin was 
expressed at moderate levels on hMDMs, typically in small focal regions associated with 
ruffles (Figure 1.7A).  A low level of diffuse stain was often seen throughout the cell. High to 
moderate sortilin expression was seen in approximately 43% of the cells whereas 57% of 
cells showed weak staining.  Since the focal expression of sortilin on ruffles was similar to 
p75NTR expression, double staining was performed to co-localize the p75NTR and sortilin 
receptors (Figure 1.7A, Merged and Figure 1.7B).  On average 16.3 + 1.4% of the p75+ foci 
overlapped with sortilin (arrows). However, the degree of overlap within each cell varied 
widely from 0 to 100%.  Most cells (86%) had less than 20% overlap of the two receptors. 
Treatment of the hMDM with NGF or proNGF had differential effects on sortilin expression 
and co-localization with p75NTR.  NGF increased the co-localization of p75NTR with sortilin 
by 104% (Fig. 1.7B, p<0.001) relative to controls and 42.6% relative to proNGF (p<0.001; 
arrows, Fig 1.7B).  ProNGF also significantly increased co-localization relative to controls 
by 49.8% (p<0.001, Fig 1.7B).  Treatment with NGF and proNGF had similar effects on co-
localization of the receptors at 24 hrs indicating that the effects were relatively rapid and 
persistent.  Total sortilin expression, based on the fluorescence stain intensity, was slightly (-
10%) yet significantly reduced by NGF (Fig. 1.7C, p<0.001) but increased 36.8% by 
proNGF relative to controls (Fig 1.7C, p<0.001) and 50.8% relative to NGF (p<0.001).  As 
noted above, these conditions did not lead to an increase in cell death suggesting that 
interactions with sortilin may serve other functions.    
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 Figure 1.7.  Sortilin receptors are expressed and co-localize with p75NTR on hMDMs. A. 
Example of focal immunostaining for sortilin (Red) and p75 (Green) in control hMDM and 
hMDM treated with 100ng/ml NGF or 1ng/ml proNGF for 1 h. B. Overlap of p75 and sortilin 
staining was quantified as in Figure 5.  100ng/ml NGF and 1ng/ml proNGF stimulation 
increased the ratio of sortilin co-localized with p75 (6A arrows) compared to control.  Many 
p75 foci were not co-localized with sortilin (6A;  n=15).  C. Sortilin immunoreactivity 
expression intensity after 1 h stimulation with 100ng/ml NGF or 1ng/ml proNGF was 
quantified in individual cells.  The mean immunoreactive intensity of sortilin was increased 
by proNGF after 1 hour (6A, ProNGF arrow;  n=15).  Results are expressed as mean + sem.   
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Neurotrophin modification of macrophage structure 
 
To view changes in macrophage structure as a result of neurotrophin stimulation, 
cultured hMDM were stimulated with NGF or proNGF for a period of 1 hour or 24 hours 
followed by fixation in 2% paraformaldehyde and staining for F-actin with phalloidin-
Alexa488.  Structural changes were seen within the first hour after stimulation.  Examples of 
the appearance of the hMDMs are illustrated in Figure 1.8A.  F-actin (green) is shown as 
well as the presence of red fluorescent beads which were used to measure phagocytosis (Fig 
1.9A).  Vehicle-treated control cultures initially contained a mixture of cells with podosome-
like structures (22.9% of cells, Fig 1.8A, podosome rich), focal ruffles (37.0% of cells, Fig 
1.8A, ruffled), or no distinctive membrane specializations (40.1% of cells, Fig 1.8A, no 
specializations).  Cells with podosomes often exhibited a highly polarized expression of 
podosomes (Fig 1.8A, polarized).  In untreated cultures similar numbers of ruffled versus 
podosome-containing cells were seen with an average ruffled: podosome ratio ranging from 
0.94 to 1.61.  After 1 hour in the presence of 100 ng/ml NGF, 27.8% of the cells 
predominantly expressed ruffles and 10.5% podosomes, yielding an increased ruffled to 
podosome ratio of 2.65 + 0.06 (Fig 8B, p<0.001, compared to controls). This was largely due 
to a decrease in the expression of podosomes. Stimulation with NGF for 24 hrs resulted in a 
similar ruffled to podosome ratio of 2.14 + 0.06_(Fig 8B, p<0.001 NGF vs. control or 
proNGF) although in this case there was a large increase in the number of hMDM with 
ruffles. After exposure to proNGF for 1 hour the opposite pattern was seen with 44.7% of the 
cells expressing podosomes and 24.2% ruffles decreasing the ruffled to podosome ratio to 
0.54 + 0.14 (Fig 1.8B, p<0.001, vs. Control or NGF).   However, 24 hour stimulation with 
proNGF did not affect the ruffled to podosome ratio relative to controls (Fig 1.8B, 0.83 + 
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0.17 vs. 0.94 + 0.20, respectively).  The effect of NGF on ruffle formation was further 
illustrated by a concentration-dependent increase in the number of cells with ruffles from 
36.4 +4.2% at 0 ng/ml NGF to 79.7 + 7.3% at 100 ng/ml NGF (Fig 1.8C). The increase in 
ruffled cells seen after 100 ng/ml NGF stimulation (62.0+0.46 %, Fig 1.8D, p=0.028) was 
blocked by inhibiting TrkA signaling with a specific inhibitor, GW 441756 (Fig 1.8D, 
p=0.01 NGF vs NGF+ GW 441756). This data indicated that NGF drives the formation of 
actin rich ruffled structure via TrkA signaling in hMDMs.     
Although NGF and proNGF produced different effects on the expression of 
podosomes, both increased the polarization of podosome-like structures after 1 and 24 hours.  
When ranked based on the degree of polarization from 1 (no polarity) to 5 (highly polarized - 
podosomes concentrated in one quadrant of the cell), controls had little polarization (1.25 + 
0.04). After 24 h, NGF- and proNGF-treated cells showed increased polarization (1.71 + 
0.12, p=0.0248 and 2.27 + 0.12%, p<0.001, respectively, Fig 1.8E).  The degree of 
polarization was significantly greater for proNGF versus NGF (p<0.001).  This trend was 
particularly evident in the relative number of cells in the 3-5 polarization categories: 3.38%, 
20.17% and 35.09% for control, NGF and proNGF, respectively.   
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Figure 1.8.  Morphological changes in hMDMs are regulated by neurotrophins. A. hMDMs 
stained with the F-actin marker phalloidin (Green) following phagocytosis of 1micron latex 
beads (Red). Four morphologies were often seen in cultures: hMDMs rich in podosomes 
(podosome rich, arrow), hMDMs containing focal ruffles (ruffled, arrows), hMDMs with no 
significant membrane specializations (no specializations) and polarized hMDM with 
podosomes concentrated at one end of the cell (polarized, arrow).  Small red fluorescent 
beads are visible reflecting phagocytosis summarized below.  B. The expression of ruffles 
versus podosomes in hMDMs changed in opposite directions in response to 100ng/ml NGF 
or 1ng/ml proNGF as summarized by the ratio of ruffled cells to cells predominantly 
expressing podosomes.  An increase in ruffled cells by NGF was seen after 1 and 24 h.  An 
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increase in podosome rich cells was seen 1 h after treatment with proNGF but was not 
sustained. (n=10). C. Dose response increase in the percentage of F-actin rich ruffled 
containing hMDMs after stimulation with various concentrations of NGF 
(0ng/ml,3ng/ml,10ng/ml,30ng/ml,100ng/ml) (n=6). D. 100ng/ml NGF increased the  number 
of cells containing ruffles. Specific inhibition of TrkA signaling with GW 441756 in the 
presence of 100ng/ml NGF decreases the percentage of cell with ruffles compared to NGF 
alone and controls. (n=4). E.  To assess polarization of the hMDMs, cultured cells containing 
podosomes were scored from 1(no polarity) to 5 (high podosome density localized to one 
quadrant of the cell).100ng/ml NGF and 1ng/ml proNGF both increased polarization of 
hMDM after 1 h, and 24 h of stimulation.  ProNGF induced a greater polarization compared 
to NGF. (n=20).    
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Phagocytosis of fluorescent beads 
 
Macrophages are important in removal of cellular debris and infectious agents 
through phagocytosis, and the appearance of ruffles has been associated with calcium-
dependent phagocytic activity[190].  To verify that the ruffled morphological phenotype was 
associated with phagocytic activity, we measured the phagocytosis of 1 micron fluorescent 
beads over a period of 4 hours. Cells were stained with calcein AM for live cell imaging 
and/or fixed and stained with phalloidin to determine ruffled vs non-ruffled cells (e.g. Fig 
1.8A).  Cells containing ruffled specializations phagocytosed more beads (Fig 1.9A) than 
non-ruffled cells (64,295 + 2,825 and 31,552 + 5,861 beads/mm2, respectively * p<0.001).  
 
MDM transmigration across a matrigel barrier 
 
As podosomes have been implicated in migration and invasion, we investigated the 
roles of NGF and proNGF during macrophage migration.  Macrophages were incubated in 
DMEM +1% FBS with or without proNGF or NGF.  An aliquot of 105 cells from each 
condition was added to the upper well of an 8.0 micron matrigel invasion chamber for 1 or 3 
days with similar medium in the lower well.  NGF increased migration but did not reach 
significance relative to untreated controls. ProNGF had no effect on migration after 1 day but 
significantly increased the transmigration of hMDM relative to controls (104.8% increase, 
p=0.051) and NGF treated cells (149% increase, p=0.011) by day 3 (Fig 1.9B). Thus, the 
transmigration of the cells was consistent with the expression and polarization of podosomes 
by proNGF.   
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Figure 1.9. Functional changes by NGF and proNGF. A. Phagocytosis of 1 µm fluorescent 
latex beads (red) by hMDMs with ruffled morphologies was significantly greater than non-
ruffled hMDMs B. The number of migratory hMDMs was increased after 3 days stimulation 
with 1ng/ml proNGF compared to controls or 100ng/ml NGF (n=4).  
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NGF and proNGF regulate intracellular calcium spiking activity in macrophages 
Calcium signaling has been linked to various types of activity in macrophages.  
Macrophages responded to both NGF and proNGF with increases in intracellular calcium but 
the patterns were different.  A plot of the average calcium responses (61-92 cells/condition), 
illustrated in Figure 1.10A, showed that both NGF and proNGF provoked a small acute 
response (Fig 1.10A and B, arrow) that was not seen in vehicle-treated macrophages.  Over 
time, both the untreated and NGF-treated macrophages showed a gradual increase in 
intracellular calcium that was not apparent in the presence of proNGF (Fig 1.10A).  The 
average acute increase in calcium was 32.5 + 3.4 fluorescence units in hMDM stimulated 
with NGF and 34.3 + 8.0 in hMDM stimulated with proNGF (Fig 1.10C, p’s < 0.001 relative 
to control, 1.2 + 1.9). A gradual rise in intracellular calcium over time was seen in 39.1% of 
the control hMDM.   Many fewer cells showed a gradual accumulation in the presence of 
NGF (16.9%) and the gradual rise was almost absent in the presence of proNGF 
(1.6%)(p<0.001, Chi square).  These average response profiles, however, obscured the 
presence of brief calcium spikes that occurred at random intervals.  Comparison of the 
spiking patterns in individual cells showed considerable variation in the magnitude and 
frequency of the calcium responses.  Examples of the various patterns seen are provided in 
Figure 1.10B.  To quantify the different response patterns, we examined the acute responses 
(Fig 1.10C) and spiking frequency (Fig 10D).  The average acute calcium increase was 
significantly greater than controls for both NGF and proNGF (Fig 1.10C).  Calcium spikes 
were seen in 39.1% of the unchallenged hMDM and 39.8% of NGF-treated cells but was 
reduced to 16.4% in the presence of proNGF (p=0.0027, Chi square).  A frequency analysis 
of the individual calcium spike magnitudes indicated that NGF shifted the calcium spikes to 
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higher magnitudes whereas proNGF shifted the responses to lower magnitudes (p < 0.001, 
Chi square).  The spike frequency per cell was also greater for NGF versus proNGF (Fig. 
1.10D, p=0.0149).  Thus, both the number of cells showing calcium changes and the 
temporal nature of the calcium response were altered in different directions by NGF versus 
proNGF.   
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Figure 1.10.  Mature NGF and proNGF have different effects on macrophage calcium 
activity. A. The average intracellular calcium in hMDM following stimulation with aCSF 
gradually increased in the absence of any acute rise.   Incubation of hMDM with 100ng/ml 
NGF induced a small acute calcium response followed by a gradual accumulation over time 
that paralleled the accumulation in controls.  In contrast, incubation of hMDM with1ng/ml 
proNGF induced an acute calcium response similar to NGF but failed to stimulate calcium 
accumulation over time.   B. Calcium traces for individual cells illustrating representative 
patterns of calcium spikes and acute calcium rises (arrows) for control, 100ng/ml NGF and 
1ng/ml proNGF treated hMDMs. C. 100ng/ml NGF and 1ng/ml proNGF treatment of  
hMDMs induced an acute calcium rise after stimulation. D. The frequency of spikes in the 
hMDM was increased by NGF relative to proNGF.   
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Effects of NGF and proNGF on protein secretion 
 
Macrophages secrete a wide array of proteins in response to external cues that reflect 
the diversity of responses of these cells.  To understand the full range of the secretory 
profiles, macrophages were stimulated with NGF or proNGF for 3 days to allow 
accumulation of proteins in the macrophage conditioned medium (MCM).  The medium was 
then analyzed in duplicate for cytokine, chemokine and growth factor content using the Ray 
Biotech L-Series Human Antibody Array L-507. Medium from cells challenged with NGF or 
proNGF were compared to the untreated MCM and to each other to assess individual effects 
and potential differences between the two peptides.  Pre-treatment and post-treatment 
samples were tightly matched with correlations of protein content ranging from r=0.982 to r= 
0.995 indicating that most proteins did not change.  Using the 99.8% confidence limit as a 
cutoff, 9% (46 out of 507 proteins) of the proteins were significantly changed by proNGF 
and 10% (53 out of 507) significantly changed by NGF.   A summary of proteins changed by 
NGF or proNGF is provided in Table 1.1.  Stimulation of secretion was twice as likely as 
suppression suggesting preferential activation of secretory pathways by each peptide. While 
the number of positive proteins was similar, NGF and proNGF induced different secretory 
patterns from the cells with only 10 proteins overlapping.  Of these ten proteins, five (GDF, 
HB-EGF, CXCR2, CCR9, CCR7) changed in opposite directions leaving five for which NGF 
and proNGF produced similar effects. Four proteins were increased by NGF and proNGF 
compared to controls (GCSF-R, IL-17F, IL-29, MIP-1β).  One protein, IL-13, was decreased 
compared to controls for both proNGF and NGF, although the suppression was greater for 
proNGF.  
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To understand the differences in the secretory profiles between NGF and proNGF, 
proteins were segregated into categories by function using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID version 6.7[188,189], a bioinformatics tool. 
Six major functional groups were identified with the following Benjamin scores reflecting 
strength of association:  response to injury (4.8 x 10-13) > inflammatory response (1.4 x 10-9) 
>, chemotaxis (1.1 x 10-6), secretion (4.1x 10-6) > immune regulation (8.5 x 10-4), cytokine 
production (2.0 x 10-4) and angiogenesis (7.1 x 10-3).  Significant “hits” for categories such as 
cytokine production would be expected due to the nature of the array, (cytokine panel) but 
the very high association seen for response to injury and chemotaxis indicated a close 
relationship between the neurotrophins and these functions.  In addition to the above 
categories, it is worth noting that DAVID also identified bone processes as a significant 
functional group for NGF but not proNGF. Conversely, adhesion/virus-associated processes 
were a relevant functional group for proNGF but not NGF. 
Although similar functional groups were identified by DAVID for both NGF and 
proNGF, the minimal overlap of the proteins indicated that the pro and mature forms were 
regulating the pathways in different ways.  To provide a more detailed examination of the 
patterns of protein secretion after NGF or proNGF stimulation, the positive proteins were 
grouped into four major clusters (growth factors, cytokines, chemokines and other proteins) 
with up to seven functional families within each group.  Of the four major clusters, growth 
factors were most highly represented (40/98; 40.8%) followed by cytokines (28/98; 28.6%), 
chemokines (19/98; 19.4%) and other proteins (11/98; 11.2%).  Within the growth factor 
cluster, seven families were assessed (neurotrophic factors, EGF, TGF, FGF, CSF, IGF and 
angiogenic factors).  NGF and proNGF induced very different growth factor secretory 
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profiles, summarized in Table 1.1.  Most of the time a growth factor was altered by one but 
not the other peptide.  The most notable effects of NGF, illustrated in Figure 1.11, were on 
proteins within the TGF family where the largest increases were seen in TGF-β3, GDF11, 
neurturin and follistatin and decreases in GDF3, GDF5 and GDF8.  ProNGF increased 
GDF5, chordin-like 2 and GDF9 and decreased BMPR-IA and GASP-1.  Other notable 
changes (Table 1.1) included increases in FGF-18, FGF-19, IGFI soluble receptor and 
ErbB2.  In contrast, the most notable changes following stimulation with proNGF were 
within the family of angiogenic factors illustrated in Figure 1.12.  Increases were seen in 
factors associated with suppression of angiogenesis: thrombospondin, thrombospondin-1, 
angiostatin.  Decreases were seen in factors that promote angiogenesis:  angiopoieitin, 
angiopoietin-like 1.  No angiogenic proteins were significantly changed with NGF 
stimulation.   Overall, this pattern suggested that proNGF stimulation of hMDMs induced an 
anti-angiogenic environment whereas NGF may regulate a variety of growth functions.         
Chemokine secretion (Table 1.1) was also differentially regulated by NGF and 
proNGF.  Opposing effects (NGF-induced increases, proNGF-induced decreases) were seen 
for CXCL16, CCR9, CXCR2 and CCR7.  Increases in MCP-1, CXCL14, MCP-3, CCL27, 
MIP 2 and CCR4 were seen after stimulation with proNGF relative to NGF.  NGF and 
proNGF both increased secretion of MIP-1β and CXCR1.   
In the cytokine group (Table 1.1), IL17C, IL-17F, IL-17BR, IL-23, IL-23R, IL-24, 
IL-26, IL-27, IL-28A and IL-29 were increased by NGF relative to control or proNGF.  IL-
4R, IL-17F, IL-18R and IL-29 were increased by proNGF.  Notably, IL-13 was decreased by 
both NGF and proNGF while IL-10 was decreased by NGF.  Many of these proteins are in 
the IL-17 family and the changes induced for IL-17 related cytokines by NGF or proNGF are 
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summarized in Figure 1.13.  This pattern suggested that the neurotrophins play a role in the 
secretion of cytokines that regulate immune responses via IL-17 mediated pathways.    
The most notable of other proteins altered by NGF or proNGF (Table 1.1, Fig 1.14) 
were the MMPs.  The relative differences in MMP secretion in response to NGF or proNGF 
are illustrated in Figure 1.14 where a distinct dichotomy is seen between the actions of NGF 
versus proNGF.  NGF selectively induced the release of MMP-7, MMP-8 and MMP-11 
whereas MMP-9 secretion was increased after proNGF stimulation.  MMP-1 did not meet the 
cutoff relative to controls but showed a significant differential increase for NGF relative to 
proNGF.     
Since macrophages are commonly categorized as classically activated (M1) or 
alternatively activated (M2)[26], we examined markers typically used to distinguish these 
phenotypes.  M1 markers were TNF-α, IL-12p70, Il-6, Il-23 IFN-γ, IL-1α,β and IP10.  M2 
markers were IL-4, IL-10, IL-13, TGF-β (1, 2, 3 & 5), and MCP-1.  Changes in the M1 and 
M2 cytokines, plotted from high to low, are illustrated in Figure 15.  The dashed lines show 
the confidence limits for positive or negative changes. The pattern of increases and decreases 
did not reveal a clear inflammatory or anti-inflammatory profile for NGF or proNGF with 
most cytokines showing no change.  The most notable effect of NGF was a decrease in IL-1 
(M1) and IL-10 and IL-13 (M2).  The only increase was for TGF-β3.  Stimulation with 
proNGF did not affect the M1 cytokines.  For the M2 cytokines an increase in MCP-1 and a 
decrease in IL-13 were the only notable effects.    
The lack of a clear M1-like or M2-like effect of NGF and proNGF on 
inflammatory or anti-inflammatory proteins was paralleled by the absence of acute 
changes in the activation markers CD16 and CD163 analyzed by flow cytometry (not 
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shown).  However, a small decrease in cells expressing CD206high was seen in 
monocytes treated with either NGF or proNGF for 1 hour (19.1% in controls to 
12.3% NGF and 10.9% proNGF, p=0.03) suggesting a small shift away from the M2 
phenotype.    
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Table 1.1.  Soluble protein changes in macrophage conditioned medium in response to NGF 
or proNGF.   
 
 
 
 
 
 
 
 
 
 
 
Table 1.1 continued 
Major Families SubFamilies Common Name Protein Name ProNGF NGF
beta- Nerve GrowthFactor beta-NGF -1906 11832
Ciliary neurotrophic factor CNTF -18712 -879
Ciliary neurotrophic factor receptor alpha CNTF R alpha -2373 7573
GDNF family receptor alpha-2 GFR alpha-2 -25026 1454
GDNF family receptor alpha-3 GFR alpha-3 -5592 6571
GDNF family receptor alpha-4 GFR alpha-4 4081 9819
Neurturin Neurturin 855 9621
Angiogenin Angiogenin 10434 -879
Angiogenin-1 Angiopoietin-1 -12531 -409
Angiopoietin-like 1 Angiopoietin-like 1 -70270 2873
Angiostatin Angiostatin 37867 36
Thrombospondin Thrombospondin (TSP) 22839 -879
Thrombospondin-1 Thrombospondin-1 32165 -879
Thrombospondin-2 Thrombospondin-2 -14164 -3587
Osteoactivin Osteoactivin / GPNMB 8 15189
Receptor tyrosine-protein kinase erbB-2 ErbB2 -803 13109
Cripto-1 Cripto-1 -966 -11589
Heparin-binding Epidermal like growth factor HB-EGF 15410 -10820
Neuregulin 2 NRG2 14881 -879
Neuregulin 3 NRG3 26006 5257
Sensory and motor neuron-derived factor/Neuregulin 1 Isoform SMDF / NRG1Isoform 385 9711
Bone morphogenic protein 3 BMP-3 -856 8762
Bone morphogenic protein receptor-1A BMPR-IA / ALK-3 -13242 3412
Chordin-Like 2 Chordin-Like 2 18113 -317
Follistatin Follistatin 151 13139
Growth/ differentiation factor 3 GDF3 -2856 -20946
Growth/ differentiation factor 5 GDF5 20785 -20505
Growth/ differentiation factor 8 GDF8 4214 -10327
Growth/ differentiation factor 9 GDF9 9003 -3250
Growth/ differentiation factor 11 GDF11 670 16710
Transforming growth factor-beta 3 TGF-beta 3 539 9859
Bone morphogenic protein receptor-1B BMPR-IB / ALK-6 -1841 7282
Fibroblast growth factor receptor 4 FGF R4 -15624 187
Keratinocyte growth factor FGF-7 / KGF 1430 -14409
Fibroblast growth factor-13 1B FGF-13 1B -10447 -337
Fibroblast growth factor-18 FGF-18 1507 28892
Fibroblast growth factor-19 FGF-19 -4230 11039
Fibroblast growth factor-11 FGF-11 -5817 -12787
Granulocyte colony-stimulating factor GCSF 14252 -2688
Granulocyte colony-stimulating factor receptor G-CSF R / CD 114 16035 9283
IGF Insulin-like growth factor 1 Soluble Receptor IGF-I SR -649 8704
Growth Factors
Neurotrophin
Angiogenic
EGF
TGF
FGF
CSF
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Shaded values represent significant changes in protein secretion by NGF or proNGF relative 
to matched control medium.  Values are expressed as relative fluorescence units.  Nine 
proteins showed strong differentials for NGF versus proNGF although no individual changes 
were seen relative to control (unshaded).    
 
Major Families SubFamilies Common Name Protein Name ProNGF NGF
Interferon-gamma IFN-gamma -1563 9178
Interleukin-1 alpha IL-1 alpha 7040 -21787
Interleukin-26 IL-26 -6437 27520
Interleukin-27 IL-27 -2125 11950
Soluble glucoprotein 130 sgp130 -566 -10926
Oncostatin M OSM -23091 -910
Interleukin-1 beta IL-1 beta -1625 -10394
Interleukin-4 receptor IL-4 R 66873 -879
Interleukin-10 IL-10 4650 -19883
Interleukin-13 IL-13 -22859 -11407
Interleukin-13 receptor alpha 1 IL-13 R alpha 1 -1344 10114
Interleukin-10 receptor alpha IL-10 R alpha -771 -9682
Interleukin-22 IL-22 9719 -1403
Interleukin-24 IL-24 -1352 34953
Interleukin-28A IL-28A -2606 31042
Interleukin-29 IL-29 28702 26242
Tumor necrosis factor receptor superfamily member 5 CD40 liagand / TNFSF5 / CD154 12839 2302
Lymphotoxin beta receptor Lymphotoxin beta R / TNFRSF3 -514 14473
Tumor necrosis factor ligand superfamily member 13 April 10082 863
Interleukin-17B receptor IL-17B R -1742 25671
Interleukin-17C IL-17C -1552 17632
Interleukin-18-binding protein a IL-18 BPa -2343 -12256
Interleukin-18 receptor alpha IL-18 R alpha (IL-1 R5) 37642 -4101
Interleukin-21 receptor IL-21 R 1289 -13178
Interleukin-23 IL-23 -6551 6152
Interleukin-23 receptor IL-23 R 143 22000
Galectin-4 Galectin-4 -18362 0
Interleukin-17F IL-17F 10426 17047
Interleukin-8 IL-8 -10328 -879
Monocyte Chemoattractant Protein-1 MCP-1 12636 -879
Monocyte Chemoattractant Protein-3 MCP-3 18210 -620
Macrophage inflammatory protein-1b MIP-1b 24631 13195
Macrophage inflammatory protein-2 MIP 2 34862 -514
C-C chemokine receptor type 4 CCR4 39880 1276
C-C chemokine receptor type 7 CCR7 -36858 25721
C-C chemokine receptor type 9 CCR9 -25369 12536
C-C chemokine ligand 27 CTACK / CCL27 25312 -879
C-X-C chemokine ligand 14 CXCL14 / BRAK 12268 -2114
C-X-C chemokine ligand 16 CXCL16 -16041 8315
C-X-C chemokine receptor type 1 CXCR1 / IL-8 RA 25821 7695
C-X-C chemokine receptor type 2 CXCR2 / IL-8 RB -32262 27759
C-X-C chemokine receptor type 6 CXCR6 524 13340
C-X-C chemokine ligand 1 GRO 3051 -13418
Human CC chemokine-4 HCC-4 / CCL16 -2532 -16397
Lymphotactin Lymphotactin / XCL1 -1283 -13629
Monokine induced by gamma interferon MIG -14265 -879
C-X-C chemokine ligand 1 GRO-a 704 9793
Matrix metalloproteinase-7 MMP-7 350 17410
Matrix metalloproteinase-8 MMP-8 -2563 10171
Matrix metalloproteinase-9 MMP-9 31915 -879
Matrix metalloproteinase-11 MMP-11 (Stromelysin-3) -3399 9606
Matrix metalloproteinase-1 MMP-1 -965 8110
Intercellular Adhesion Molecule-1 ICAM-1 9536 -2207
Sialic acid-binding Ig-like lectin-9 Siglec-9 -7361 -16393
Leukemia inhibitory factor receptor alpha LIF R alpha -4998 5291
Inhibin B Inhibin B -443 15725
Growth and differentiation factor-associated serum protein 1 GASP-1 / WFIKKNRP -12014 1903
Other
MMP
Adhesion 
Misc.
Inflammatory
Inflammatory
Anti-Inflammatory
TNF
Il-17
Chemokines Chemokines
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Figure 1.11.  Changes in TGF-β family proteins in macrophage conditioned medium induced 
by NGF or proNGF. Values represent the change in fluorescence signal intensity on the 
protein array for NGF or proNGF treated cells relative to matched control medium collected 
prior to stimulation.  Differential effects of 100ng/ml NGF and 1ng/ml proNGF were seen for 
most proteins.  Significance limit for the difference scores was +9207 fluorescence units.   
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Figure 1.12.  Changes in angiogenesis family proteins in macrophage conditioned medium 
induced by NGF or proNGF.  Values represent the change in fluorescence signal intensity on 
the protein array for 100ng/ml NGF or 1ng/ml proNGF treated cells relative to matched 
control medium collected prior to stimulation.  Only proNGF induced changes in this family 
of proteins.   Significance limit for the difference scores was +9207 fluorescence units.   
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Figure 1.13.  Changes in IL-17 family proteins in macrophage conditioned medium induced 
by NGF or proNGF.  Values represent the change in fluorescence signal intensity on the 
protein array for 100ng/ml NGF or 1ng/ml proNGF treated cells relative to matched control 
medium collected prior to stimulation.  Differential effects of NGF and proNGF were seen 
for most proteins except IL-17F where both NGF and proNGF increased expression.   IL-23 
showed a large differential between NGF vs. proNGF but individually was not significant 
relative to controls.  Significance limit for the difference scores was +9207 fluorescence 
units.   
 
 
  
79 
M
M
P
-1
 
M
M
P
-7
 
M
M
P
-8
 
M
M
P
-9
 
M
M
P
-1
1
-20000
0
20000
40000 NGF
ProNGF
F
lu
o
re
s
c
e
n
c
e
 C
h
a
n
g
e
 
 
Figure 1.14.  Changes in MMP family proteins in macrophage conditioned medium induced 
by NGF or proNGF.  Values represent the change in fluorescence signal intensity on the 
protein array for 100ng/ml NGF or 1ng/ml proNGF treated cells relative to matched control 
medium collected prior to stimulation.  NGF selectively increased MMP-7, 8, and 11 
whereas proNGF induced a selective increase in MMP-9.  MMP-1 showed a significant 
differential relative to proNGF.   Significance limit for the difference scores was +9207 
fluorescence units.     
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Figure 1.15.  Release profile of proteins typically associated with M1 (inflammatory) or M2 
(anti-inflammatory) macrophage polarization in response to NGF or proNGF.  The dashed 
line represents the magnitude of change needed to be considered significant.  100ng/ml NGF 
suppressed the release of several proteins (IL-1α,β, IL-10 and IL-13) and increased TGF-β3.  
1ng/ml ProNGF affected the release of only two proteins, an increase in MCP-1 and a 
decrease in IL-13.  Overall, there was no strong trend toward either an M1 or M2 phenotype.   
Significance limit for the difference scores was +9207 fluorescence units (dashed lines).   
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Neurotoxic activity of the hMDM 
 A prominent response of macrophages to inflammatory stimuli is the secretion of 
factors that are toxic to neurons [191-196].  Since neurotrophins are prominent in the nervous 
system we evaluated the ability of the neurotrophins to modulate toxic activity in the 
macrophage conditioned medium (MCM).  Cells were stimulated with NGF or proNGF for 
30 min, washed and medium from the conditioned cells was collected after 1 or 24 hours.  
Toxicity of the MCM was tested on rat cortical/hippocampal neurons pre-loaded with the 
calcium indicator dye Fluo-4.  Previous studies have shown that macrophages activated by 
inflammatory stimuli release factors that injure neurons via a destabilization of intracellular 
calcium [197,198].   The effects of the pre-conditioned MCM on calcium regulation are 
illustrated in Figure 1.16.  MCM from hMDM pre-treated with proNGF resulted in a large 
acute calcium rise followed by partial recovery and then a delayed calcium increase which 
correlated with the appearance of cell damage in the form of focal varicosities.  MCM from 
cells pre-treated for 30 minutes with NGF showed a larger acute calcium response but no 
significant delayed rise relative to untreated hMDM.  Conditioned medium collected 24 
hours after a 30 minute neurotrophin pre-treatment showed negligible calcium responses for 
both NGF and proNGF (2.2-11.3% of the maximum rise seen in the 1 hour samples) 
indicating that the toxic effect of proNGF decays over time.  Removal of the proNGF was 
necessary for the decay of activity since continuous treatment with proNGF for 24 hour 
resulted in similar toxic effects.  Medium collected after prolonged stimulation with NGF 
showed some toxic activity albeit at a reduced level relative to proNGF.   Thus, proNGF 
provoked the secretion of neurotoxic substances from the macrophages whereas NGF had 
little effect.   
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Figure 1.16.  Mature and proNGF have opposing effects on the secretion of neurotoxic 
factors by hMDM.  Toxic effects on calcium regulation were monitored by measuring acute 
(every 6 s for 6 min) and delayed changes in intracellular calcium (every min for 60 min).   
A-B. Conditioned medium from hMDMs stimulated with 100ng/ml NGF or 1ng/ml proNGF 
was collected and placed onto cultured rat cortical neurons to assess calcium dysregulation. 
Macrophages were pretreated with neurotrophins to establish a change in phenotype and then 
washed and incubated for 1 h in serum free DMEM to generate the macrophage conditioned 
medium (MCM).   A. Addition of MCM at a dilution of 1:5 resulted in an acute increase in 
calcium for both proNGF and NGF treated cells.  NGF caused a larger acute increase 
compared to proNGF. Delayed accumulation of calcium which correlates with the 
development of structural pathology was induced by MCM from proNGF treated cells but 
not NGF-treated cells.  Basal calcium levels are illustrated for neurons treated with aCSF.  B. 
Conditioned medium collected 1 day after treatment failed to provoke significant changes in 
intracellular calcium.  Data points are mean + sem. 
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Discussion 
Trk and p75NTR expression on hMDM 
As early as 1996 Levi-Montalcini introduced the idea that neurotrophins may regulate 
the immune response[177]. Since this early observation, a few studies have explored 
neurotrophin receptor gene transcript expression and immunoreactivity in cells of monocyte 
lineage [169,172,178-184].  These studies showed neurotrophin receptor expression on 
macrophages but the specific receptor profiles have been variable depending on the tissue 
and conditions. For example, Hikawa et al. [199] found no Trk receptors in alveolar 
macrophages whereas Nakajima et al. [178] reported 99% of rat microglia were 
immunoreactive for all neurotrophin receptors and Garaci et al. [171] found 30% of HIV-
infected macrophages were immunoreactive for TrkA and 15% for p75NTR.  In our study of 
hMDM, we found that 47.4% were immunoreactive for p75NTR and 44.3% for TrkA.  TrkB 
was expressed at a much lower level and we observed no significant staining of TrkC.   
Receptor expression varied from cell to cell suggesting that different phenotypes may be 
expressed in vitro and in vivo depending on local influences.  Nakajima et al. [178] noted a 
similar variable neurotrophin receptor expression in rat microglia.  However, we also noted 
that morphological specializations associated with receptor foci were quite labile and 
changed rapidly in response to various challenges emphasizing the dynamic nature of these 
features.  
We compared the expression levels of neurotrophin receptors on monocytes, the 
circulating precursors of macrophages, and found that 59% and 29% were positive for 
p75NTR and TrkA receptors, respectively.  High and low p75NTR and TrkA expressing 
populations of monocytes could be distinguished but separate populations were not evident 
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for the macrophages.  Overall, the expression of p75NTR was not altered after differentiation 
of the monocytes to macrophages whereas the expression of TrkA may increase.   
In neurons, Trk receptors can form homodimers or heteromeric complexes with p75. 
The strong co-localization of both TrkA and p75 to actin rich membrane specializations in 
the form of ruffles or finger-like folds on the outer extremities of the cells and the increase in 
overlapping stained foci induced by NGF indicated that these receptors are poised for 
interactions.  Only a subset of the receptors were precisely co-localized at the membrane 
folds and within small endosome-like structures in untreated cells but this increased 
substantially with neurotrophin stimulation.  The endosome-like structures were typically 
positive for either p75NTR or TrkA with a smaller subset positive for both.  This pattern was 
consistent with more detailed studies of endosomal trafficking where p75NTR and TrkA were 
found to predominantly associate with different endosomes [200].  Although not pursued in 
the current study, TrkB staining was occasionally seen in these endosome-like structures 
suggesting some capacity for BDNF signaling in the hMDM.   
A large literature on the actions of NGF and proNGF in neurons has highlighted the 
opposing effects of the pro-form versus mature neurotrophin [185].  Prominent among these 
effects is the ability of proNGF to induce apoptosis in neurons when p75NTR associates with 
sortilin [137,201] and the ability of NGF engagement with TrkA/p75NTR to promote 
survival[121].  The current studies indicated that, like neurons, separate signaling pathways 
exist for the regulation of innate immune responses.  
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NGF and proNGF induce different functional macrophage phenotypes 
A limited number of studies have identified functional effects of NGF on 
macrophages.  NGF has been shown to increase SDF-dependent migration in human 
monocytes[202], enhance TNF production in mouse macrophages after lipopolysaccharide 
(LPS) stimulation[180]  and increase macrophage viability during HIV infection[171].   In 
our study we found that NGF increased the co-localization of TrkA and p75NTR in hMDM, 
promoted phosphorylation of Akt, and increased survival in serum free medium.  NGF also 
induced ruffling of the macrophages in culture where neurotrophin receptors were found to 
be enriched. The role of p75NTR and TrkA accumulation at these membrane specializations is 
not well understood.  Patel et al. (2008) suggested that the ruffling of the membrane was 
associated with phagocytic activity [203].  Indeed, the ruffled cells in our studies showed 
significantly more phagocytic activity than non-ruffled cells. Other studies in macrophages 
and microglial cells have shown that increases in intracellular calcium were necessary for 
cytokine and chemokine release [204] and that calcium spikes, in particular, were correlated 
with ruffled actin structures and increased phagocytosis [205-207]. In our study, NGF caused 
an acute calcium rise followed by small random calcium spikes in a subset of cells.  A 
gradual increase in the basal calcium level was also seen in untreated and NGF-treated 
hMDM that in microglia has been associated with a decrease in LPS-stimulated cytokine 
secretion[204].   Calcium oscillations have been documented in mouse peritoneal 
macrophages during attachment and spreading of the cell [206] and in greater than 40% of 
mouse bone marrow-derived macrophages during phagocytosis[205].  Increases in 
intracellular calcium are often tightly linked to modifications of the actin cytoskeleton.  In 
the RAW 264.7 mouse macrophage cell line, spontaneous polarization and migration are 
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associated with influx of extracellular calcium at the leading edge of movement.  The 
calcium increase was necessary for maintenance of F-actin and the ruffled membrane via a 
PI3K-dependent pathway [208].  Ruffled areas were associated with the accumulation of 
signaling molecules suggesting that these structures were hotspots for local signaling.  In 
particular these studies suggest that the neurotrophin receptors might be involved in cell 
migration.  In contrast to the leading edge calcium signaling, calcium spikes are thought to be 
dependent on release of calcium from intracellular stores [205,206] which are necessary for 
phagocytosis and membrane ruffling. The role of the calcium spikes seen in response to NGF 
are not known have a potential role in the induction of membrane ruffles and increased 
phagocytosis.    
   The effects of proNGF on hMDM function differed substantially from the effects of 
NGF.  No effects were seen on neurotrophin receptor co-localization relative to controls 
following stimulation with proNGF indicating that the pro-neurotrophin does not promote 
interactions between p75NTR and TrkA.  ProNGF was also closely tied to changes in the 
cytoskeleton but, in contrast to NGF, induced the expression of podosome-like structures.  
The podosomes often accumulated in one quadrant of the cell suggesting a polarization that 
might be associated with migration.  This possibility was supported by the transmigration of 
an increased number of proNGF-treated hMDM across the transwell Matrigel barrier and the 
lack of an effect on phagocytosis.  The calcium response to proNGF also differed from NGF.  
Although a similar acute rise in calcium was seen, the calcium spikes were greatly reduced 
relative to NGF and control cells.  The reduction was often due to a rundown of spike 
frequency over time and correlated with the loss of membrane ruffles.   
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An important effect of proNGF signaling that might be anticipated could be through 
the interaction of the p75NTR receptor with sortilin a known signaling partner in neurons 
[201,209].  Only a couple studies have explored sortilin receptor content and function on 
cells of the mononuclear phagocyte lineage.  Sortilin expression was observed on the cell 
membrane of peritoneal macrophages and bone marrow derived macrophages of rats [210]. 
Sortilin expression was also found in a microglial cell line, C13NJ. Stimulation of these cells 
with neurotensin, another endogenous ligand of sortilin, resulted in Akt-dependent extension 
of actin rich filopodia and migration [211]. We found that sortilin receptors localized to the 
same ruffled regions as the neurotrophin receptors and the expression of sortilin receptors 
was increased in the presence of proNGF while NGF slightly decreased its expression.  A 
small proportion of the sortilin receptors co-localized with p75NTR.  However, this co-
localization was increased by both proNGF and mature NGF.  In neurons sortilin/p75NTR 
signaling after engagement with proNGF often leads to apoptosis of the cell [201]. In the 
macrophages, proNGF did not induce cell death.  Unexpectedly, proNGF, like NGF, 
increased phosphorylation of Akt.  A similar effect was seen in microglial cell lines treated 
with the sortilin ligand neurotensin [211,212].  Although the sortilin-mediated death pathway 
has been studied extensively in neurons, sortilin participates in other less studied cellular 
processes such as sorting of proteins in the Golgi compartment [201] and anterograde 
transport of neurotrophin receptors to enhance neurotrophin signaling [213].  While we 
cannot rule out a potential role in cell death, our results suggest that sortilin receptors may 
have alternative functions in macrophages.    
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Differences in hMDM secretory profiles induced by NGF and proNGF 
Secretion of proteins is a primary macrophage function in defense and repair. Of the 
507 proteins assessed, approximately 20% changed in response to NGF or proNGF, 
emphasizing the extensive response diversity of these cells. The ability of NGF and proNGF 
to activate very different secretory responses indicated that the neurotrophins are capable of 
shifting macrophage phenotype.  In the characterization of the responses, it is notable that the 
highest scoring functional group using the bioinformatics tool DAVID was response to 
injury. The next highest scoring groups were inflammatory response, chemotaxis and 
secretion, all consistent with the structural and functional changes in the cells.  Many studies 
have categorized macrophages into two or three distinct groups based on their secretory 
profiles and receptor content [26].  Categorizing the response based on classical pro-
inflammatory (M1) and anti-inflammatory (M2) cytokines provided little insight into the 
actions of the neurotrophins as neither peptide induced a clear M1 or M2 secretory profile.  
We also failed to see changes in surface receptors CD16 or CD163 although NGF stimulation 
produced a slight downregulation of CD 206, an M2 marker in monocytes. These results 
along with many other studies have shown that macrophages express a wide variety of 
phenotypes that extend beyond these two subgroups [214]. Our study in particular indicated 
that specific protein changes tended to segregate into four alternative functional groups:  
growth factors, IL-17 family, angiogenic factors and matrix metalloproteases.  
The functional group most affected by proNGF and NGF was growth factors.  This 
response highlights the potential importance of neurotrophins in the control of protective and 
restorative properties of macrophages in disease processes [215].  While 
macrophages/microglia have previously been shown to secrete neurotrophic factors 
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[171,178] our profile indicated that other growth factors may be important factors used by 
these cells.  Most prominent were proteins in the TGF-β family including TGF-β3, growth 
and differentiation factors (GDF3, 5, 8, 9 and 11) and neurturin.  Like the neurotrophins, 
these proteins play a prominent role in growth and differentiation of the nervous system.  
Most were affected by NGF and the few that were changed by proNGF were invariably in the 
opposite direction as NGF, again highlighting the opposing actions of the pro and mature 
forms of the peptide.  Little is known about the potential contribution of these growth factors 
to macrophage and microglial associated tissue protection and should be further explored.   
Another family of growth factors that control angiogenesis was almost exclusively 
affected by proNGF.  ProNGF increased angiostatin, thrompospondin and thrombospondin -
1, factors that inhibit angiogenesis while also decreasing factors that promote angiogenesis, 
angiopoietin and angiopoietin-like 1. Many studies have reported NGF’s positive role in 
angiogenesis [216] however proNGF’ s role is less understood.  A potential role of the 
p75NTR has been suggested in some studies. The p75NTR may be particularly important in 
suppression of tumor metastasis mediated by NGF as p75NTR expression was inversely 
proportional to formation and metastasis of satellite tumors induced by NGF.  [217]. 
Together these results suggest that macrophages respond to proNGF, perhaps through the 
p75NTR, by the induction of anti-angiogenic activity.   
IL-17 cytokines share structural features with NGF [218] and are involved in host 
defense against extracellular bacterial and fungal infection[219] as well as the pathogenesis 
of autoimmune inflammatory diseases[220].  The IL-17 family of cytokines was affected 
predominantly by NGF.  With the exception of IL-17F where NGF and proNGF both 
stimulated an increase, the effects of the two neurotrophins were different. To our 
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knowledge, no study has examined the effects of NGF on IL-17 levels. However, IL-17 
stimulation of human PBMCs upregulates NGF mRNA levels and PBMCs isolated from 
relapse-remitting multiple sclerosis patients had reduced levels of NGF after IL-17 
stimulation [221]. This suggested that IL-17 may influence secretion of NGF and is likely to 
be a fruitful area which could reveal new insights into regulation of neuroinflammation.   
The dichotomy between the actions of NGF versus proNGF persisted for the MMP 
family of proteins.  NGF upregulated secretion of MMP-1, MMP-7, MMP-8, and MMP-11 
but had no effect of MMP-9 which was strongly upregulated by proNGF.   The secretion of 
MMPs by macrophages is thought to be mediated in part by podosomes.  Since proNGF 
induced the formation of podosome-like structures in the hMDM, a strong correlation with 
MMP secretion was expected.  MMP 2 and 9 have been localized to podosomes [222].  
However, only MMP-9 was increased by proNGF.  Secretion of MMP-9 at neuronal 
synapses is thought to support synaptic plasticity although excess levels can impair long term 
potentiation (LTP) [223].  Excess secretion in response to proNGF may contribute to the 
deleterious effects of proNGF in the CNS.  Increases in MMP-7 in the CSF have been 
associated with brain atrophy in HIV-infected patients [158].  In vitro, MMP-7 has been 
shown to induce atrophy of neuronal synapses via inhibition of vesicle recycling [224].  
While this would suggest that MMP-7 secretion in response to NGF is deleterious, a study by 
Le et al. [156] indicated that the MMP-7 had a protective function during kainic acid-induced 
seizures by converting proNGF to NGF.  More work is needed to clarify the role of 
macrophage-derived MMP-7.  Given the many functions of monocytes and macrophages, the 
differential regulation of MMPs by NGF and proNGF may have widespread relevance to 
CNS damage, tumorigenesis, atherosclerosis and other diseases[225,226].   
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Neurotrophins regulate neurotoxic activity of hMDM 
Macrophage infiltration and/or microglial activation often play a key role in the 
etiology of neuronal damage during neurodegenerative diseases such as Alzheimer and HIV 
associated dementia (HAD) [227]. The neuropathology has been linked in some cases to the 
secretion of soluble factors that are toxic to neurons [228,229].  Our understanding of the 
signaling that gives rise to the pathological actions of macrophages/microglia is poor and 
considerable effort has been invested to identify therapeutic approaches that control 
macrophage/microglial activation in neurodegenerative diseases. Changes in the ratio of 
NGF to proNGF in degenerative diseases such as Alzheimer disease correlate with disease 
progression and support the idea that a decrease in the ratio of mature, pro-survival 
neurotrophins to the proneurotrophins is detrimental [230-232].  The different actions of pro- 
and mature NGF in our studies indicated that the balance of pro- and mature forms may also 
differentially influence the toxic activity of macrophages/microglia.  Our assessment of the 
neurotoxic activity of macrophage-conditioned medium using calcium homeostasis as a 
sensitive endpoint indicated that a brief exposure to proNGF induced the secretion of toxic 
factors.  A large delayed calcium dysregulation was seen in neurons treated with MCM 
which mimicked the toxic activity seen after viral infection of macrophages [197].  
Conditioned medium from macrophages stimulated with NGF did not cause the same 
calcium dysregulation in spite of a similar acute rise in calcium.  These observations indicate 
that the dichotomy between the effects of NGF versus proNGF extend to differences in the 
ability of the macrophages to exert toxic effects on vulnerable target tissues.  These 
differences have important implications for the control of macrophage activity by 
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neurotrophins and indicate that p75NTR and TrkA signaling pathways may be fertile ground 
for the development of strategies to regulate macrophage phenotypes that impact 
neurodegenerative diseases.   
 
Conclusions  
These studies provide an initial characterization of the ability of neurotrophins to 
influence the phenotype of macrophages.  Both NGF and proNGF induce changes in the 
actin cytoskeleton which favor ruffling of the membranes or formation of podosomes, 
respectively.  Ruffles appear to be a focal point for the expression of p75NTR and TrkA.  NGF 
supported phagocytosis, calcium spiking, ruffle formation, phosphorylation of Akt and the 
release of growth factors, IL-17 related cytokines and various MMPs.  In contrast, proNGF 
facilitated transmigration, podosome formation and the secretion of anti-angiogenic factors, 
MMP-9 and factors that induce toxicity in neurons.  Like neurons, macrophages are poised to 
respond to pro- and mature neurotrophins in different ways.  These functional differences 
offer the potential for the development of therapeutic approaches that adjust the balance 
between beneficial and deleterious macrophage functions.  
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CHAPTER 3: NEUROTROPHINS MODULATE MACROPHAGE RESPONSES TO 
HIV 
 
Introduction 
Macrophages and microglia play a pivotal role in the development of HIV-associated 
neurological disease.  Soon after HIV infection, activated monocytes infiltrate the central 
nervous system where they differentiate into perivascular macrophages.  These perivascular 
macrophages are CD16+/CD163+ and harbor a greater viral burden than other cells in 
brain[30].  It is believed that viral replication by these macrophages spreads to microglia 
creating a slowly replicating, protected reservoir of virus in the brain leading to chronic 
inflammatory activation of these cells with an accompanying secretion of neurotoxins 
[191,192,233].  Much of the current work on these cells strives to identify the macrophage-
derived toxins responsible for neural damage and to develop strategies to suppress the toxic 
activity of the macrophages.  This effort is complicated by the fact that macrophages are 
known to be dynamic cells that can secrete pro-inflammatory cytokines, anti-inflammatory 
cytokines, enzymes that modify extracellular proteins and/or growth factors depending on 
their external cues [234].  Thus, an understanding of the impact of the macrophage response 
to HIV must take into consideration both the positive and negative actions.  This is important 
from a therapeutic perspective since increasing evidence indicates that appropriate 
interventions may be capable of shifting the balance of activity to decrease damage while at 
the same time taking advantage of the macrophage’s natural ability to protect and repair 
tissues.  
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Studies of cultured monocyte-derived macrophages (MDM) in Chapter 2 have shown 
that MDM robustly expressed neurotrophin receptors TrkA and p75NTR and respond 
differently to mature nerve growth factor (NGF) and pro-NGF.  NGF facilitated a ruffle-
bearing phenotype, active calcium signaling and the secretion of proteins associated with 
growth and repair, and phagocytosis without driving the cells toward a classical M1 or M2 
phenotype.  In contrast, proNGF favored podosome formation, reduced calcium activity, 
migration and an anti-angiogenic and neurotoxic secretory profile.   
In HIV-infected humans several studies have shown that neurotrophin levels are 
decreased in brain suggesting a deficit in neurotrophin signaling[235], a scenario similar to 
other neurodegenerative diseases such as Alzheimer disease where decreases in the ratio of 
NGF to proNGF correlate with disease progression [230,232,236] [237].  The idea that 
alterations in neurotrophin signaling may contribute to degeneration in the diseased nervous 
system is supported by studies showing that neurotrophins and related ligands are protective 
in models of HIV-associated neuropathogenesis and Alzheimer disease[153,238-241].   
While the presumed effects of these treatments were on neurons our demonstration of 
neurotrophin receptors on macrophages raised the possibility that an alteration in 
macrophage neurotrophin signaling may contribute significantly to the disease process.  
Studies have also suggested that NGF may alter CXCR4 expression, the receptor for SDF 
and co-receptor to HIV but there is conflicting data on the role of NGF in HIV replication in 
macrophages[171,174,175].  A major function of both the neurotrophin receptors and the 
chemokine receptors is to modify the cytoskeleton and data in Chapter 2 indicated substantial 
overlap in the morphological features induced by each.  Indeed the known interactions of 
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HIV with CXCR4 suggested activation of signaling pathways associated with podosome 
formation that might be similar to the effects of proNGF.  Since the polarization of 
cytoskeletal changes seen with the neurotrophins suggested the possibility for functional 
overlap with HIV signaling we hypothesized that mature NGF promotes an anti-
inflammatory, neuroprotective macrophage phenotype that counterbalances excessive 
inflammatory activation induced by HIV and/or proNGF.   The following studies evaluated 
the response of macrophages to HIV and potential interactions with neurotrophin receptor 
stimulation.  
Materials and Methods 
Isolation and culture of human monocyte-derived macrophages 
Human buffy coat leukocytes were purchased and shipped within 24 hours after blood 
draw from healthy donors at the New York Blood Center (http://nybloodcenter.org/), a non-
profit organization specific for the collection and distribution of blood for clinical and 
research purposes. All research use was screened by the center and no personal identifiers 
were sent with the shipment. Such use is exempt from review  under NIH guidelines, 
exemption 4 of 46-101(b). Blood was diluted 1:1 with phosphate buffered saline (PBS) and 
was layered on top of Ficoll-Paque (GE Healthcare 17-1440-03). Blood/Ficoll-plaque was 
centrifuged at 500 X g for 25 min and the peripheral blood mononuclear cells (PBMCs) were 
collected from the PBS/Ficoll-Paque interface.  PBMCs were washed in red blood cell lysis 
buffer (Sigma R7757) to remove any red blood cell contamination. PBMCs were centrifuged 
at 450 X g, the supernatant aspirated and the pellet re-suspended in Dulbecco’s modified 
eagle medium (DMEM) with high glucose, 10% fetal bovine serum (Gibco 160000-044) and 
20 µg/ml gentamicin (Gibco 15750-60).  Cells were aliquoted into low adhesion 6 well plates 
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(Corning 3471) at a density of approximately 107 cells/well. PBMCs were cultured for 5-7 
days to allow monocyte attachment. Remaining white blood cells were washed, from the 
plate yielding a pure monocyte/macrophage culture.  The adherent cells were differentiated 
into monocyte-derived macrophages (hMDM) using human GM-CSF (15 ng/ml) in complete 
DMEM for one week.  Monocyte experiments were carried out within 1 hour of PBMC 
isolation to prevent cell attachment.   
Primary cultures of rat forebrain 
All animal work was done in accordance with NIH animal welfare guidelines and was 
approved by the University of North Carolina- Chapel Hill Institutional Animal Care and Use 
Committee board (approval number 14-147.0). Timed gestational embryonic day 9 (E9) 
pregnant female Long-Evans rats were delivered from Charles Rivers and allowed to rest in 
UNC animal husbandry until time of experiments. At gestational day E17, rats were 
sacrificed by anesthetizing with isoflurane drop method until breathing and heart stopped. A 
thoracotomy was then performed prior to removal of the fetal material. For primary neuronal 
cultures, fetal material was rinsed in 70% ethanol and placed in HEPES-buffered Hank's 
balanced salt solution (HBSS) on ice for anesthesia before removal of the brain. The tissue 
was extensively washed and the cortex/hippocampus was dissected from each brain and 
cleaned of Dura-arachnoid membrane and visible vessels. The tissue was transferred to a 15 
ml tube containing 5 ml calcium-magnesium free-HBSS + 2.4 U/ml dispase + 2 U/ml DNase 
I and incubated for 25-30 min at 36° C.  Tissue was triturated and allowed to settle for 2 min.  
The suspended cells were transferred to a 50 ml culture tube containing 25 ml of minimum 
essential medium (MEM) with glutamine + 10% fetal bovine serum + 20 µg/ml gentamicin.  
After several rounds of trituration in 2-3 ml calcium-magnesium free HBSS, dissociated cells 
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were seeded at a density 20,000 cells/cm
2
 on poly-D-lysine-treated coverslips for imaging 
and staining or 50,000-100,000 cells/cm2 in 100 mm plastic dishes for Western blots.  After 
24 hours, cultures were transferred to Neurobasal medium with B27 supplement.  The 
resulting cultures were >90% neurons at day 4 after seeding.  
 
Immunostaining 
Differentiated hMDM grown on poly-D-lysine coated coverslips were transferred to 
DMEM containing 1% FBS and stimulated for 1 or 24 hours using three different conditions: 
HIV (106virion/ml), HIV +NGF human recombinant protein (100 ng/mL, Sigma N1408), 
HIV +proNGF human recombinant protein targeted to high affinity sites (1 ng/ml, Alamone 
N-280), or vehicle (aCSF).  The cells were gently washed and fixed in 2% paraformaldehyde 
in PBS.  Cells were washed 3X in PBS and incubated in 3% normal goat serum for one hour. 
Incubation of primary antibodies was carried out overnight at 4o C. Cells were stained using 
antibodies to: p75NTR (Millipore cat #07-476, 1:500), TrkA (Santa Cruz cat #SC-80961, 
1:500) and sortilin (Millipore AB9712, 1:500). Cells were washed in PBS and incubated with 
species specific secondary antibodies conjugated to Alexa 488, 568 or 593 (Molecular 
Probes) in the dark for 1 hour at room temperature.  F-actin was stained using Alexa488 or 
rhodamine conjugated phalloidin (1:50, Molecular Probes) to show structural changes.  
Coverslips were then mounted using Fluoromount (Southern Biotech 0100-01) and digitally 
imaged on an Olympus XI71 microscope.   
Analysis of stain intensity for individual cells or regions of interest within the cells 
was accomplished using Metamorph software.  Co-localization of p75NTR foci with TrkA 
or sortilin staining was analyzed by staining one receptor red and the other green followed by 
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thresholding by intensity of stain, computer identification of stained objects and then 
documentation of each object’s central X/Y coordinate for each wavelength.   Objects with 
X/Y coordinates that overlapped within 0.46 microns were scored as co-localized. 
 
Western blots 
Human monocyte-derived macrophages were stimulated with HIV for time periods of 
0 min, 10 min.  At the appropriate time, cells from two 60 mm or one 100 mm dish were 
harvested using 1.5 ml lysis buffer (1X Ripa buffer (Thermo Scientific 89900), 1:100 
phenylmethylsulfonyl fluoride (PMSF, Pierce Chemicals PI 36978), 1:100 Halt® protease 
inhibitor cocktail (Thermo scientific cat# 1861228).  Protein concentration was measured by 
BCA assay (Thermo Scientific 23225). Protein lysate was resolved on SDS-Page gels 
(Biorad cat# 456-1034) and transferred to a nitrocellulose membrane (Biorad 162-0112). The 
membranes were blocked in 2% Bovine Serum Albumin (BSA, Sigma BP1605-100), 
Odyssey Blocking Buffer (1:1 dilution, Licor 927-40000 for Odyssey) and PBS or milk plus 
0.01%Tween (for film) for one hour at room temperature. The primary antibodies were 
incubated overnight at four degrees. The membranes were then washed in PBS+1% Tween 
and incubated in secondary antibody for one hour at room temperature. The membranes were 
then washed again and imaged using the Odyssey or film imaging system. The primary 
antibodies used were 1:500 p75NTR (Millipore 07-476), 1:500 TrkA (Santa Cruz SC80961). 
Secondary Antibodies were goat anti-rabbit 680RD (Licor 926-68071) and donkey anti-
mouse 800CW (Licor 926-32212), for Odyssey.  Film was processed using hoseradish 
peroxidase (HRP) conjugated secondary antibody and SuperSignal West Pico detection 
(Thermo Scientific, #34080).   .   
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Phagocytosis of fluorescent beads 
Human MDM were stimulated overnight in 1% DMEM with HIV, HIV+ NGF or 
HIV+proNGF.  Fluorescent 1 micron beads (Molecular Probes/Invitrogen F-8887) were 
placed into each well for 4 hours at a concentration of 4.3 x 105 beads/ml. Excess beads not 
phagocytosed by hMDMs were washed from the plate. The hMDMs were stained with the 
live cell stain calcein AM (1 µM, 20 min) and digital images of the live cells captured at a 
magnification of 674X.  Some cells were then fixed in 2% paraformaldehyde and stained 
with phalloidin-Alexa488 (1:50).  Cells were individually traced and Metamorph software 
was used to measure the number of beads in each cell for each condition.  The bead density 
was calculated by dividing the number of beads by the area of the cell.  The average bead 
density was then calculated and compared between the treatment conditions.   
 
Transmigration Assay 
Following an overnight stimulation of hMDMs with HIV, NGF+NGF or 
HIV+proNGF in DMEM with 1% FBS, cells were harvested by incubating in ice-cold 
calcium-, magnesium-free HBSS for approximately 20-30 minutes to facilitate release of the 
hMDM from the low adhesion plate.  Cells were washed from the plate with a 1 ml Rainin 
pipette using the flow of medium from the tip of the pipette to dislodge any remaining cells.  
The hMDM were centrifuged at 80 x g for 5 min, the supernatant carefully aspirated and the 
soft pellet was re-suspended in DMEM containing 1% FBS.  The cells were counted and 
seeded into 8.0 micron Matrigel invasion chambers (BD Biocoat cat# 354480) in the 
incubation medium at a density of105 cells/chamber.  Migratory behavior was measured by 
the number of cells entering the bottom chamber which also contained DMEM with 1% FBS.  
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Cells in the bottom chamber were labeled with the fluorescent live cell marker calcein AM 
(Life Technologies, C3100MP, 1 µM 20 minutes) and counted at 1 and 3 days after seeding. 
 
Flow Cytometry 
PBMCs and hMDMs were stimulated with HIV, HIV+NGF or HIV+proNGF in 1% 
DMEM for 1 hour (PBMCs) or overnight (hMDM).  Cells were removed from low adhesion 
wells and centrifuged for 5 minutes at 450 x g. Cellular pellets were re-suspended and fixed 
in a Fluorfix solution (Biolegend 420801) for 20 minutes at room temperature. Fixed cells 
were then treated with permeabilization buffer (EBioscience 020-8333-56) and centrifuged 
for five minutes at 450 x g at 4o C. The cell pellet was re-suspended in permeabilization 
buffer and centrifuged at 450 X g at 4o C. Cells were re-suspended in 100 µl of 
permeabilization buffer plus antibody (1.5 μl p75); Alamone Labs ANT-007-F and 20μl; 
TrkA R&D Systems FAB1715P; 5μl CD 206 Biolegend 321114; 5μl CD16 Biolegend 
302008 and 5μl CD 163 Biolegend 333607) at room temperature for twenty minutes.  The 
stained cells were washed three times in cell staining buffer (Biolegend 420201). Flow 
cytometry was performed on a FACS Calibur (Becton Dickinson, San Jose, CA) using direct 
immunofluorescence with at least 100,000 events. Monocytes were determined by 
populations of cells with high forward scatter and low side scatter. All cells were gated to 
remove debris. Three color staining analysis was utilized. Cells were analyzed according to 
side scatter and receptor bound fluorescence, and data was collected with logarithmic 
amplifiers. Fluorescence spillover compensation was estimated using single-stained and 
unstained samples with the Cell Quest software (BD). After collection, data was further 
analyzed with FlowJo software (TreeStar Inc., Ashland, OR). 
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Protein profiles 
Conditions for the analysis of secreted proteins were established to maximize the 
detection of toxic activity as described. The hMDMs were chronically stimulated for 3 days 
in 1% DMEM with HIV, HIV+NGF or HIV+proNGF. Medium was collected and 
centrifuged at 400 X g for 5 minutes to remove any floating cells in the medium. The cell 
free medium was added to a RayBiotech human antibody array L-507 and processed 
according to the RayBiotech Biotin Label-based human antibody array protocol. Slide arrays 
were scanned using an Agilent technologies DNA microarray scanner, and the analysis was 
carried out using Metamorph software.  Internal negative controls were used to establish 
basal fluorescence and variation across the array.  The minimum detectable fluorescence 
signal was set at 3.2 standard deviation units above the average background to give a 
probability of 0.001 that a protein signal would be identified as positive by chance.  The 
linearity of signal detection was verified from internal positive standards.  Since signal 
intensity varied between different arrays, protein expression was normalized to the total 
signal for all proteins on the array and expressed as a relative optical density value to indicate 
the strength of each signal.  Expression of each protein was compared for HIV versus 
untreated controls.  A comparison of HIV to NGF+HIV and proNGF+HIV was then run to 
determine if the pro and mature peptides interact differently with HIV. Proteins on the array 
that met the cutoff for a significant change were clustered into functional groups using 
DAVID software [188,189] and the relative enrichment of various functional classes 
determined taking into account the focused nature of the array.  Based in part on this 
information, specific functional subgroups were analyzed in greater detail to determine which 
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classes of proteins were preferentially modified by HIV in the presence or absence of NGF or 
proNGF.   
 
Neurotoxicity of macrophage-conditioned medium 
Pilot studies indicated that a 30 minute stimulation of hMDM was sufficient to induce 
secretion of toxic factors which persisted for several hours after removal of the stimulus.  
Thus, the cells could be primed with neurotrophin, washed and the neurotrophin free medium 
subsequently tested for activity.  Macrophages were stimulated with NGF or proNGF in 
serum free DMEM for 30 minutes. The medium was then replaced with serum free DMEM, 
the cells were challenged with HIV and the medium collected after 1 hour or 24 hours.  The 
macrophage-conditioned medium (MCM) was centrifuged at 2500 rpm for 10 minutes to 
remove any cells and then frozen in aliquots at -80o C.  The neurotoxic activity of the 
medium was tested on primary rat neurons cultured on coverslips.   Neurons at 6-12 days in 
vitro were loaded with the calcium indicator, Fluo-4 AM (2 µM, Molecular Probes, Inc., 
Eugene, OR) in aCSF (aCSF: NaCl 137 mM, KCl 5.0 mM, CaCl
2
 2.3 mM, MgCl
2
 1.3 mM, 
glucose 20 mM).  After 30 minutes, the coverslip was transferred to a specialized stage for 
imaging.  Cells were maintained in aCSF and time lapse digital images were captured 
automatically by the Metamorph System.  Images were captured every 6 seconds for 6 
minutes to assess acute effects and every min for 60 minutes to assess delayed effects.  Three 
pre-stimulation measurements were taken to establish basal levels of fluorescence at the 
beginning of each experiment.  Neurons were stimulated with MCM at a 1:5 dilution. The 
increase in fluorescence intensity within each cell was then measured relative to the baseline 
fluorescence to correct for cell to cell differences in dye loading and intrinsic fluorescence.  
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For most studies, cellular responses were averaged across all cells from at least triplicate runs 
to provide an indication of the “typical” response.  In some cases individual cell response 
patterns are shown where the average masked important cell-specific profiles.    
HIV suppresses macrophage calcium activity 
Macrophages cultured on coverslips were incubated with 100 ng/ml NGF or 1 ng/ml 
proNGF and the calcium indicator, Fluo-4 AM in aCSF for 30 minutes. Time lapse digital 
images were captured automatically every 6 sec for 20 min and changes in fluorescence 
intensity within each cell measured as described above. 
Statistical analyses 
Graphpad Prism software was used for data summaries and graphics.  Parametric 
statistics were used to evaluate most changes induced by HIV +NGF or proNGF.  In cases 
where the data were not normally distributed non-parametric statistics were used.  Means 
were calculated for at least three replicate experiments and the standard error of the mean 
calculated.  T-tests were used for paired comparisons, analysis of variance with repeated 
measures for temporal data and Chi-square for the analysis of cell populations.  The 
statistical values in the text represent results from t-tests unless otherwise indicated.  A 
probability of <0.05 for rejection of the null hypothesis was considered significant unless 
otherwise indicated.    
Protein array data was analyzed in a stepwise fashion with increasing stringency.  
First, negative controls on the arrays were used to establish variation within the array.  A 
value 3.2 standard deviation units above and below the mean was calculated and represented 
the threshold values for a significant increase or decrease.  This set the confidence limit at 
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0.001 so there was only one chance in 1000 that a protein would meet the cutoff by chance.  
The proteins that were significantly increased or decreased by these criteria were then 
analyzed using DAVID software to identify functional groups. For comparisons between two 
conditions, a linear regression analysis was performed to provide an index of how well the 
arrays matched.  This analysis assumed that the majority of proteins on the array would not 
be changed by the challenge.  The data fit this assumption well with all correlations 
exceeding an r value of 0.9.  Proteins that deviated from the linear regression could then be 
identified on scatter plots as well as by the differential expression between challenge and 
control conditions.  To increase the stringency we then asked how well the changes in protein 
expression could predict the neurotoxicity of the medium using the maximum delayed 
increase in intracellular calcium.  A cutoff representing strong correlations was set at 2.3 
standard deviations above 0 (p<0.001) based on the correlation matrix for all proteins across 
all of the defined functional categories on the array.      
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Results  
p75NTR and TrkA expression in the presence of HIV and neurotrophins  
In chapter 2 we identified the expression and localization of neurotrophin receptors 
p75NTR and TrkA on human monocyte derived macrophages and monocytes. To assess 
whether HIV could regulate the expression p75NTR and TrkA, monocyte derived 
macrophages were exposed to HIV virions for 24 hours followed by flow cytometry analysis. 
Under normal conditions, 53.03 +8.5% of macrophages expressed p75NTR and 14.1 + 1.7% 
expressed TrkA.  Exposure to HIV virions failed to significantly influence the expression of 
p75NTR (45.2 +8.5 % of cells,17.3% decrease, p=0.08) or TrkA (11.6 + 2.0% of cells,17.7% 
decrease). Similarly, 59.2 + 14.9% of monocytes expressed the p75NTR and 29.5 + 12.6% 
expressed TrkA.  Exposure of HIV virions for 1 hour did not change the expression of p75 
and TrkA on monocytes.   
Interactions between p75NTR and TrkA have been widely studied in neurons but little 
is known about their interactions in macrophages. The p75NTR and TrkA are located in 
overlapping actin rich regions of hMDM (Figure 2.1A, p75NTR-green, TrkA, red, yellow 
shows overlap). To assess the potential for p75NTR and TrkA to interact in hMDMs, TrkA 
was precipitated from hMDM protein lysate. Western blot analysis with an antibody specific 
to the p75NTR identified a 75kDa band in the immunoprecipitated complex confirming that 
TrkA formed complexes with the p75NTR (Fig 2.1B). This interaction was not changed in 
hMDMs during exposure to HIV. Flow cytometry analysis confirmed that 71.0% of TrkA 
expressing hMDMs co-expressed p75NTR.  At a cellular level, exposure to HIV for one day 
did not affect the proportion of cells co-expressing TrkA and p75NTR (65.5%  p75 on TrkA). 
We then sought to determine if regional co-localization of p75NTR and TrkA within 
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individual hMDMs was altered by HIV exposure. Cultured hMDM were double stained for 
p75NTR and TrkA, and the overlap of the staining was analyzed at a resolution of 0.46 µm.  In 
the absence of stimulation, an average of 15.9+ 2.7% of p75NTR and TrkA foci were 
overlapping in cells. HIV stimulation increased the overlap of p75NTR/TrkA foci  to 56.4 + 
0.5% in hMDM (Fig 2.1C; p<0.001) indicating that HIV exposure induced a translocation of 
the receptors into overlapping domains, consistent with data from neurons showing that these 
receptors normally interact to influence the efficiency of TrkA signaling [118]. 
 In previous studies stimulation of hMDM with NGF greatly increased the co-
localization of p75NTR and TrkA.  To determine if HIV interacted with the neurotrophins to 
influence the receptor association we also measured overlap of p75NTR+ with TrkA+ foci 
after co-stimulation with HIV+NGF or HIV+proNGF(Figure 2.1C).  NGF+HIV and 
proNGF+HIV both increased co-localization of p75NTR and TrkA in hMDMs by 132.1% and 
343.4%, respectively compared to control cells (p<0.005 vs control for both).  However, 
when compared to HIV alone, the overlap was reduced by 34.6% for NGF+HIV (p=0.006) 
and increased 47.7% for proNGF+HIV (p=0.002) indicating a small synergistic relationship 
with proNGF and antagonistic relationship with NGF.  
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Figure 2.1 .TrkA and p75NTR interactions are increased by HIV in hMDMs. A . A 
representative picture of p75NTR (green) and TrkA (red) expression on macrophages . p75NTR 
and TrkA foci are in adjacent and overlapping domains  (Inset: yellow regions). B. TrkA was  
immunoprecipitated  from hMDM lysate. Western blot analysis identified a 75kDa band with 
a p75NTR specific antibody.  The p75NTR and TrkA complexes were not changed in hMDM 
with HIV exposure. Regional overlap of p75NTR and TrkA  foci was increased in HIV 
exposed hMDM. NGF costimulation with HIV reduced TrkA/p75NTR  overlap compared to 
control while proNGF synergistically increased this HIV effect (n=6).  
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HIV increases p75 and Sortilin co-localization  
Because of the relatively robust expression of p75NTR on the macrophages, we 
examined the expression of other receptors known to partner with p75NTR.  Sortilin, a well-
known signaling partner with p75NTR, was also expressed at high to moderate levels in 43% 
of hMDMs. Sortilin foci were located in similar domains and overlapped 30.7 + 0.3% of the 
p75NTR+ foci.  HIV had no effect on sortilin expression (Figure 2.2A) but induced a small 
39.3% increase in the overlap of p75NTR stained foci with sortilin (Figure 2.2B; p=0.015). 
NGF and proNGF had opposing effects on sortilin expression on hMDM’ s exposed to HIV 
although the magnitude of the changes was quite small.  NGF+HIV stimulation increased 
sortilin expression by 10.16% (p<0.05) compared to hMDMs only exposed to HIV. 
ProNGF+HIV, however, were not different than hMDMs treated with HIV alone. Also the 
addition of NGF or proNGF to HIV did not significantly affect the increased co-localization 
of sortilin and p75NTR induced by HIV. This data suggested that although HIV may not have 
the ability to regulate neurotrophin and sortilin expression, it fosters interactions between 
p75NTR with signaling partners TrkA and sortilin, creating an optimal environment for 
potential divergent signaling in response to the natural ligands NGF and proNGF, 
respectively.   
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Figure 2.2. HIV  increases Sortilin/p75NTR interaction without altering sortilin expression . A 
HIV  and the costimualtion of proNGF +HIV has no effect on sortilin Expression. Co-
stimulation with NGF and HIV increases sortilin expression in hMDMs while proNGF. B. 
HIV increases the p75NTR/sortilin foci overlap in hMDMs. HIV co-stimulation of hMDMs 
with NGF  or proNGF did not affect this p75NTR/sortilin overlap (n=5).  
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HIV does not trigger death in hMDM 
Since signaling of pro-neurotrophins through the p75NTR and sortilin receptor can 
promote cell death [134,242], we stained hMDMs stimulated with HIV, 100ng/ml NGF+HIV 
or 1ng/ml proNGF+HIV overnight with the dead cell marker ethidium homodimer and then 
fixed the cells in 2% paraformaldehyde before staining with the nuclear stain bisbenzimide to 
identify all nuclei as well as apoptotic nuclei.  No difference in dead cells was seen with 
ethidium bromide staining in any conditions (Figure 2.3; 10-12% loss under all conditions).  
Condensed and/or fragmented nuclei stained with bisbenzimide were seen in 7-10% of 
unstimulated MDM or MDM exposed to HIV or NGF+HIV (Figure 2.3B). Cultures co-
stimulated with proNGF+HIV showed a small but significant increase to 16% ( p=0.01 vs 
HIV). This indicated that HIV does not cause cell death in hMDM but may synergize slightly 
with proNGF to induce apoptosis in a small proportion of cells (6%).  
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Figure 2.3. HIV does not cause cell death in hMDMs.  A .No changes in total cell death in 
hMDMs stimulated with HIV, 100ng/ml NGF+HIV or 1ng/ml proNGF+HIV overnight with 
the dead cell marker ethidium homodimer. B. Fixed hMDM stained with bisbenzimide 
showed no change in the number of fragmented nuclei after exposure to HIV or 100ng/ml 
NGF+HIV. 1ng/ml proNGF+HIV induced a small increase in the presence of apoptotic 
nuclei in culture (n=12). 
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HIV suppresses macrophage calcium activity 
Macrophages in culture show a low intrinsic rate of small calcium spike generation.  
Our data in the previous chapter showed that NGF increased and proNGF suppressed the rate 
of calcium spiking in the macrophages.  HIV interactions with chemokine receptors have also 
been shown to increase intracellular calcium in cultured human macrophages [103].  The 
calcium accumulation was due to opening of a non-selective cation channel which was 
blocked by the CRAC channel blocker, lanthanum. The calcium accumulation triggered the 
tyrosine phosphorylation of proline rich tyrosine kinase 2 (Pyk2), a protein kinase linked in 
other studies to the expression of podosomes[243]. Natural chemokine ligands also induced 
calcium responses but had different effects than gp120 suggesting a unique interaction.  
However, in these studies the nature of the calcium signaling was not documented.  To better 
understand the effects of HIV on intrinsic and NGF-induced increases in calcium spikes we 
loaded hMDM with Fluo-4 and measured the frequency of spikes over a 20 min interval.  
Examples of the patterns of calcium spikes are illustrated in Figure 2.4C as the composite 
activity of 10 adjacent cells that provide a representative view of the mean responses under 
each condition.  No evidence was seen for synchronization of the spike patterns.  Untreated 
hMDM had an average intrinsic spiking rate of 0.263 + 0.025/min (Figure 2.4B ).  This was a 
slight underestimate of the actual rate in active cells since only 76% of the cells showed 
significant spikes.  Exposure to HIV virions decreased the average spike rate to 0.088 + 
0.011/min (p<0.001).  This was due to both a decrease in the spike frequency and number of 
cells that showed spiking behavior (46.4%).  When HIV was added in the presence of NGF 
the rate was increased to 0.382 + 0.091 (p<0.001).  ProNGF+HIV were not significantly 
113 
different from HIV alone.  Since the calcium spikes were random the patterns were lost in the 
average data across all cells (Figure 2.4A).  The averaged responses showed a small, gradual 
accumulation of intracellular calcium in vehicle treated (aCSF) hMDM which was also 
evident in the hMDM treated with HIV+NGF.  Stimulation with HIV alone induced a small 
acute increase in intracellular calcium (arrow) which recovered after approximately 1.5 min.  
The gradual rise in intracellular calcium was significantly lower than untreated cells.  In the 
presence of HIV+proNGF intracellular calcium decreased over a period of 7-8 min and then 
increased but failed to reach baseline levels over the 20 min time period. These data indicate 
that although stimulation of hMDM with HIV results in a small acute influx of calcium, there 
is a suppression of ongoing calcium spiking. This suppression was reversed by co-treatment 
with NGF. 
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Figure 2.4. HIV and neurotrophins altered the pattern of calcium responses in human 
monocyte-derived macrophages (hMDM).  A. Mean changes in intracellular calcium in 
hMDM.  Treatment with HIV virions suppressed the gradual increase in average intracellular 
calcium levels seen in vehicle treated hMDM (aCSF).  Addition of NGF to the HIV 
challenged hMDM partially restored the calcium accumulation whereas proNGF with HIV 
provoked a large decrease in calcium.  B.  Average spike frequencies within individual cells 
was greatly suppressed by HIV (and was completely reversed by co-stimulation with NGF 
(n=10).  C.  Examples of the spiking patterns for a composite of 10 cells treated with aCSF, 
HIV, NGF+HIV or proNGF+HIV.  HIV decreased the number of spikes reaching the scoring 
criterion (dashed line).  NGF+HIV increased the frequency of spikes whereas proNGF 
decreased the frequency of spikes. 
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Modification of macrophage structure 
Because of the mobility and diverse phenotypes of macrophages, the regulation of 
actin structures is extremely important. Findings in Chapter 2 showed that NGF and 
proNGF induced very different structural phenotypes.  To assess changes in actin structures 
induced by HIV and potential interactions with the neurotrophins, cultured hMDM were 
stimulated with HIV, NGF+HIV or proNGF+HIV in serum free medium for one hour or 
overnight , fixed with 2% paraformaldehyde and stained with phallodin-Alexa488 to 
visualize F-actin. After 1 hr, 37.0 + 5.1% of untreated cells possessed ruffles (Fig 1.8A 
Ruffled) while 22.9 + 3.0% were rich in podosomes  (Fig 1.8A, Podosome).  A significant 
number of cells lacked distinctive specializations (40.1 + 4.6%, Fig1.8A, No 
specializations).   The day after medium exchange most untreated cells exhibited 
specializations with an almost equal mix of cells with ruffles (50.7+0.3%) versus cells with 
podosomes (46.9+0.3%).  HIV stimulation increased the relative number of macrophages 
possessing podosomes at 1 hour (55.9% increase, p=0.03) relative to the untreated cells (Fig 
2.5A). Many of the podosome rich cells also exhibited an increased polarization of the 
podosomes (Fig 1.8A, Polarized) based on a five point scoring system ranging from a 
uniform distribution of podosomes (1=no polarization) to a large collection of podosomes 
restricted to one quadrant of the cell (5= high polarization).  Untreated macrophages had 
little polarization (1.32+0.4, Figure 2.5B ) while HIV treated cells showed increased 
polarization (1.78 + 0.7, p<0.001, 1h ).   
The changes in macrophage actin structures after HIV exposure recapitulated changes 
previously seen in response to proNGF suggesting the activation of common pathways and 
the possibility that neurotrophins might modify the response to HIV. We therefore evaluated 
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the interactions between HIV and mature NGF or proNGF.  The addition of NGF to the HIV 
challenged cells reduced podosome expression to control levels (Figure 2.5A; p=0.03).  
Also, the increased polarization of podosomes by HIV at 1 hour was reversed by treatment 
with NGF (Figure 2.5B; p<0.001).  Co-stimulation with proNGF + HIV had no effect on 
podosomes relative to HIV alone at 1 hour.(Figure 2.5A) but did provoke a small increase 
the HIV induced degree of polarization by an additional 16.8% over HIV alone (1.7 to 2.1, 
p=0.002; Figure 2.5B).  Since the changes in structural phenotypes correlated with changes 
in the calcium responses, hMDM from eight experiments were segregated into groups by 
morphological phenotype, (podosome vs. ruffled) and the corresponding calcium activity 
evaluated.  Flat, amoeboid podosome bearing cells showed a suppressed rate of calcium 
spiking activity relative to cells with ruffles as illustrated in Figure 2.5C. On average ruffled 
cells displayed 2.6 times the spike frequency of podosome bearing cells 0.287 + 0.043/min 
vs. 0.108 + 0.022/min, p< 0.001).  In addition, it has been suggested that calcium entry 
through CRAC channels may activate a signaling pathway associated with the formation of 
podosomes so we also pretreated the cultures with the CRAC/Trp channel antagonist YM 
58483.  Overall, there was no significant effect on the proportion of cells expressing 
podosomes suggesting that the CRAC channel is not involved in HIV induced podosome 
formation.     
 
Podosome formation is p75NTR-dependent 
Since HIV and proNGF both increased podosome expression in hMDMs we 
evaluated neurotrophin receptor involvement in HIV induced podosome formation. 
Stimulation of hMDM with HIV resulted in an increase in the proportion of cells expressing 
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podosomes from 0.261 + 0.039 to 0.536 + 0.042 (Figure 2.5A) When the p75NTR was 
blocked with a neutralizing antibody the effect of HIV was not only blocked but the 
proportion of cells expressing podosomes was reduced below control levels to 0.105 + 
0.031(p<0.01).  Blockade of TrkA with the specific inhibitor GW441756 did not have a 
significant effect on HIV-induced podosome expression (0.479 + 0.041, Figure 2.5D).  These 
data indicated that HIV induced podosome formation is dependent on p75 signaling and not 
TrkA.  
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Figure 2.5.  Podosome expression and calcium activity in hMDM.  A.  HIV increased the 
relative proportion of hMDM expressing podosomes.  This effect was blocked by NGF 
whereas proNGF had no effect (n=20).  B.  The degree of polarization of podosomes 
paralleled the expression in A with HIV and proNGF+HIV showing increased polarization 
(n=20).  C.  The HIV-induced increase in podosome expression was blocked by inhibition of 
the p75NTR but not TrkA (n=10).  D. Measurement of intrinsic calcium spike frequency in 
cells expressing ruffles was significantly higher than cells expressing podosomes (n=20). 
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HIV induces Migration of hMDMs 
Stimulation of macrophages with HIV protein, Nef, has been shown to induce 
podosomes and migratory activity[244].  Stimulation of hMDMs with HIV increased 
migration across a transmembrane well by 93.2 + 0.4% compared to controls (p=0.013; 
Figure 2.6A). Co-stimulation with NGF or proNGF did not have any additional effect on 
HIV induced migration.  
 
HIV has no effect on phagocytic activity in hMDMs  
 Phagocytosis is one of the main functions of macrophages and has been correlated 
with cell ruffling [245].  Since HIV decreased the ruffled phenotype in culture we asked if it 
also suppressed phagocytic activity.  One micron red fluorescent beads were added to 
macrophage cultures for 4 hours to track phagocytosis.  At the end of the 4 hour period cells 
were stained with the green live cell marker calcein AM. HIV stimulation did not alter the 
ability of macrophages to phagocytize the beads (Figure 2.6B).  However, NGF+HIV 
reduced phagocytosis by 22.1% compared to controls (p=0.002) and by 25.5% compare to 
HIV alone (p<0.005). ProNGF+HIV had no effect on phagocytosis compared to control or 
HIV-treated cells.  This result was counterintuitive since previous studies had shown that 
NGF shifts the hMDM to a more ruffled phenotype which was associated with phagocytic 
activity.  However, in the presence of HIV we noted that while NGF reduced the number of 
cells with podosomes a large number of cells lacked both podosomes and ruffles indicating 
only a partial reversal of the phenotype to an intermediate phenotype with little activity.   
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Figure 2.6. HIV increases migration in hMDMs but not phagocytosis. A hMDMs exposed to 
HIV for one day had increased ability to migrate through a Matrigel barrier compared to 
untreated cells. The addition of NGF or proNGF did not affect HIV induced migration 
(n=11). B. Stimulation overnight with HIV +proNGF had no effect on phagocytic activity of 
hMDMs. The addition of NGF with HIV decreased phagocytic activity in cultures.  
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HIV induction of neurotoxin secretion is modulated by neurotrophin signaling 
Secretion of unknown neurotoxins from macrophages in response to HIV has been 
strongly linked to neuronal damage. This neuronal damage includes dysregulation of calcium 
homeostasis and formation of varicosities along neuronal processes, often referred to as 
beading (Figure 2.7A). To assess the generation of neurotoxic activity in the macrophage 
conditioned medium (MCM), hMDMs were stimulated with HIV.  Conditioned medium was 
collected and added to rat cortical neurons at a dilution of 1:5.  Calcium accumulation was 
measured acutely over 6 min followed by assessment of the delayed calcium rise over a 
period of 60 min.  Responses to HIV with or without neurotrophins were compared to control 
responses in the presence of vehicle (aCSF) or medium collected prior to the challenge.  
MCM from cells challenged with HIV virions induced a rapid increase in intracellular 
calcium that recovered partially during the acute phase and was then followed by a prolonged 
rise in calcium and subsequent formation of varicosities in the delayed phase.  The time 
course of toxin release after stimulation with HIV showed a rapid release peaking at 
approximately 1 hour followed by a relative stabilization of medium toxicity that lasted for at 
least 3 days.  The rapidity of the response provided the opportunity to pre-condition the 
hMDM with neurotrophins followed by HIV stimulation and rapid testing of the medium.  
This was important since any residual neurotrophins would be expected to have direct effects 
on the neurons.  Therefore, hMDMs were pretreated with NGF or proNGF for 30minutes, 
washed and then stimulated for 1 hour with HIV.  When HIV was applied to MDM 
pretreated with proNGF a significant increase in the toxicity of the MCM was seen based on 
both the level of calcium destabilization and formation of varicosities(Figures 2.7B and C).  
In contrast, MCM from cells treated with NGF followed by HIV showed partially reduced 
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calcium dysregulation and beading. This data indicated that NGF and proNGF have opposing 
effects on the activation of the hMDM with NGF partially suppressing HIV-induced 
neurotoxicity while proNGF exacerbated damage. 
To understand the role of neurotrophin receptors in the formation of neurotoxin 
production, TrkA and the p75NTR were blocked with a specific inhibitor, GW 441756, and a 
neutralizing antibody, respectively, before exposure to HIV virions.  A role for endogenous 
TrkA signaling in the suppression of toxin secretion was indicated by increases in toxic 
activity after blocking TrkA.  Blocking p75NTR with a neutralizing antibody partially reduced 
toxicity (Figure 2.8A). This data indicated that the activation of the MDM by HIV is 
influenced by endogenous signaling through TrkA and p75NTR.  
Since all stimuli that led to the expression of podosomes were also associated with 
higher levels of toxicity, medium was collected from hMDM predominantly expressing 
podosomes or ruffles.  MCM collected from MDM with ruffles was consistently less toxic 
than MCM from macrophages with podosomes (Figure 2.8B) providing support for the 
relationship between podosomes and macrophage toxicity.    
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Figure 2.7 HIV increased neurotoxicity is increased by proNGF and partially suppressed by 
NGF. A. A representation of calcium accumulation and neuronal damage (beading) after 40 
minute treatment with conditioned medium from untreated macrophages (Control), HIV 
(hMDM), HIV+NGF (hMDM+NGF) or HIV+proNGF (hMDM+proNGF).  B. Mean calcium 
accumulation over time illustrating the dysregulation caused by macrophage conditioned 
medium. Conditioned medium from HIV stimulated macrophages increased calcium influx 
acutely followed by delayed calcium influx that persisted through the 66 minute experiment. 
ProNGF increased calcium dysregulation while NGF partially suppressed the delayed rise in 
calcium. C. Swellings along the dendrites were virtually absent from untreated neurons and 
dramatically increased by HIV.  NGF significantly decreased the number of swellings 
whereas proNGF had no significant effect (n=6). 
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Figure 2.8. TrkA and membrane ruffling blocks meurotoxin formation. A.  Graphical 
depiction of calcium dysregulation caused by macrophage conditioned medium. Conditioned 
medium from HIV stimulated macrophages increased calcium influx acutely deceasing 
within 2 minutes, followed by delayed calcium influx that persist through the 60 minute 
experiment. Inhibition of TrkA signaling with specific inhibitor GW441756 increases 
neurotoxicity. Blockade of p75 signaling with Ro-08-2750 decreases neurotoxicity.  B. 
Conditioned medium from cultures with mostly podosome bearing cells increases neurotoxin 
production while cultures with primarily membrane ruffling results in reduced neurotoxicity.  
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HIV induced a protein secretory profile similar to proNGF which was largely reversed by 
NGF  
Macrophages secrete a wide array of proteins in response to external cues that reflect 
the diversity of responses of these cells. Secretion of neurotoxins during HIV has been shown 
to be the main culprit in inducing neuronal damage to the central nervous system. However 
the neurotoxins causing this damage are unknown. In the previous chapter we showed that 
NGF and proNGF produced different effects on the macrophage secretome and that the 
significance of these effects could not be appreciated by a simple analysis of traditional 
proinflammatory cytokines.  To understand the full range of the secretory profile in response 
to HIV and then to evaluate potential interactions with NGF or proNGF we challenged the 
hMDM chronically with HIV in the presence or absence of the neurotrophins.  The medium 
was tested on primary neurons to verify toxic activity to ensure that the analysis was relevant 
to HIV-associated neuropathogenesis.  The medium was then analyzed in duplicate for 
cytokine, chemokine and growth factor content using the Ray Biotech L-Series Human 
Antibody Array L-507. Medium from cells challenged with HIV, NGF+HIV or 
proNGF+HIV was compared to untreated MCM to assess the primary effect of HIV and 
changes in the HIV profile in the presence of NGF or proNGF.  Pre-treatment and post-
treatment samples were tightly matched with correlations of protein content ranging from 
r=0.982 to r= 0.995 indicating that most proteins did not change.  Using the 99.8% 
confidence limit as a cutoff, 29.8% (150 out of 503 proteins) of the proteins assessed in this 
array were significantly changed by HIV, NGF+HIV or proNGF+HIV. A protein was 
included in the analysis if a significant “hit” was seen in any of the three conditions.  A 
summary of proteins changed by HIV, NGF+HIV or proNGF+HIV relative to controls is 
126 
provided in Table 2.1.  Changes in the secretory profile of the hMDM in the presence of HIV 
are illustrated in Figure 2.9.  The strong overall correlation (r= 0.901) illustrated the 
consistency of the arrays with deviations from the line showing proteins that increased 
(above the line) or decreased (below the line) in the presence of HIV.  Notable proteins 
increased by HIV included MMP-9, TIMP-1, MIP-2, MCP-1, IL-8 and FGF-9.  Notable 
decreases included ICAM-1, angiostatin, and thrombospondin.  
Overall, HIV significantly increased the secretion of 30 proteins and decreased 
secretion of 37 proteins compared to untreated cells. To understand how HIV exposure 
altered the secretory profiles in hMDMs, proteins were segregated into categories by function 
using the Database for Annotation, Visualization and Integrated Discovery (DAVID version 
6.7[188,189]), a bioinformatics tool. Six major functional groups were identified with the 
following Benjamini scores, in parentheses, reflecting strength of association: Immune 
response (8.1E-12), inflammatory response (2.1E-11), defense response (3.5E-11), 
chemotaxis (5.6E-11), response to wounding (1.8E-10), and regulation of cell proliferation 
(2.0E-9). DAVID also recognized these functional groupings when evaluating conditioned 
medium from NGF+HIV and proNGF+HIV stimulated hMDM.  
This overlap in functional groupings identified by DAVID did not show the vast 
differences in protein profiles between HIV stimulated cells and NGF treated cells in 
particular since it does not discriminate between increases and decreases. To provide a more 
detailed examination of the patterns of protein secreted after HIV exposure, the significant 
proteins were grouped into five major clusters that dovetailed with the functional groups 
identified by the bioinformatics analysis (growth factors, cytokines, chemokines, 
adhesion/MMP and other proteins) with up to nine functional families within each group.  
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Within these groups the greatest changes were seen in proteins that regulate angiogenesis, 
growth, chemotaxis and inflammation.   
The most notable changes following stimulation with HIV were within the family of 
angiogenic factors.  Decreases in secretion were seen in factors that promote angiogenesis: 
angiopoieitin, angiopoietin-like 1 and increases were seen in anti-angiogenesis proteins: 
thrombospondin and thrombospondin-1, but also suppressed angiostatin and 
thrombospondin-2. Overall, this pattern indicated that HIV stimulation of hMDMs induced 
an anti-angiogenic environment. 
Other growth factors secreted in response to HIV largely belonged to the TGF and 
FGF families. HIV increased the secretion of TGF family proteins GDF3, GDF5, GDF15, 
Chordin like-2 and Activin RIIA but suppressed BMPR-1A and Activin A. In the FGF 
family, FGF9 and FGF13 1B were increased by HIV exposure while FGFR4, FGF11, and 
FGF16 were decreased.  
 Similar to previous reports from cultured hMDM the chemokines MIP-1β, and MCP-
1 were increased by HIV [103]. In addition proteins within the MMP family which regulate 
macrophage invasion and migration were among the more robust changes.  HIV increased 
MMP-9 and tissue inhibitor of metalloprotease-1 (TIMP-1). These changes again indicated 
that MDM responded to HIV by secreting both damaging proteins such as MMP-9 and 
protective proteins such as TIMP-1.  Thus, there appears to be a constant balance of 
damaging and protective factors in an attempt to maintain homeostasis. 
HIV also increased both inflammatory (IP-10 and IL-17F) and anti-inflammatory 
cytokines (IL-13). Since macrophages are commonly categorized as classically activated 
(M1) or alternatively activated (M2) [23], we examined markers typically used to distinguish 
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these phenotypes. M1 markers were TNF-α, IL-12p70, IL-6, IL-23, IFN−γ, IL-1α,β, and IP-
10. M2 markers were IL-4 , IL-10, IL-13, TGF-β (1,2,3&5) and MCP-1. HIV increased M1 
marker IP-10 and M2 markers IL-13 and MCP-1. No other proteins classically associated 
with these activation states were influenced by HIV. Thus, secretory profiles of hMDMs 
exposed to HIV did not reveal a clear M1 or M2 phenotype.  Instead, a combination of 
inflammatory and anti-inflammatory cytokines was observed highlighting the complexity of 
the macrophage response.   
 
Neurotrophins reverse HIV induced secretory profiles 
In Chapter 2 we saw that macrophage secretory profiles were vastly different after 
stimulation with proNGF versus NGF.  It was therefore anticipated that the presence of HIV 
might alter these responses in different ways and vice versa.  To analyze potential 
interactions, the HIV secretory response was correlated with the secretory response to 
HIV+NGF or HIV+proNGF.  Strong correlations were seen in both cases (0.951 - 0.956) 
indicting that changes were restricted to a small subset of proteins. Co-stimulation of 
macrophages with NGF in the presence of HIV normalized the expression of 58 out of 67 
secreted proteins (increased or decreased) by HIV with a synergistic effect seen in only 2 
proteins.  In contrast proNGF reversed changes in 24 proteins but showed 11 synergistic 
effects with HIV.  To add an additional level of stringency we evaluated the ability of the 
protein changes to predict the calcium dysregulation seen in neurons under each condition by 
correlating the protein level to the average maximal delayed calcium level.  A cutoff was 
arbitrarily set at a value that would account for approximately 50% of the variation 
(r=0.7071).   Twenty four proteins met the dual criteria of a response to HIV and a 
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moderately strong correlation.  A summary of the response to HIV, HIV+NGF and 
HIV+proNGF is illustrated in Figures 2.10 and 2.11. Two response profiles were possible: 1) 
reversal of an HIV-induced increases or 2) reversal of an HIV-induced decrease in protein 
secretion and are plotted separately in Figure 2.10 and 2.11, respectively. 
The most notable responses in the first group (reversal of HIV increases, Figure 2.10) 
were MMP-9, TIMP-1, erythropoietin, FGF-9 and IL-4R suggesting modulation of 
metalloprotease activity and growth.  The large effects on MMP-9 and TIMP-1 are 
particularly notable as MMP-9 has been shown to have deleterious effects on neurons.  The 
normalization of both by NGF is consistent with a protective effect and the increase in MMP-
9 with a corresponding decrease in TIMP-1 could explain the synergistic effects of proNGF 
with HIV stimulation. Other proteins with more moderate changes included IL-17F, CTACK, 
IL-8, thrombospondin, GDF3, and the insulin receptor.  Notable responses in the second 
group (reversal of HIV decreases, Figure 2.11) included angiostatin, CNTF, FGF-16 and 
ICAM-1 suggesting normalization of growth and adhesion functions.  The potential role of 
the other proteins is less clear.  Overall, these patterns indicate that NGF is a relatively strong 
antagonist of the effects of HIV, whereas, proNGF has less potent or mixed effects.  
In addition to modification of the effects of HIV, NGF in particular also exerted effects that 
were independent of HIV actions.  Twenty proteins changed in response to HIV+NGF and 
showed high, largely negative, correlations with toxicity indicating the potential modification 
of toxicity by proteins not linked to HIV activation (Figure 2.12).  A striking feature of the 
response was that, with only one exception, all proteins were decreased by NGF.  In addition, 
a high proportion of the proteins were growth related including most colony stimulating 
factor proteins (G-CSF R, GM-CSF R, M-CSF, M-CSF R, GDNF, NT-4, IGFBP-3 IGFBP-6, 
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FGF-7, crypto-1, PDGF-AA and PDGF-BB).  This heavy weighting of growth factors 
indicates a strong role for NGF in the regulation of growth factor secretion.  The additional 
proteins included osteoprotegerin, sgp130, IL-15, IL-19, CCL-16, LFA-1 alpha, HCR, and 
SCF.  An increase in CXCR1 was the only change associated with proNGF reflecting the low 
overall effect of proNGF on protein secretion.  An additional 59 proteins were altered by 
HIV+NGF and 7 proteins for proNGF, but with low correlations.  Notable protein changes in 
this category were decreases in IL-10, MIP-1alpha, GDF-9, TGF-beta 2, TGF-beta 3, 
IGFBP-1, MMP-1, and MMP-12 and increases in IL-15, IL-23 and MMP-11.  An increase in 
NGF was also seen, most likely representing the NGF added to the culture. 
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Table 2.1 Soluble protein changes in macrophage conditioned medium in   response to HIV, 
NGF+HIV or proNGF+HIV 
 
 
Major Family Sub Family Protein Name Gene Name
HIV minus 
Control
HIV+NGF 
minus CTRL
HIV+proNGF 
minus CTRL
VEGF-B vegfb -185 -11909 -304
VEGF-D vegfd -13125 3386 -5559
Angiopoietin-1 angpt1 -17080 -1586 -11899
Angiopoietin-like 1 angptl1 -49282 8542 -110478
Angiostatin plg -54257 6379 -13720
Thrombospondin (TSP) tsp 44047 -9962 42308
Thrombospondin-1 thbs1 25437 -16953 4236
Thrombospondin-2 thbs2 -24096 786 -19596
Osteoactivin / GPNMB GPNMB 11287 4754 6057
Activin A inhba -20263 7199 -17269
Activin RIIA acvr2a 14199 12185 58291
BMP-3b / GDF-10 gdf10 -1312 10445 -563
BMP-4 bmp4 -1106 8198 -1332
BMP-5 bmp5 -1071 10833 -2172
BMP-6 bmp6 1236 -11543 1560
BMPR-IA / ALK-3 BMPR1A -13149 8409 -12042
BMPR-II bmpr2 -2095 34591 -616
Chordin-Like 2 CHRDL2 21377 7035 48721
Follistatin-like 1 fstl1 2055 14194 6712
GDF3 gdf3 37468 11906 28889
GDF5 gdf5 20089 -23433 17850
GDF9 gdf9 6574 -24475 3796
GDF-15 gdf15 38494 7441 12545
TGF-beta 2 tgfb2 231 -23445 1293
TGF-beta 3 TGFB3 950 -15079 1422
Cripto-1 cr1 -1381 -18412 1129
HB-EGF hbegf 7775 -5145 -13674
NRG2 nrg2 9778 -16420 5278
NRG3 nrg3 -28587 -16577 -18529
SMDF / NRG1Isoform NRg1 936 10643 1788
PDGF R beta pgdfrb -1106 -12636 -2312
PDGF-AA pdgfa -379 -23299 520
PDGF-AB pdgfb -6929 -33398 2959
beta-NGF ngf -1838 12453 -283
CNTF CNTF -19306 -6085 -44125
GDNF gdnf -681 -12207 -644
GFR alpha-2 gfra2 -35235 -670 -32253
GFR alpha-4 gfrA4 -7283 10727 -4795
NT-4 nt4 -2303 -22062 888
G-CSF R / CD 114 CSF3R -2864 -16524 -2135
GM-CSF R alpha gmcsfra -2609 -12023 424
M-CSF mcsf -1993 -16525 -1785
M-CSF R mcsfr -557 -12217 2940
IGFBP-1 igfbp1 1060 -26282 -3869
IGFBP-3 igfbp3 -599 -17394 72
IGFBP-6 igfbp5 566 -13172 -62
FGF Basic fgf2 7775 13589 1207
FGF R4 FGFR4 -49276 -582 -69610
FGF-7 / KGF fgf7 -918 -13262 888
FGF-9 fgf9 74890 -4036 52647
FGF-11 fgf11 -11998 -10355 -3011
FGF-13 1B fgf13 16375 -10825 1045
FGF-16 fgf16 -14550 21568 1512
Growth Factors
VEGF
Angiogenesis
TGF
EGF
PDGF
Neurotrophins
CSF
IGF
FGF
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Table 2.1 Continued 
Major Family Sub Family Protein Name Gene Name
HIV 
minus 
Control
HIV+NGF 
minus CTRL
HIV+proNGF 
minus CTRL
CD40 / TNFRSF5 cd40 -11340 5848 -3945
DR6 / TNFRSF21 tnfrsf21 -3187 -23074 -1360
GITR / TNFRF18 tnfrf18 -1454 26152 -777
LIGHT / TNFSF14 tnfsf14 -2541 -13899 6301
Osteoprotegerin / TNFRSF11B tnfrsf11b -149 -18609 1112
TNF-beta tnfb -1789 -25326 -5149
APRIL TNFSF13 3396 31518 88043
IL-1 alpha il1a 9421 -23446 -2808
IL-1 F8 / FIL1 eta il36b -20017 -4114 -14850
IL-1 R4 /ST2 st2 -1016 -19799 -807
IL-1 sRII il1r2 -545 11245 2855
IL-26 il26 -5508 32911 -2308
IL-27 il27 -1658 10586 -668
IP-10 cxcl10 11265 -9136 499
OSM Osm -27554 -709 -19998
sgp130 Il6st 996 -16620 -528
IFN-alpha / beta R2 ifnar2 -568 15180 170
Granzyme A gzma 26226 -15237 36111
IL-2 R gamma il2rg 300 -10766 -1290
IL-5 il5 4891 30011 4620
IL-5 R alpha il5ra -1767 12712 -88
IL-7 il7 1493 22820 -2631
IL-15 il15 10047 28605 -3101
IL-15 R alpha il15ra -19659 4242 -12974
IL-19 il19 1631 -17579 2047
IL-22 R il22r -18851 238 -5978
IL-24 il24 -1614 45688 -390
IL-28A il28a -646 22930 -1345
IL-29 il29 -14217 25263 -9329
MAC-1 itgam -12227 -443 -7499
IL-1 ra il1rn -16038 -15624 -23347
IL-4 R il4r 45779 -11282 84454
IL-10 il10 10058 -24325 4061
IL-13 il13 13340 -21469 -7266
Galectin-3 LGALS4 -11800 -8186 -20596
IL-17B R IL17rb -1165 40417 -4660
IL-17F il17f 27543 10329 21993
IL-18 BPa iL18bp 4288 -14816 1959
IL-18 R alpha /IL-1 R5 iL18r1 -30292 -2067 -19414
IL-23 il23 -6346 38599 -5799
IL-23 R il23r -750 38582 249
CCL28 / VIC ccl28 -18558 -12844 4544
CCR4 ccr4 -35225 -8620 -28281
CCR5 ccr5 -1268 10886 -1407
CCR7 ccr7 -39192 10268 -64016
CCR9 ccr9 -32106 182 -60976
CTACK / CCL27 ccl27 32895 -7986 58913
CXCL14 / BRAK cxcl14 3255 -928 14003
CXCR1 / IL-8 RA cxcr1 3645 -3979 12469
CXCR2 / IL-8 RB cxcr2 -43054 13919 -70144
GRO gro 1617 -21430 -25753
HCC-4 / CCL16 ccl16 -5128 -31160 -3516
IL-8 il8 57102 1737 30797
I-TAC / CXCL11 cxcl11 -15833 -18464 -4994
Lymphotactin / XCL1 xcl1 -1151 -23908 266
MCP-1 ccl2 67321 -27212 22672
MIG cxcl9 25792 -15279 693
MIP-1a ccl3 -1042 -11729 -400
MIP-1b ccl4 14233 -2676 23874
MIP 2 cxcl2 49392 2112 15954
PARC / CCL18 ccl18 1308 -15427 358
Tarc ccl17 -1837 -14297 -236
Chemokine
TNF
Cytokine
inflammatory
Anti-inflammatory
IL-17
Chemokine
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Table 2.1 Continued  
Shaded values represent significant changes in protein secretion by HIV, NGF+HIV or 
proNGF+HIV relative to matched control medium.  Values are expressed as relative 
fluorescence units.  Nine proteins showed strong differentials for NGF versus proNGF 
although no individual changes were seen relative to control (unshaded).    
 
Major 
Family
Sub Family Protein Name Gene Name
HIV minus 
Control
HIV+NGF 
minus CTRL
HIV+proNGF 
minus CTRL
ICAM-1 icam1 -72035 -5932 -33392
ICAM-5 icam5 2057 -6589 -19847
LFA-1 alpha itgal -1644 -11311 -47
PECAM-1 /CD31 pecam1 -30058 3581 8167
Siglec-5/CD170 siglec5 -1769 -14842 1588
Siglec-9 SIGLEC9 -14322 -25798 -13727
MMP-1 mmp1 310 -14836 -115
MMP-9 mmp9 102248 -20867 128646
MMP-11 /Stromelysin-3 mmp11 -2294 13945 -2748
MMP-12 mmp12 2499 -23637 4174
MMP-24 / MT5-MMP mmp24 16827 -8076 -1368
TIMP-1 timp1 145157 -12463 65864
Artemin artn 123 35914 -2377
BIK bik -1189 12164 -781
Coagulation Factor III / Tissue Factor f3 -10565 4760 -11684
CRTH-2 ptgdr2 25855 -776 -6070
EDA-A2 eda -15802 2885 -11625
EN-RAGE s100A12 16991 6437 -1523
Erythropoietin epo 127491 -9141 67874
Frizzled-1 gprasp1 -2030 11373 -356
GASP-1 / WFIKKNRP WFIKKN2 -21077 -6537 -20815
Glut2 slc2a2 819 -14430 1280
Growth Hormone (GH) gh1 1398 -14215 -2703
HCR / CRAM-A/B hcr -730 -19280 -612
Insulin ins -3031 16510 -364
Insulin R insr 42477 3277 10739
LIF R alpha LIFR 10688 -14564 -7603
MDC ccl22 -7676 -10891 -8984
Musk musk -9152 -30051 -9911
Progranulin grn 19744 -2990 21624
Prolactin prl -10844 -371 -10935
SCF kitlg 74 -14389 769
SIGIRR sigirr -16940 -1658 -10231
SPARC sparc 9826 -10990 10450
Thrombopoietin (TPO) thpo 98 -18007 -1086
ICAM
MMP
others
MISC
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Figure 2.9. Changes in secretory profiles induced by HIV. Values represent the correlation of 
changes in fluorescence signal intensity on the protein array for HIV versus untreated 
hMDMs. r=the correlation coefficient. The solid line represents the 99.9% confidence limits. 
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Figure 2.10. Proteins that were increased by HIV and correlated with toxicity. Values 
represent the change in fluorescence signal intensity on the protein array for HIV, 100ng/ml 
NGF+HIV or 1ng/ml proNGF+HIV treated cells relative to matched control medium.  NGF 
reversed the HIV-induced increase in almost all cases, largest of which were MMP-9, TIMP-
1 and erythoropoietin.   
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Figure 2.11. Proteins which were decreased by HIV and also correlated with toxicity. Values 
represent the change in fluorescence signal intensity on the protein array for HIV, 100ng/ml 
NGF+HIV or 1ng/ml proNGF+HIV treated cells relative to matched control medium 
collected prior to stimulation. NGF reversed these decreases with only one exception.  
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Figure 2.12. Effects of NGF in the absence of significant effects of HIV.  Values represent 
the change in fluorescence signal intensity on the protein array for HIV, 100ng/ml NGF+HIV 
or 1ng/ml proNGF+HIV treated cells relative to matched control medium collected prior to 
stimulation.  Thirteen of the 22 proteins were growth factors or related proteins and all except 
IL-15 and NGF decreased in the presence of HIV+NGF. 
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Analysis of cell surface phenotypic markers     
Although we did not identify a classical M1 or M2 phenotype in our secretory 
analysis we evaluated changes in three cell surface markers that had previously been 
associated with HIV infection and migration into the CNS, CD16, CD163 and CD206.  
Expression of CD16, CD163 or CD206 on both monocytes and hMDM was evaluated by 
flow cytometry and no significant changes in total expression were seen under any of the 
conditions.  However, an analysis of a subset of monocytes expressing high levels of CD206 
indicated that HIV induced a small but significant decrease in the CD206high population (-
22.7%, p=0.018; Figure ). A decrease was also seen with NGF+HIV (-33.4% relative to 
control, p=0.04) and HIV+proNGF (-60.7%, p=0.006).  
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Figure  2.13. HIV decreases the M2 surface marker CD206. A.  Stimulation with HIV 
decreased a subset of CD206high  expressing monocytes, a M2 marker which was 
synergistically decreased by the addition of proNGF(n=3). 
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Discussion 
 
HIV induces a neurotoxic phenotype in hMDM 
Macrophage activation is the key correlate of damage severity during HIV 
neuropathogenesis; however, how this activation leads to toxicity is still not fully understood. 
This lack of understanding has been a significant hurdle for the development of interventions 
that control inflammation. In this study we showed that macrophage activation by non-
infectious HIV virions induced the expression of more podosome like structures and fewer 
ruffles. The podosomes were often polarized, accumulating in one quadrant of the cell 
suggesting a potential role in migration. Podosomes are sites of adhesion thought to facilitate 
migration through tissues via the release of MMPs.  Our previous studies have shown that 
NGF and proNGF are naturally occurring stimuli that also induce (proNGF) or suppress 
(NGF) the expression of podosomes.  Consistent with this observation, we observed an 
increase in podosomes when proNGF was added to HIV and a decrease with NGF co-
stimulation. 
Increases in intracellular calcium are necessary for podosome formation as well as 
many other cytoskeletal modifications.  HIV induced a small acute calcium response but the 
most prominent effect was a suppression of calcium spiking.  Calcium spiking in 
macrophages has been correlated with membrane ruffling [205-207,246]. The loss in cells 
containing membrane ruffles during HIV exposure may explain why calcium spiking is 
suppressed and why we saw no change in phagocytic activity.  
Neurotrophins differentially regulate HIV-induced macrophage functions  
An imbalance of pro-neurotrophin versus mature neurotrophins in the central nervous 
system has been implicated in neurodegenerative diseases such as Alzheimer disease [247-
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249] and has been measured in the hippocampus of HIV-gp120 transgenic mice [152] .  
Much of the work assessing the impact of pro and mature neurotrophin imbalance has been 
done in the context of neuronal damage. However it is now clear that macrophages and 
microglia are significant targets of the neurotrophins largely due to expression of the p75NTR 
and TrkA.  Although HIV exposure did not influence p75NTR and TrkA expression on 
hMDMs it increased the co-localization of the receptors suggesting HIV regulation of p75NTR 
/ TrkA signaling.  Blocking TrkA signaling enhanced neurotoxin production and the 
formation of podosomes in response to HIV, while blocking the p75NTR reduced neurotoxin 
production, possibly through another signaling partner.  In fact, our studies showed that HIV 
induced a modest increase in the co-localization of the p75NTR with another known signaling 
partner, sortilin. Differential interactions of the p75NTR with TrkA versus sortilin has been 
widely cited in the literature, in part, to explain the detrimental effects of pro-neurotrophin 
signaling.  The p75NTR/TrkA receptor complex engages with NGF and leads to pro-survival 
signaling events whereas p75NTR /sortilin engage with proNGF and has been associated with 
cell death. In this current study however no cell death was seen with HIV exposure, 
suggesting another role for sortilin in hMDMs. HIV’s ability to encourage interaction 
between the p75NTR and both TrkA and sortilin suggests that the cell is primed to interact 
with both NGF and proNGF with different consequences.  Consistent with this possibility, 
we found that NGF and proNGF exerted opposing effects in almost all assays.   
As many of the results seen during HIV in the study overlapped with our previous 
findings for proNGF we characterized the impact of stimulation with proNGF or NGF during 
HIV stimulation. The addition of proNGF to HIV treated macrophages did not alter many 
functions seen during HIV stimulation such as increased co-localization of p75NTR with 
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TrkA, sortilin expression, suppression of calcium spiking, podosome formation, and 
phagocytosis. However the addition of proNGF did increase the number of cells with 
polarized podosomes and the toxicity of the conditioned medium. Unlike proNGF, NGF co-
stimulation resulted in a vastly different phenotype in HIV treated macrophages. NGF 
reduced HIV’s ability to increase p75NTR and TrkA co-localization. Ironically NGF increased 
sortilin expression but decreased its overlap with immunopositive p75NTR foci. Importantly, 
NGF reversed each of the major effects of HIV. Podosome expression and polarization were 
reduced by increasing the number of cells with no specializations. Calcium spikes were 
increased and we saw a reduction in phagocytic activity. Since phagocytic activity has been 
linked to calcium spikes this decrease in phagocytic activity was counter intuitive. However 
phagocytic activity has also been correlated with membrane ruffling and the shift in away 
from podosomes and ruffles may explain the reduction of phagocytosis and suggest a 
transitional phenotype caused by NGF and HIV stimulation in macrophages.   
 
HIV and hMDM neurotoxin production  
Neuronal damage in HIV infection has been linked to the secretion of soluble factors, 
or neurotoxins from hMDMs, but the factors that cause neural damage are not well defined. 
In this study we assessed the secretory profile of hMDM after HIV exposure. Many groups 
have tried to classify macrophage activation states as inflammatory (M1) or alternative anti-
inflammatory (M2). However in our study there were no classical M1 or M2 activation 
phenotypes seen during HIV exposure although a small down regulation of the M2 surface 
receptor CD206 was seen. Although cytokines did not match a M1 or M2 phenotype HIV did 
increase cytokines and chemokines that have previously been shown to be increased by HIV 
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including MCP-1, MIP1b, and MIP-2.   Co-stimulation with NGF and HIV returned these 
proteins back to control levels indicating an antagonistic relationship between the effects of 
HIV and NGF.  ProNGF addition either had no effect on proteins increased by HIV (MIP-1β) 
or reduced them (MCP-1, MIP2).  
To understand the changes seen in the secretome we utilized DAVID, a 
bioinformatics tool, which characterized these proteins as being involved in immune 
response, defense response, chemotaxis response, wound healing and regulation of cell 
proliferation consistent with known functions of hMDM during interactions with virus. 
Instead of traditional inflammatory categories, HIV influenced specific proteins that were 
segregated into four major functional groups: growth factors, cytokine, chemokines, and 
other proteins.   
The family most affected by all stimulations was the growth factor family and 
highlighted the importance of assessing both beneficial and detrimental properties. Similar to 
the results in Chapter 2 for proNGF, HIV and co-stimulation with proNGF facilitated the 
secretion of proteins that favored an anti-angiogenenic environment while co-stimulation of 
hMDMs with NGF blocked the increased secretion of all anti-angiogenic factors induced by 
HIV. This is consistent with the breadth of literature implicating NGF’s role in promoting 
angiogenesis [216].  Although little is known about the significance of angiogenesis in HIV 
infection much of the work done on angiogenesis has been in the context of Kaposi sarcoma, 
an angioproliferative mesenchymal cancer often seen in AIDS and other immune deficient 
patients. HIV Tat and nef have been shown to promote Kaposi sarcoma induced 
angiogenesis[250,251]. Anti-angiogenic factor thromposondin-1 inhibits HIV-Kaposi 
sarcoma induced angiogenic activity[252]. In our studies, thrombospondin and 
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thrombospondin -1 were increased with HIV and angiostatin was reduced by HIV suggesting 
that HIV may have a role in halting angiogenic activity. ProNGF co- stimulation of 
macrophages with HIV increased the secretion of thrombospondin, thrombospondin-1, and 
angiostatin. The increase in anti-angiogenic factors induced by proNGF suggests that there 
may be a role for p75NTR in anti-angiogenesis. This is  consistent with a study that showed 
P75NTR expression was upregulated in endothelial cells of type one diabetic mice and was 
involved in inhibiting neovascularization [253]. These findings suggested an important role 
in proNGF signaling in macrophages during cancer prevention including HIV-Kaposi 
sarcoma . 
The TGF and FGF families were most highly represented however not much is 
known about these families in the context of HIV. The most robust changes came from the 
GDF subgroup of the TGF family. However the only member of this subgroup that correlated 
with toxicity was GDF3. Likewise, in the FGF family, FGF-9 was increased and FGF-16 was 
decreased with HIV. Not much work has been done on FGF-9 or FGF16 in macrophages or 
in the context of HIV. FGF-9 has been shown to be secreted from neurons and support basal 
forebrain cholinergic neurons [254]. However, more work needs to be done to understand the 
importance of these factors in the context of HIV neuropathogenesis.  
Few of the results from the protein arrays provided leads that might identify the 
protein(s) responsible for neurotoxicity.  The strongest candidates from these studies were 
proteins within the MMP family. NGF increased MMP-7 and MMP-11 in the presence and 
absence of HIV. Support for the importance of the MMPs has come from studies showing 
their involvement in synaptic damage and remodeling.  MMP-7 was low in the medium of 
unstimulated cells and largely unaffected by HIV, however, it was increased by NGF.  MMP-
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7 has been shown to be one of the enzymes that cleaves proNGF to NGF [255] and has also 
been implicated in positive synaptic remodeling by altering presynaptic terminals without 
affecting neuronal survival [224]. NGF’s ability to increase MMP-7 secretion may be a 
feedback mechanism to support NGF signaling while also aiding in reconstruction of any 
damage caused to neurons during HIV exposure.  A potential positive influence of MMP-7 
was supported by the negative correlation with toxicity.  
MMP11 secretion was also increased by NGF stimulation. Most of the work looking 
at MMP-11 in the central nervous system involves gliomas [256,257]. It is unclear if it is 
involves in HIV neuropathogenesis but the anti-angiogenic phenotypic switch with proNGF 
stimulation in macrophages found in this thesis may provide a new therapeutic avenue in 
brain cancer research and should be explored further.  
One of the most striking observations from the protein array analysis was the increase 
in MMP-9 and the tissue inhibitor of metalloprotease-1 (TIMP-1) in response to HIV.  Both 
proteins were robustly expressed and had positive correlations to calcium dysregulation. The 
increase in both MMP-9 and its endogenous inhibitor TIMP-1 suggested that the hMDM 
constantly provide potentially deleterious and protective proteins at the same time in an effort 
to maintain tissue homeostasis.  The balance between MMP-9 and TIMP-1 may be a crucial 
factor in the regulation of tissue damage and has been seen in other brain injury models 
including ALS [258-261]. Evidence for deleterious effects when the balance is changed was 
seen in the effects of proNGF which primarily decreased the secretion of TIMP-1, a result 
that would predict the increase in neurotoxicity of MCM after stimulation with both HIV and 
proNGF. MMP-9 is involved in activity dependent reorganization of dendritic spines and 
long term potentiation and has been implicated in abnormalities in spine morphology in a 
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fragile X syndrome mouse model [223,262,263].MMP-9 has also been associated with 
neuronal damage including synapse degeneration and axonal demyelination in HIV infection 
and other neurodegenerative diseases [264-267]  In addition to the role of MMP-9 in the 
remodeling  of the synapses during disease, part of MMP-9’s damaging effects may be 
related to its ability to metabolize NGF [268] creating a favorable environment for a high 
ratio of proNGF to mature NGF.  The partially protective role of NGF could also be 
explained by its effects on MMP-9.  NGF decreased MMP-9 and TIMP-1 in the presence of 
HIV suggesting its role in suppressing MMP-9 toxicity. MMP-9 was also increased with 
proNGF stimulation alone but had no effect on TIMP-1 secretion from macrophages. This 
increase in MMP-9 secretion may explain why conditioned medium from proNGF stimulated 
macrophages in the absence of HIV is neurotoxic. Finally, studies of macrophage invasion 
have demonstrated a strong relationship between podosomes and MMP-9 secretion providing 
a link between the MDM phenotype and toxic activity [269,270].  The consistency of these 
observations makes MMP-9 a putative candidate for the neurotoxin.  Indeed preliminary 
results indicate that MMP-9 induces a gradual accumulation of calcium in neurons and MMP 
inhibitors reduce toxicity.  Much work is needed to understand how MMP-9 may be involved 
in neuropathogenesis, but it may serve as a potential biomarker or early indicator for disease 
prognosis.   
 
Conclusion  
These studies describe a new phenotypic characterization of neurotoxic macrophages 
that can be induced by HIV. This phenotype includes the formation of polarized podosomes, 
suppression of calcium spiking in macrophages and increased neurotoxin production that 
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correlated with the ability of conditioned medium from these cells to induce calcium 
dysregulation in neurons. Proteins showing the most robust changes in the medium in 
response to HIV included antiangiogenic factors and MMP-9. The formation of podosomes 
and neurotoxin production was dependent on neurotrophin p75NTR signaling and 
neurotoxicity was partially suppressed by TrkA signaling. Stimulation of macrophages with 
HIV increased p75NTR co-localization with both TrkA and sortilin providing the opportunity 
for receptor interactions. Co-stimulation of macrophages with proNGF resulted in an 
increased neurotoxic phenotype although many functions were not changed compared to 
HIV. This suggested that proNGF and HIV are producing the neurotoxic phenotypes through 
converging pathways. The most significant effects were the observations that co-stimulation 
with NGF and HIV suppressed the neurotoxic phenotype in macrophages by increasing 
calcium spiking, suppressing podosomes and reversing many of the protein secretory changes 
induced by HIV, including MMP-9. These differential effects of proNGF and NGF on HIV 
activation provides a potential novel therapeutic avenue for controlling macrophage 
phenotypes during HIV associated cognitive disorders and other inflammatory diseases.  
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CHAPTER 4: NEUROTROPHIN-CXCR4 INTERACTIONS REGULATE THE 
TOXIC ACTIVATION OF MACROPHAGES BY HIV 
 
Introduction 
Macrophages and microglia are the cellular targets that carry the major burden of 
HIV in the central nervous system. Activation of these mononuclear phagocytes by HIV has 
been correlated to disease severity in patients with HIV associated cognitive disorders[79]. 
Though mechanisms of macrophage activation by HIV are not fully understood, engagement 
of the surface protein on the viral envelope, gp120, with the chemokine receptors, CCR5 or 
CXCR4, on the host cell is thought to play a major role [86,102,271,272]. This gp120 
induced macrophage activation is independent of infection and binding to the HIV primary 
receptor, CD4 [86,100,103,271,273,274].  CCR5 preferring viral strains are the main HIV 
variants in the brain although distinct brain variants preferring CXCR4 have been identified 
in cerebrospinal fluid (CSF)[48].  The binding of these virions is not exclusively restricted to 
their preferred receptors and CXCR4 preferring strains can activate and infect macrophages 
although with reduced efficiency relative to CCR5 preferring strains.  Although most virus in 
the CNS is CCR5 preferring, studies have shown that both CXCR4 preferring and CCR5 
preferring envelope proteins can cause neurotoxicity [275].  The specific role of viral 
interactions with each chemokine receptor has been extensively debated but interactions with 
CXCR4 have always been associated with neurotoxicity whereas CCR5 has been implicated 
in both toxicity and neuroprotection depending on the context.  The exact contribution of 
each co-receptor to the development of neural damage remains controversial. 
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In the previous chapter we showed that hMDM stimulation with CCR5 preferring 
virions, HIVADA, produced a neurotoxic phenotype consisting of podosome formation and the 
secretion of neurotoxins. This toxic phenotype was similar to what was seen during hMDM 
stimulation with proNGF in Chapter 1, and HIV toxicity was exacerbated during co-
stimulation with proNGF. However co-stimulation with mature NGF was able to reduce 
toxicity caused by HIV. This suggested a close relationship between neurotrophin and HIV 
signaling in the hMDMs.  Interactions between neurotrophins and CXCR4 signaling have 
been suggested by studies of HIV infection and macrophage activation.  NGF has been 
reported to suppress or enhance viral replication in hMDMs [171,174].  Samah et. al has 
shown that NGF can increase SDF induced migration in HIV infected and non-infected 
macrophages by increasing the cell surface expression of the SDF-1 receptor, CXCR4 
[175,176]. However the nature of the interaction of NGF with CXCR4 expression or function 
has not been addressed. 
NGF-CXCR4 interactions may be direct or indirect.  The possibility of direct 
interactions was raised by data from Moses Chao’s group showing that Trk receptors can be 
transactivated by G-protein coupled receptors [276-280].  In addition, transactivation of 
CXCR4 by the insulin-like growth factor-1 receptor has been reported in human breast 
cancer cells[281].  These studies and our previous observations raised the possibility that 
neurotrophin receptors and chemokine receptors may interact to control cytoskeletal 
dynamics and macrophage functions.  In this study we show for the first time that CXCR4 
forms complexes with the p75NTR and TrkA to modulate neurotoxin production during HIV 
exposure.   
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Materials and Methods 
Isolation and culture of human monocyte-derived macrophages 
Human buffy coat leukocytes were purchased and shipped within 24 hours after blood 
draw from healthy donors at the New York Blood Center (http://nybloodcenter.org/), a non-
profit organization specific for the collection and distribution of blood for clinical and 
research purposes. All research use was screened by the center and no personal identifiers 
were sent with the shipment. Such use is exempt from review under NIH guidelines, 
exemption 4 of 46-101(b). Blood was diluted 1:1 with phosphate buffered saline (PBS) and 
was layered on top of Ficoll-Paque (GE Healthcare 17-1440-03). Blood/Ficoll-plaque was 
centrifuged at 500 X g for 25 min and the peripheral blood mononuclear cells (PBMCs) were 
collected from the PBS/Ficoll-Paque interface.  PBMCs were washed in red blood cell lysis 
buffer (Sigma R7757) to remove any red blood cell contamination. PBMCs were centrifuged 
at 450 X g, the supernatant aspirated and the pellet re-suspended in Dulbecco’s modified 
eagle medium (DMEM) with high glucose, 10% fetal bovine serum (Gibco 160000-044) and 
20 µg/ml gentamicin (Gibco 15750-60).  Cells were aliquoted into low adhesion 6 well plates 
(Corning 3471) at a density of approximately 107 cells/well. PBMCs were cultured for 5-7 
days to allow monocyte attachment. Remaining white blood cells were washed, from the 
plate yielding a pure monocyte/macrophage culture.  The adherent cells were differentiated 
into monocyte-derived macrophages (hMDM) using human GM-CSF (15 ng/ml) in complete 
DMEM for one week.  Monocyte experiments were carried out within 1 hour of PBMC 
isolation to prevent cell attachment.   
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Primary cultures of rat forebrain 
All animal work was done in accordance with NIH animal welfare guidelines and was 
approved by the University of North Carolina- Chapel Hill Institutional Animal Care and Use 
Committee board (approval number 14-147.0). Timed gestational embryonic day 9 (E9) 
pregnant female Long-Evans rats were delivered from Charles Rivers and maintained in 
UNC animal husbandry until the time of experiments. At gestational day E17, rats were 
sacrificed by anesthetizing with isoflurane drop method until breathing and the heart stopped. 
A thoracotomy was then performed prior to removal of the fetal material. For primary 
neuronal cultures, fetal material was rinsed in 70% ethanol and placed in HEPES-buffered 
Hank's balanced salt solution (HBSS) on ice for anesthesia before removal of the brain. The 
tissue was extensively washed and the cortex/hippocampus was dissected from each brain 
and cleaned of Dura-arachnoid membrane and visible vessels. The tissue was transferred to a 
15 ml tube containing 5 ml calcium-magnesium free-HBSS + 2.4 U/ml dispase + 2 U/ml 
DNase I and incubated for 25-30 min at 36° C.  Tissue was triturated and allowed to settle for 
2 min.  The suspended cells were transferred to a 50 ml culture tube containing 25 ml of 
minimum essential medium (MEM) with glutamine + 10% fetal bovine serum + 20 µg/ml 
gentamicin.  After several rounds of trituration in 2-3 ml calcium-magnesium free HBSS, 
dissociated cells were seeded at a density 20,000 cells/cm
2
 on poly-D-lysine-treated 
coverslips for imaging and staining or 50,000-100,000 cells/cm2 in 60-100 mm plastic dishes 
for Western blots.  After 24 hours, cultures were transferred to Neurobasal medium with B27 
supplement.  The resulting cultures were >95% neurons at day 4 after seeding.  
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HIV activation of hMDM 
Differentiated hMDM grown on poly-D-lysine coated coverslips were transferred to 
DMEM containing 1% FBS and stimulated for 1 or 24 hours using four different conditions: 
HIVADA, HIVADA +NGF human recombinant protein (100 ng/mL, Sigma N1408), HIVADA 
+proNGF human recombinant protein targeted to high affinity sites (1 ng/ml, Alamone N-
280), or vehicle.  A replication incompetent stock of inactivated HIVADA was used for these 
studies.  The concentration of each neurotrophin was selected to maximize the effects of 
NGF on the macrophages while also maximizing the difference between NGF and proNGF. 
In inhibition studies the following inhibitors were used: AMD3100 (CXCR4), CCR5 
neutralizing antibody or Maraviric (CCR5) and GW441756 (TrkA). 
 
Immunostaining 
The cells were gently washed and fixed in 2% paraformaldehyde in PBS.  Cells were 
washed 3X in PBS and incubated in 3% normal goat serum for one hour. Incubation of 
primary antibodies was carried out overnight at 4o C. Cells were stained using antibodies to: 
p75NTR (Millipore cat #07-476, 1:500), TrkA (Santa Cruz cat #SC-80961, 1:500), pCXCR4 
(ABCAM ab74012) or CXCR4 (R+D System cat# MAB170). Cells were washed in PBS and 
incubated with species specific secondary antibodies conjugated to Alexa 488, 568 or 594 
(Molecular Probes) in the dark for 1 hour at room temperature.  F-actin was stained using 
Alexa488 phalloidin (1:50, Molecular Probes) to show structural changes.  Coverslips were 
then mounted using Fluoromount (Southern Biotech 0100-01) and digitally imaged on an 
Olympus XI71 microscope.    
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Analysis of stain intensity for individual cells or regions of interest within the cells 
was accomplished using Metamorph software.  Co-localization of pCXCR4  foci with TrkA 
or p75NTR staining was analyzed by thresholding the regions of interest and using the co-
localization tool in MetaMorph software to quantify the extent of overlap.  
 
Co-immunoprecipitation  
Human monocyte-derived macrophages were stimulated with HIV, NGF+HIV or 
proNGF+HIV for 10 min in serum free DMEM which was previously determined to be the 
peak time for identification of protein-protein interactions. Cells from two 60 mm or one 100 
mm dish were harvested using 1.5 ml lysis buffer (1X RIPA buffer (Thermo Scientific 
89900), 1:100 phenylmethylsulfonyl fluoride (PMSF, Pierce Chemicals PI 36978), 1:100 
Halt® protease inhibitor cocktail (Thermo scientific cat# 1861228).  Protein concentration 
was measured by BCA assay (Thermo Scientific 23225). 50 μl of ProteinA/G Plus-Agarose 
beads (Santa Cruz Cat#sc-2003) and 10 μg of CXCR4 antibody (Alamone cat#ACR-014 was 
added to 1ml of lysate and incubated overnight. Excess antibody was washed three times in 
RIPA buffer and beads containing immunoprecipitated protein were boiled in Laemelli 
sample buffer to isolate protein from beads.  The Isolated proteins were resolved on SDS-
Page gels as discussed below.  
 
Western blots 
Human monocyte-derived macrophages were stimulated with HIVADA, HIVADA 
+NGF or HIVADA +proNGF for time periods of 10 min. The hMDMs were pretreated with 
the specific inhibitor for 30 minutes prior to stimulation. At the indicated time, cells from 
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two 60 mm or one 100 mm dish were harvested using 1.5 ml lysis buffer (1X Ripa buffer 
(Thermo Scientific 89900), 1:100 phenylmethylsulfonyl fluoride (PMSF, Pierce Chemicals 
PI 36978), 1:100 Halt® protease inhibitor cocktail (Thermo scientific cat# 1861228).  Protein 
concentration was measured by BCA assay (Thermo Scientific 23225). Protein lysate was 
resolved on SDS-Page gels (Biorad cat# 456-1034) and transferred to a nitrocellulose 
membrane (Biorad 162-0112). The membranes were blocked in 2% milk plus 0.01%Tween 
for one hour at room temperature. The primary antibodies were incubated overnight at four 
degrees. The membranes were then washed in PBS+1% Tween and incubated in secondary 
antibody for one hour at room temperature. The membranes were then washed again and 
imaged using the Odyssey or film imaging system. The primary antibodies used were 1:500 
p75NTR (Millipore 05-446), 1:500 TrkA (Millipore 06-574), 1:500 pCXCR4 (ABCAM 
ab74012), 1:500 CXCR4 (R+D System cat# MAB170), 1:500 GRK2 (ABCAM 
cat#AB113643). Secondary antibodies were hoseradish peroxidase (HRP) conjugated 
secondary antibodies (Goat anti-Rabbit IgG, cat# AP132P and Goat anti Mouse IgG cat# 
AP124P) and SuperSignal West Pico detection (Thermo Scientific, #34080).   
 
Flow Cytometry 
PBMCs and hMDMs grown in ultra-low adhesion 6-well plates were stimulated with 
NGF or proNGF in 1% DMEM for 1 hour (PBMCs) or overnight (hMDM).  Cells were 
removed from the low adhesion wells and centrifuged for 5 minutes at 450 x g. Cellular 
pellets were re-suspended and fixed in a Fluorfix solution (Biolegend 420801) for 20 minutes 
at room temperature. Fixed cells were then treated with permeabilization buffer (EBioscience 
020-8333-56) and centrifuged for five minutes at 450 x g at 4o C. The cell pellet was re-
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suspended in permeabilization buffer and centrifuged at 450 X g at 4o C. Cells were re-
suspended in 100 µl of permeabilization buffer plus antibody (1.5 μl p75NTR Alamone Labs 
ANT-007-F ; 20μl; TrkA R&D Systems FAB1715P; 5μl CD 206 Biolegend 321114; 5μl 
CD16 Biolegend 302008 and 5μl CD 163 Biolegend 333607) at room temperature for twenty 
minutes.  The stained cells were washed three times in cell staining buffer (Biolegend 
420201). Flow cytometry was performed on a FACS Calibur (Becton Dickinson, San Jose, 
CA) using direct immunofluorescence with at least 100,000 events. Monocytes were 
determined by populations of cells with high forward scatter and low side scatter. All cells 
were gated to remove debris. Three color staining analyses were utilized. Cells were 
analyzed according to side scatter and receptor bound fluorescence, and data was collected 
with logarithmic amplifiers. Fluorescence spillover compensation was estimated using 
single-stained and unstained samples with the Cell Quest software (BD). After collection, 
data was further analyzed with FlowJo software (TreeStar Inc., Ashland, OR). 
 
Neurotoxicity of macrophage-conditioned medium  
Pilot studies indicated that a 30 minutes stimulation of hMDM in serum free DMEM 
was sufficient to induce an MDM phenotype which persisted for several hours after removal 
of the stimulus.  Thus, the cells could be primed with neurotrophin in serum free DMEM for 
30 minutes, washed and replaced with serum free medium containing HIVADA virions. The 
resulting macrophage-conditioned medium (MCM) was collected and centrifuged at 2500 
rpm for 10 minutes to remove any cells and then frozen in aliquots at -80o C.  The neurotoxic 
activity of the medium was tested on primary rat neurons cultured on coverslips.  Neurons at 
6-12 days in vitro were loaded with the calcium indicator, Fluo-4 AM (2 µM, Molecular 
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Probes, Inc., Eugene, OR) in aCSF (aCSF: NaCl 137 mM, KCl 5.0 mM, CaCl
2
 2.3 mM, 
MgCl
2
 1.3 mM, glucose 20 mM).  After 30 minutes, the coverslip was transferred to a 
specialized stage for imaging.  Cells were maintained in aCSF and time lapse digital images 
were captured automatically by the Metamorph® system.  Images were captured every 6 
seconds for 6 minutes to assess acute effects and every min for 60 minutes to assess delayed 
effects.   Three pre-stimulation measurements were taken to establish basal levels of 
fluorescence at the beginning of each experiment.  Neurons were stimulated with MCM at a 
1:5 dilution. The increase in fluorescence intensity within each cell was then measured 
relative to the baseline fluorescence to correct for cell to cell differences in dye loading and 
intrinsic fluorescence.  For most studies, cellular responses were averaged across all cells 
from at least triplicate runs to provide an indication of the “typical” response.  In some cases 
individual cell response patterns are shown where the average masked important cell-specific 
profiles.    
Measurement of macrophage calcium responses 
Macrophages cultured on coverslips were pretreated with the specific inhibitor and 
the calcium indicator, Fluo-4 AM in aCSF for 30 minutes. Three time lapse digital images 
were captured followed by stimulation with HIVADA. Changes in fluorescence intensity 
within each cell were measured every 6 sec for 20 min and analyzed as described above.  
Peaks were assessed by calculating sequential changes in fluorescence intensity and 
identifying increases that were greater than 2 standard deviations above the average baseline 
(>20 fluorescence units). 
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Statistical analyses 
Graphpad Prism software was used for data summaries and graphics.  Parametric 
statistics were used to evaluate most changes induced by NGF or proNGF relative to matched 
or unmatched control samples depending on the experiment.  In cases where the data were 
not normally distributed non-parametric statistics were used.  Means and standard errors 
were calculated for at least three replicate experiments.  T-tests were used for paired 
comparisons, analysis of variance with repeated measures for temporal data and Chi-square 
for the analysis of cell populations.  The statistical values in the text represent results from t-
tests unless otherwise indicated.  A probability of <0.05 for rejection of the null hypothesis 
was considered significant unless otherwise indicated.    
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Results  
CXCR4 but not CCR5 is necessary for neurotoxin production  
To understand co-receptor involvement in neurotoxicity, hMDMs were pretreated 
with a CCR5 neutralizing antibody or CXCR4 specific inhibitor , AMD3100, for 30 minutes, 
washed and then exposed to HIVADA for 1hour.  Conditioned medium was collected and 
placed onto rat cortical neurons preloaded with the calcium indicator dye, Fluo-4. 
Macrophage conditioned medium (MCM) collected after HIVADA treatment induced a rapid 
increase in calcium that recovered partially during the acute phase followed by a prolonged 
rise in delayed calcium and subsequent formation of varicosities.  Vehicle (aCSF), virus 
alone or medium from unchallenged macrophages produced negligible or modest 
(unchallenged MCM) calcium increases and no neuronal damage was seen.  Blocking CCR5 
signaling before HIVADA exposure slightly increased delayed calcium dysregulation while 
conditioned medium from macrophages with the CXCR4 antagonist had significantly 
reduced neurotoxin production (Fig.3.1). This indicated that CXCR4 is the principle co-
receptor necessary for release of neurotoxins, even when stimulated with CCR5-preferring 
virions.   
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Figure 3.1 CXCR4 but not CCR5 is necessary for neurotoxicity. A. Human monocyte 
derived macrophages were pretreated with the CXCR4 specific inhibitor AMD3100 or a 
CCR5 neutralizing antibody before exposure to HIVADA for 1 hour. Conditioned medium was 
collected and placed onto rat cortical neurons and calcium dystabilization was assessed in 
two phases. HIV (white circle) induced a rapid rise in calcium acutely followed by a plateau.  
A gradual and prolonged increase in calcium was seen during the delayed phase. Blocking 
CCR5 (yellow square) slightly increased calcium dysregulation during both the acute and 
delayed phase while inhibition of CXCR4 signaling (orange triangle) reduced calcium 
dysregulation.  
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CXCR4 regulates podosome and ruffle formation in hMDMs 
In the previous chapter, we showed that conditioned medium from cells that possess 
more actin rich ruffled structures were less toxic to neurons while medium from cells with 
podosomes were correlated with greater neurotoxin production.  In addition, exposure to 
HIVADA induced the formation of the podosome bearing phenotype in a p75
 NTR-dependent 
manner.   To assess the role of the HIV co-receptors, CXCR4 or CCR5, in toxin formation 
we inhibited CXCR4 signaling with AMD3100 and CCR5 signaling with maraviroc during 
exposure to HIVADA virions for 1 hour. As previously shown, the proportion of cells 
expressing podosomes was increased in response to HIV.  Inhibition of CCR5 signaling 
during HIVADA exposure had no significant effect on the expression of ruffles (Fig. 3.2A) or 
podosomes (Fig 3.2B) compared to HIV treated cells. In contrast, in the absence of CXCR4 
signaling, a large increase in the proportion of ruffled cells was seen (p=0.008 vs. HIV).  
There was no significant difference in the total number of podosome bearing cells; however, 
the density of podosomes within cells was significantly reduced compared to HIV treated 
cells.  Low numbers of podosomes were often seen diffusely scattered through the cell and 
fewer cells had distinct clusters of podosomes (p=0.012, AMD3100+HIV vs. HIV, not 
shown).   
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Figure 3.2 CXCR4 but not CCR5 suppressed ruffles in hMDMs. A. HIV had no effect on 
cells bearing actin rich ruffled structures in hMDMs. Suppression of CXCR4 signaling with 
specific inhibitor AMD3100 increases the number of ruffled bearing cells in culture. 
Suppression of CCR5 signaling with the specific inhibitor maraviroc had no effect on ruffled 
structures. B. HIV increased the number of hMDM with podosomes. Suppression of CCR5 
and CXCR4 signaling had no effect on the proportion of cells possessing podosomes (n=10). 
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CXCR4 neutralizing antibody blocks intrinsic and NGF-induced Calcium Spiking  
Blockade of CXCR4 with a neutralizing antibody prior to the addition of HIV or HIV 
in combination with NGF or proNGF strongly suppressed calcium spikes across all 
conditions (Fig 3.3;p<0.001, 2 way ANOVA).  Calcium spiking in normal cells in the 
absence of any treatments was blocked by 81.1% in the presence of the CXCR4 antibody (p 
<0.05), and spiking induced by NGF in the presence of HIV was blocked by 98.6% 
indicating that CXCR4 activation may be necessary for the NGF-induced increase in calcium 
signaling.  To test this possibility, CXCR4 was blocked and the hMDM stimulated with NGF 
in the absence of HIV.  The CXCR4 block significantly suppressed the spike frequency by 
61.4% indicating that most of the calcium channel activity was CXCR4 dependent.   
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Figure 3.3 CXCR4 signaling is necessary for calcium spiking.  HIV and proNGF+HIV 
normally suppressed calcium spiking in hMDMs whereas co stimulation of NGF with HIV 
increased calcium spiking.  In each case calcium spikes were strongly suppressed by 
inhibition of CXCR4 (n=10, controls; n=3 cxcr4 block).  
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NGF increases CXCR4 phosphorylation   
The activation of CXCR4 with its natural ligand stromal derived factor-1 (SDF-1) is 
dependent on phosphorylation, however it is unclear if HIV causes phosphorylation of 
CXCR4. To determine if HIV and neurotrophins influence CXCR4 phosphorylation, we 
exposed hMDMs to HIVADA for 10 minutes and evaluated CXCR4 phosphorylation by 
western blotting.  A 10 minute exposure to HIVADA slightly increased phosphorylation of 
CXCR4 by 13+0.5% compared to untreated hMDMs (Fig3.4; p=0.03). Co-stimulation of 
hMDM with proNGF + HIVADA had no effect on HIVs ability to phosphorylate CXCR4. In 
contrast, HIV induced CXCR4 phosphorylation was increased by co-stimulation with NGF 
(+13.27%; p=0.02 vs HIVADA). The role of NGF was supported by demonstrating that 
CXCR4 phosphorylation was reduced by 43.75% in the presence of the TrkA inhibitor, GW 
441756 (p=0.005 vs NGF+HIVADA).   
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Figure 3.4 NGF induced phosphorylation of CXCR4 in response to HIV.  A. HIV slightly yet 
significantly increased phosphorylation of CXCR4. Co-stimulation with NGF further 
increased HIV induced phosphorylation of CXCR4. TrkA inhibition with the specific 
inhibitor GW441756 reversed the phosphorylation of CXCR4 induced by NGF + HIV.  
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CXCR4 is expressed in same regions as TrkA and p75 NTR  
To understand how NGF may regulate CXCR4 signaling, we assessed CXCR4 
localization in hMDMs. Total CXCR4 was diffusely expressed in hMDM while 
phosphorylated CXCR4 (pCXCR4) was expressed in more sequestered regions in actin rich 
regions where neurotrophin receptors are expressed as illustrated in Chapter 1(Fig 3.5B and 
C).  To assess the potential overlap of pCXCR4 with either p75 NTR or TrkA in double stained 
cells, regions of interest were identified, thresholded for stained objects and quantified by 
Metamorph® software. PCXCR4 overlapped with TrkA staining by 68.4+0.3% (Fig 3.5B 
and D) and p75 NTR by 64.3+0.5% (Fig.3.5c and E). HIVADA exposure reduced 
pCXCR4/TrkA and pCXCR4/p75NTR overlap to 14.3% and 35.8%, respectively (p<0.001, 
pCXCR4/TrkA and p=0.001, pCXCR4/p75 NTR) (Figs 3.5D and E). Co-stimulation with 
proNGF+HIVADA further decreased pCXCR4/p75
NTR overlap relative to HIVADA alone (-
54.78%; p=0.02) (Fig 3.5E) but had no effect on pCXCR4/TrkA overlap.  In contrast, co-
stimulation with NGF+HIVADA resulted in a recovery of pCXCR4/p75
 NTR overlap compared 
to HIVADA (35.76+0.8% HIVADA to 57.89+0.5% NGF+HIVADA; p=0.05) (Fig 3.5D) and 
partially recovered pCXCR4/TrkA overlap (14.26+0.3% HIVADA to 30.66+0.5% NGF+HIV; 
p=0.008) (Fig 3.5E). These data suggest that activated pCXCR4 is expressed in overlapping 
domains with neurotrophin receptors, p75NTR and TrkA. This overlap is downregulated by 
HIVADA and can be reversed or exaggerated by mature NGF or proNGF signaling. 
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Fig 3.5 CXCR4 interacts with neurotrophin receptors.   A. Total CXCR4 (green) is diffusely 
expressed in human macrophages. B. The p75 NTR (green) and pCXCR4 (red) were located in 
the same domains on human macrophages (co-localized, arrow). C. TrkA (green) and 
pCXCR4 (red) was located in the same domains on human macrophages (co-localized, 
arrow). D. Quantification of pCXCR4 overlaps with p75NTR. HIV decreases this overlap. 
NGF co-stimulation with HIV restores pCXCR4/p75 NTR overlap while proNGF co-
stimulation further decreases the overlap of these receptors(n=4). E. Quantification of 
pCXCR4 overlaps with TrkA. All treatments decreased this overlap. NGF co-stimulation 
with HIV partially restored pCXCR4/p75 NTR overlap while proNGF co-stimulation had no 
effect (n=4).   
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CXCR4 forms complexes with neurotrophin receptors 
To confirm the interaction between CXCR4 and neurtrophin receptors, we 
immunoprecipitated total CXCR4 from hMDM lysates and probed for p75NTR and TrkA. 
Total CXCR4 co-immunoprecipitated with both a 75 kDa band recognized by a p75NTR 
antibody(Figs 3.6A and B) and a weak 140 kDa band recognized by an anti-TrkA antibody.  
However, for TrkA a stronger band at approximately 280 kDa was also seen which may 
represent a TrkA dimer as identified in other studies [282,283]. Stimulation of hMDMs with 
HIVADA for 10 minutes had no effect on co-immunoprecipitation of CXCR4 with p75
 NTR or 
TrkA.   
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Figure 3.6 CXCR4 forms complexes with neurotrophin receptors p75 NTR and TrkA. A. A 
representative blot of p75NTR (located at 75kDa) co-immunoprecipitated with CXCR4. HIV 
had no effect on p75 NTR /CXCR4 complexes. B. A representative blot of TrkA co-
immunoprecipitated with CXCR4. A faint band was seen at 140kDa.  A stronger band was 
seen at 280kDa representing a possible TrkA dimer.  HIV had no effect on TrkA/CXCR4 
complexes.  
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NGF increased GRK2/CXCR4 interactions in macrophages 
The G-protein receptor kinase (GRK) family, and particularly GRK2, is thought to be 
responsible for phosphorylation of CXCR4  [284]. To assess the potential role of GRK2 
interactions with CXCR4 during HIV and neurotrophin signaling, hMDMs were stimulated 
with HIV for 10 minutes in the presence or absence of proNGF or NGF. CXCR4 was 
immunoprecipitated from hMDM lysates and GRK2 was probed using western blotting 
techniques. CXCR4 co-immunoprecipitated with GRK2, however, HIV decreased CXCR4 
interactions with the GRK2 band by 21% compared to untreated cells (p=0.02)(Fig 3.7A and 
B).Co stimulation of hMDM with proNGF + HIV had no effect relative to HIV alone, 
however, co-stimulation with NGF + HIV increased the interaction between GRK2 and 
CXCR4 by 46.8% compared to HIV(p,<0.01). These data indicate that NGF stimulation 
encourages an interaction between GRK2 and CXCR4 that is down regulated during HIV 
exposure and may explain the NGF mediated increase in phosphorylation of CXCR4. 
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Figure 3.7 NGF encourages GRK2 and CXCR4 complex formation.  A. A representative blot 
of GRK2 (located at 80kda) co-immunoprecipitated with CXCR4. B. HIV reduces 
GRK/CXCR4 complexes.  NGF co-stimulation increases GRK2/CXCR4 complexes during 
HIV signaling. ProNGF has no effect on the ability for GRK2 and CXCR4 to form 
complexes (n=4).  
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Discussion 
In our studies we have shown that both HIV and the neurotrophins encourage the 
development of unique hMDM phenotypes best characterized by the expression of ruffles 
(induced by NGF) or podosomes (induced by HIV or proNGF).  The activation of toxin 
production in the macrophages was closely related to the presence of podosomes and 
inversely related to ruffles and calcium spikes.  In this study we have shown that the 
secretion of neurotoxins in response to HIV is dependent on CXCR4 but not CCR5 signaling. 
This was a surprising result because the HIV variant used in these studies is a CCR5 
preferring strain.  However, studies showing co-receptor preference have been based on 
infection data and may have less relevance to CD4-independent interactions of the virus with 
the MDM.  Indeed, even with infection as the endpoint, studies have shown overlap in the 
ability of virions to use each receptor.  The effects of HIV virions appear to be closely tied to 
structural changes in the MDM.  Evidence from our studies and the studies of others that 
HIV encourages podosome remodeling [285] indicate that the podosome bearing phenotype 
is more neurotoxic.  This is supported by the observation that cells possessing actin rich 
ruffles produced medium that was much less neurotoxic.  CXCR4’s involvement in 
suppressing ruffled bearing cells and encouraging a denser population of podosomes in 
macrophages further suggest that CXCR4 is the co-receptor necessary for neurotoxicity as 
blockade of CCR5 had no effect on actin structures.  
Inhibition of CXCR4 signaling resulted in many phenotypes that were seen with NGF 
stimulation of macrophages in Chapter 1. The Gras group laid the foundation for an 
interaction between NGF signaling and CXCR4 by showing that NGF increased the 
migration of monocytes in the presence of CXCR4’s natural ligand SDF-1.  The effect was 
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independent of the absence [176] or presence of HIV [175].  Samah et.al, (2009) also showed 
that NGF increased the surface expression of CXCR4. However, they did not explain how 
NGF may be regulating CXCR4 activity. In this study we show that HIV increased 
phosphorylation of CXCR4, albeit at low levels. This HIV induced phosphorylation was 
increased by NGF co-stimulation but was not changed during proNGF co-stimulation.  
Activated pCXCR4 was specifically found in overlapping domains with NGF receptors 
p75NTR and TrkA at the outer edges of the hMDMs.  Also, HIV decreased the overlap of 
pCXCR4 and neurotrophin receptors.  The ability of NGF to restore the overlap suggested 
that these interactions may suppress neurotoxin secretion during HIV exposure. ProNGF co-
stimulation with HIV exacerbated HIVADA’s ability to decrease pCXCR4/p75 overlap which 
could explain the increased secretion of toxins from hMDMs treated with HIV and proNGF.  
Complexes formed between total CXCR4 and neurotrophin receptors p75NTR and TrkA 
confirmed an interaction between the two classes of receptors.  In this case HIV did not 
affect the ability of CXCR4 to form complexes with p75 and TrkA.  However these 
experiments did not address specific interactions with pCXCR4 complexes which may 
represent a fraction of the total signal.    
A possible mode of CXCR4 phosphorylation may be through GRK2. The G protein 
kinase (GRK) family has been implicated in phosphorylation of CXCR4 although the exact 
family member has not been identified. Overexpression of GRK2 has been shown to increase 
SDF-1 mediated internalization of CXCR4, the step known to follow phosphorylation of this 
receptor. However, GRK2 has been suggested to downregulate CXC4 signaling[284], 
leaving doubt regarding the possible functional role of GRK2 mediated phosphorylation of 
CXCR4. Currently there are no good inhibitors of individual members of this family to 
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determine which, if any, GRK member is involved in the phosphorylation of CXCR4.  
Complexes of CXCR4 with GRK2 were reduced by HIV while co-stimulation of NGF and 
HIV encouraged CXCR4/GRK2 complexes. This increased interaction of GRK2 and CXCR4 
with NGF stimulation may explain the NGF induced phosphorylation of CXCR4, but more 
studies are needed to confirm the potential role of GRK2 in CXCR4 signaling.  
 Conclusion.   
In these studies we have shown that interactions of HIV with the HIV co-receptor 
CXCR4 are necessary for the formation of HIV induced neurotoxic phenotypes seen in 
macrophages. A direct interaction of neurotrophin receptors with CXCR4 was found 
indicating that neurotrophin and chemokine signaling are intimately related.  NGF-dependent 
calcium spikes are substantially blocked by CXCR4 antagonists and NGF stimulation 
facilitated co-localization of CXCR4 with the neurotrophin receptors and interactions with 
GRK2, effects that may encourage phosphorylation since blockade of the p75NTR suppressed 
the phosphorylation of CXCR4.  Thus, p75NTR/CXCR4 interactions lead to phosphorylation 
and toxicity whereas TrkA/CXCR4 interactions reduce toxicity.  Importantly, the ability of 
NGF and CXCR4 antagonists to suppress toxicity suggests an important avenue for the 
development of therapies that control toxic activity.    
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DISCUSSION 
Summary of findings 
In this study we have identified a neurotoxic phenotype in human monocyte derived 
macrophages that is stimulated by HIV interactions with CXCR4 and regulated by 
neurotrophins. We have confirmed that macrophages and monocytes express p75NTR and 
TrkA in high abundance and respond to their natural ligands proNGF and NGF, respectively. 
Macrophages also express another known p75NTR signaling partner, sortilin. A direct 
interaction of CXCR4 with both neurotrophin receptors was confirmed by 
immunocytochemistry and co-immunoprecipitation techniques.  The p75NTR, TrkA, sortilin 
and phosphorylated CXCR4 were all found in focal regions on the outer extremities of 
macrophages in overlapping domains. This expression provided an optimal environment for 
signaling interactions between HIV and the neurotrophins, proNGF and NGF. 
Medium from HIV stimulated macrophages caused calcium dysregulation and cytoskeletal 
damage in neurons. Key macrophage phenotypes involved in neurotoxin production were the 
formation of podosomes and suppression of calcium spiking.  In contrast, macrophages that 
expressed actin rich ruffled structures and increased calcium spiking were associated with 
less neurotoxin production.  Treatment with proNGF enhanced the effects of HIV producing 
a more neurotoxic phenotype and increasing podosome formation in a p75NTR and CXCR4 
dependent manner. The podosomes were often clustered in one quadrant of the cell and 
correlated with an increase in migration across a matrigel barrier.  CXCR4 mediated calcium 
spiking was also reduced with both proNGF and HIV.  HIV induced neurotoxin production 
was partially suppressed by inhibition of p75NTR and increased by blocking TrkA signaling. 
Proteomic analysis of conditioned medium showed that proNGF and HIV induced a similar 
profile by increasing anti-angiogenic factors and MMP-9 secretion.  Proteins that antagonize 
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the effects of these factors such as TIMP-1 were reduced.  These effects were not closely 
related to the secretion of conventional inflammatory cytokines. Taken together, these data 
indicate that proNGF and HIV produce similar neurotoxic phenotypes in macrophages by 
signaling through converging pathways that synergize to produce a more neurotoxic 
inflammatory phenotype.  
NGF signaling produced an opposing phenotype in the macrophages. NGF under 
normal conditions increased actin rich ruffled cells and calcium spiking which correlated 
with a non-neurotoxic phenotype. NGF ruffle formation was mediated through TrkA.  When 
co-stimulated with HIV, NGF reversed the effects of HIV on calcium spiking and podosome 
polarization. While neurotoxin production was suppressed with NGF stimulation alone, co-
stimulation of NGF+HIV partially suppressed neurotoxicity. In the proteomic analysis of 
medium from macrophages treated with NGF+HIV the proteins induced by HIV were 
normalized to control levels including many growth factors with unknown functions. To 
determine the basis for the differential interactions between HIV and the neurotrophins, we 
explored signaling interactions with the HIV chemokine co-receptors. We identified CXCR4 
as the co-receptor necessary for the neurotoxic phenotype induced by HIV. A small increase 
in CXCR4 phosphorylation was seen when macrophages were stimulated with HIV. This 
was significantly increased with the addition of NGF in a TrkA dependent fashion. ProNGF 
had no effect on phosphorylation suggesting that phosphorylation of the receptor may be 
involved in suppressing the neurotoxic phenotype. The possibility that phosphorylation of 
CXCR4 may be mediated by direct interactions between neurotrophin receptors p75NTR and 
TrkA and CXCR4 was confirmed for the first time by co-immunoprecipitation and co-
localization in the same cell domains.  CXCR4 also co-immunoprecipitated the G- protein 
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receptor kinase GRK2, an interaction that was reduced by HIV and enhanced by NGF. 
Together, these data have identified unique interactions of the neurotrophin receptors p75NTR 
and TrkA with HIV induced signaling through CXCR4. ProNGF and NGF exert opposing 
effects on the macrophages which have unique phenotypes and may offer new avenues for 
therapeutic intervention in HIV neuropathogenesis and other neurodegenerative diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
178 
Discussion 
Though the presence of activated macrophages in the brain has been a key correlate 
of the severity of HIV associated cognitive dysfunction, there are still many unanswered 
questions. The mechanisms that underlie both MDM activation and neuronal pathology are 
still poorly understood and are significant hurdles for the development of interventions that 
reduce CNS damage.  Groups have reported that macrophages can be activated by HIV 
proteins independent of infection and binding to the primary receptor, CD4 [86,271]. This 
activation is thought to be through the engagement of the HIV surface protein, gp120, with 
the co-receptors CCR5 and/or CXCR4 on the host cell. Macrophage activation by HIV has 
been linked to the release of unknown toxins in the brain which lead to neuronal damage 
[18,286].  This process has provided a pivotal theoretical base for many different studies of 
HIV neuropathogenesis yet the identity of the toxins and their specific actions on neurons are 
still largely unknown.  In spite of enormous effort over the past two decades no effective 
therapies have been discovered.  To improve current therapeutic options we must have a 
better understanding of macrophage activation and neurotoxin production.  
Macrophages are classically thought to be inflammatory cells widely linked to tissue 
destruction.  However, it is now well accepted that macrophages are dynamic cells that 
respond to a wide range of cues driving diverse phenotypes ranging from anti-inflammatory, 
pro-inflammatory to reparative functions. This has led researchers to characterize the 
macrophage activation states into two groups: classical activation or M1 representing 
inflammatory phenotypes and alternate activation or M2 possessing anti-inflammatory 
qualities. As the anti-inflammatory functions became more diverse the category was further 
sub-divided into M2a induced by IL-4 and IL-13, M2b induced by immune complexes in 
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combination with IL-1b or LPS and M2c induced by IL-10, TGF-b, or glucocorticoids 
[23,31,287]. However, detailed studies of macrophage functions and phenotypes in response 
to different challenges, including results from this thesis, have shown that these cells can 
simultaneously express markers from different groupings. This is exemplified in HIV 
infections where some studies have classified macrophages driving M1 like phenotypes after 
HIV-Nef stimulation of M2 like cells [31], while others have suggested that macrophages 
take on both activation states depending on the stage of HIV replication [287].  This 
ambiguity in macrophage activation solidifies the complexity of macrophage activation and 
the need for a more detailed understanding of macrophage phenotypes outside of this 
classification system.   
In spite of the large repertoire of macrophage functions, efforts to control their 
activation have generally been very crude.  This is evident in the widespread use of steroidal 
and non-steroidal anti-inflammatory compounds as well as compounds with ill-defined 
actions such as minocycline. In this thesis a novel role for neurotrophin signaling has been 
identified which regulates inflammation in response to HIV. Currently there is very little data 
regarding neurotrophin signaling in macrophages and microglia despite their abundance in 
the central nervous system.  In addition, over the past few years, it has become increasingly 
clear that the expression of the p75NTR, in particular, is upregulated under pathological 
conditions. The reason for the upregulation and the function of these receptors under 
pathological conditions is largely unknown. Not only is receptor expression changing but 
studies have also shown that an imbalance in pro-neurotrophin versus mature neurotrophin 
levels is present in aging and neurodegenerative diseases such as Alzheimer disease [249].  
Considerable effort has been expended to understand the significance of these changes for 
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neuronal function.  Findings from this thesis show that macrophages and microglia are also 
primary targets of the neurotrophins and will need to be factored into studies of the role of 
neurotrophins in CNS function.   Understanding how these neurotrophic factors may regulate 
macrophage functions is an important issue in the field and a potential novel avenue for 
therapeutic development.  
 
HIV Neurotoxicity 
The secretion of unknown neurotoxins from activated macrophages is necessary for 
neurotoxicity in response to HIV as neurons are unable to be infected [17,18,86]. Although 
the essential role of macrophages and microglia has been recognized for over 20 years, the 
mechanisms that underlie neurotoxicity are still poorly understood.  In almost all studies 
neurotoxicity in response to HIV proteins and macrophage conditioned medium has been 
correlated with an abnormal rise in intracellular calcium.  Most studies have shown that the 
N-methyl-D-aspartate (NMDA) glutamate receptor contributes to the calcium rise although 
voltage-gated calcium channels and IP3 receptors have also been implicated.  Some studies 
have emphasized the delayed and sustained rise in neuronal calcium levels [87,288] showing 
that the long term elevation of calcium is specifically associated with and precedes the 
formation of dendritic beading and neuronal injury [75,92,289]. In previous work done from 
our lab conditioned medium from macrophages infected with feline immunodeficiency virus 
caused calcium dysregulation in cultured feline neurons and varicosity (beading) formation 
along the neuronal processes[90,288]. Though this was an infection model, other studies 
demonstrated that gp120 binding independent of infection was sufficient to trigger secretion 
of neurotoxins leading to calcium dysregulation and varicosities [86,87]. Similar 
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neurotoxicity was seen using cerebrospinal fluid from HIV infected patients verifying the in 
vivo relevance of this toxicity [290,291]. Consistent with previous data, human monocyte 
derived macrophages exposed to HIVADA also secreted unknown neurotoxins in culture that 
were damaging to neuronal cells as assessed by a delayed rise in calcium and the formation 
of varicosities. Since this is a well-established and reliable correlate of HIV-associated 
neuropathogenesis, the assessment of neurotoxin secretion was used as a disease relevant 
functional endpoint for the studies in this thesis.  Surprisingly, studies in this thesis 
demonstrated that secretion of the neurotoxic factors from macrophages was dependent on 
CXCR4 activation and not CCR5. This was counter intuitive because the virion used in our 
studies preferentially targets the CCR5 HIV co-receptor and CCR5-preferring virus is most 
commonly seen in brain. This data suggested that HIV induced macrophage activation via the 
CXCR4 receptor is necessary for toxin production but the virus strain was not of primary 
importance.  
Much attention on macrophage activation has been given to their ability to secrete 
both pro-inflammatory and anti-inflammatory proteins dependent on their external cues. To 
understand how HIV induced macrophage activation influenced secretion of pro-
inflammatory and anti-inflammatory cytokines, we analyzed the conditioned medium from 
HIV stimulated macrophages and evaluated patterns for M1 or M2 activation. M1 markers 
assessed were TNF-α, IL-12, p70, IL-6, IL-23 IFN-γ, IL-1α,β and IP10.  M2 markers were 
IL-4, IL-10, IL-13, TGF-β (1, 2, 3 & 5), and MCP-1.  In our secretome analysis we did not 
see a clear M1 or M2 response to HIV. We also did not see HIV-induced changes in CD16 or 
CD163 cell surface expression, markers of M1 and M2 respectively. However, this 
classification system does not take into account the many key actions of macrophages.  In 
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addition, in spite of the widespread use of markers of “inflammation,” there is little evidence 
to show that they contribute directly to neuronal degeneration, and their release has only 
occasionally been directly linked to deleterious functional outcomes.    
 
Changes in actin structures and calcium spiking in macrophages correlate with toxin 
production  
When macrophages were challenged with HIV, changes in cell morphology were 
seen that indicated a shift toward the expression of podosomes. Previous studies showed that 
the migration of macrophages and infiltration into tissue in response to HIV-Nef required the 
formation of actin rich podosome foci. These Nef-induced podosomes were clustered in 
rosettes or along the outline of the cells known as belts or podonuts and the overall 
expression of podosome number and stability within the cell was dependent on HIV 
stimulation [244]. In our study, untreated cultured macrophages possessed a mix of cells with 
actin rich podosome structures, ruffled structures or neither of these actin specializations. 
During HIVADA exposure in culture, the number of podosome bearing cells and podosome 
clusters increased. This induction of podosomes was correlated to neurotoxin production 
while cultures with more ruffled bearing cells had significantly less neurotoxin production.  
Blocking CXCR4 activity during HIV stimulation increased the number of ruffled cells in 
culture and reduced the density of podosomes found in the cells. Ironically, the HIV co-
receptor CCR5 had no effect on the development of these morphological specializations. 
These data indicated that neurotoxin and podosome formation during HIV exposure is 
dependent on CXCR4 activation and not CCR5.    
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Changes in actin structures have been linked to calcium influx in macrophages. In the 
RAW 264.7 mouse macrophage cell line, spontaneous polarization and migration were 
associated with influx of extracellular calcium at the leading edge of movement.  The 
calcium increase was necessary for maintenance of F-actin and membrane ruffles via a PI3K-
dependent pathway [208].  Other studies correlated calcium spiking in macrophages to 
ruffled structures and increased phagocytosis [205-207]. In our studies, hMDM with more 
ruffled structures had increased calcium spiking and more phagocytic activity than non-
ruffled cells which was negatively correlated with neurotoxin production. The Collman group 
reported elevated intracellular calcium in macrophages after stimulation with HIV JFRL (R5 
tropic) and IIIB (X4 tropic) virons [271] although the nature of the calcium response was not 
documented. Though we saw an acute increase in calcium influx, the overall calcium buildup 
was minimal and calcium spiking was suppressed with HIV exposure. This was consistent 
with a reduction in ruffled cells in culture. This data indicated that modification in specific 
actin rich structures can be useful in identifying toxic phenotypes in macrophages. As 
discussed below this dissertation has discovered that neurotrophin signaling also plays a 
prominent role in the differentiation of these structural phenotypes.  
 
Macrophages express neurotrophin receptors 
Though the idea of immune cell interactions with neurotrophins was postulated 
almost 20 years ago [116], not much work had been done to understand the interplay of these 
systems. The current data documenting expression of p75NTR and Trk receptors on immune 
cells is inconsistent, often only measures gene transcripts or identified in pathology tissue 
where it was hard to distinguish expression on various cell types. The data in this thesis 
184 
assessed the expression of neurotrophin receptors on isolated macrophages and monocytes 
and for the first time determined the level of expression and cellular localization. TrkA and 
the p75NTR were found in higher quantities than other neurotrophin receptors under normal 
conditions on both monocytes and monocyte derived macrophages. Low amounts of TrkB 
were seen but we found no evidence for TrkC receptors on macrophages. Reports for TrkB 
and TrkC expression on macrophages have been citied in lymphoid tissues and microglial 
cells [179,292,293]. It is possible that these receptors are expressed in higher quantities in 
various tissues and may be upregulated under pathologic conditions. In this study TrkB 
expression during HIV stimulation was not assessed nor was the presence of its natural 
ligand, BDNF. Although p75NTR and TrkA were more robustly expressed, it does not 
diminish the need for better understanding of BDNF/TrkB signaling in macrophages.  
Several reports indicate that BDNF may be neuroprotective in HIV models of 
neuropathogenesis, and its upregulation was associated with protection in response to 
memantine administration in a SIV model [98,154,155,294]. Though its neuroprotective 
effects focused on neuronal cells in these studies, TrkB’s appearance in endosome like 
structures in our studies suggests a potential role for signaling in macrophages that needs to 
be understood. However, due to the abundance of the p75NTR and TrkA found on hMDMs, 
this thesis focused on the potential regulation of macrophage activation with their 
endogenous ligands proNGF and NGF respectively.  
 
ProNGF vs. NGF 
With recent interest in the imbalance between pro vs mature neurotrophins during 
neurodegenerative diseases, this study for the first time investigated the role of proNGF on 
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human macrophages and how it differs from mature NGF signaling. Unlike other 
neurotrophin receptors, the p75NTR lacks a catalytic domain and requires the assistance of 
other receptors to carry out signaling. The two common classes of receptor interactions with 
the p75NTR are the neurotrophin receptors (TrkA, B and C), the sorting protein sortilin, and 
the Nogo receptor.  Heteromeric interactions of the p75NTR with Trk receptors increases the 
affinity of the mature neurotrophin/Trk interaction by about 100-fold and enhances pro-
survival and growth signaling [295,296] while pro-neurotrophins bind with high affinity to 
the sortilin-p75NTR complex and initiate cell death signaling[134]. Results from this thesis 
showed for the first time that the p75NTR co-localized with both TrkA and sortilin in human 
monocyte derived macrophages providing an environment conducive to signaling with 
mature NGF and proNGF.  
In addition to the expression of neurotrophin receptors, activated 
microglia/macrophages can release neurotrophins [297,298] providing the capacity for 
autocrine feedback although only a few studies have provided functional data evaluating 
NGF production by macrophages. NGF has been shown to increase cell viability in two 
microglia cell lines [299] and increased the expression of FC receptors and phagocytosis on 
murine macrophages [300,301]. Consistent with these reports, our studies showed that NGF 
stimulation of serum deprived hMDM increased cell viability in a dose dependent manner 
that was mediated by TrkA signaling.  Under normal conditions, NGF increased ruffling of 
the membrane, phagocytic activity and calcium spiking in hMDMs. Similar to the Samah 
et.al. study, results from the protein arrays and flow studies in Chapter 1 showed NGF did 
not increase TNF secretion or the expression of M2 surface markers CD163 and CD206. 
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Conditioned medium from these cells showed low levels of neurotoxicity, indicating that 
macrophage activation by NGF does not produce a neurotoxic phenotype.     
ProNGF stimulation, however, resulted in a vastly different phenotype than NGF. 
This comparison was important because of our demonstration of robust p75NTR expression 
and the absence of previous studies of proNGF signaling in macrophages/microglia.  
Responses to proNGF are of particular importance since increases in proNGF secretion from 
macrophages/microglia have been described during LPS treatment, brain injury and 
neurodegenerative diseases [302,303]. Minocycline, a broad anti-inflammatory modulator, 
inhibited proNGF production from microglia during spinal cord injury [304] while direct 
administration of proNGF into the hippocampus of mouse brain increased activation of 
microglia as measured by increased CD11b/BrdU co-stains and more ramified bushier 
morphologies of microglial-like cells in brain tissue [305]. Though proNGF has been 
associated with apoptosis through interactions with the p75NTR and sortilin, we did not see 
any cell death despite an increase in sortilin expression.  In this context, it is important to 
note that sortilin also functions as a sorting protein and is found mostly within late 
endosomes derived from the trans-Golgi network. Sortilin expression has been seen on 
microglial mouse cell lines and is involved in phosphorylation of AKT, migration and 
increased appearance of actin flilopodia and increased MIP-2, MCP-1, IL-1β  and TNF-α 
secretion during stimulation with sortilin’s other ligand, neurotensin [211,212,306]. 
Consistent with this data, both NGF and proNGF stimulation increased phosphorylation of 
AKT in macrophages in our studies.  Actin rich structures were remarkably changed with 
proNGF stimulation as shown by an increase in the number of cells expressing podosomes. 
These podosomes were often polarized to one quadrant of the cell which is consistent with 
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increased migration seen in these cells. ProNGF also suppressed calcium spiking in 
macrophages and neurotoxin production was increased compared to NGF stimulated cells. 
Taken together these data indicate that proNGF and mature NGF regulate macrophage 
activation differentially and raise the possibility that neurotrophin intervention may be able to 
control inflammation in response to HIV.  
The molecular interactions that control neurotoxin production by macrophages are 
still poorly understood.  The phenotype induced by proNGF stimulation of macrophages was 
similar to that seen in response to HIV exposure, resulting in podosome formation and 
polarization, decreased calcium spiking and increased neurotoxin production. Importantly, 
the induction of podosomes and to a lesser extent neurotoxin production by HIV was 
dependent on p75NTR signaling while TrkA signaling was involved in suppressing 
neurotoxicity.  Also, HIV exposure increased the co-localization of both p75NTR/TrkA and 
p75/sortilin, suggesting that the macrophages respond to the pathogen by increasing the 
availability of interactions between these receptors. The similarities seen between HIV and 
neurotrophin stimulation and the ability of HIV to foster neurotrophin signaling suggested 
that neurotrophin signaling may modulate HIV effects in macrophages.  To determine the 
relationship between HIV and neurotrophin signaling we investigated the interactions of the 
neurotrophins, proNGF and NGF, with HIV induced macrophage activation.  
Since proNGF has been strongly linked to apoptosis in various cells, we first explored 
the possibility that HIV and proNGF might synergize to induce the death of the MDM.  This 
was not only important mechanistically but was an important control for investigation of the 
effects of proNGF.  Although we saw no cell death of  MDM in culture with proNGF or HIV 
stimulation alone, a very small increase in apoptotic nuclei was seen when the MDM were 
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co-stimulated with proNGF and HIV suggesting a small synergistic effect. However, 
although proNGF and HIV alone each had similar effects on the suppression of calcium 
spiking in macrophages, co-stimulation had no synergistic effect. This suggested that 
proNGF and HIV may be acting through common pathways to suppress calcium spiking. 
Similarly, one hour co-stimulation of proNGF and HIV had no synergistic effect on HIV 
induced podosome formation although an increase in the polarization of podosomes was 
seen. Consistent with this observation, co-stimulation with proNGF + HIV increased 
migration in these cells.  Lastly, co-stimulation of proNGF and HIV exacerbated the HIV 
induced neurotoxicity caused by macrophages. This data indicated that while proNGF did not 
have a synergistic effect on calcium spiking it did cause a more damaging phenotype in 
macrophages during HIV exposure which was strongly associated with increases in the 
number of podosome bearing cells.  
Macrophage phenotypes in response to co-stimulation with NGF and HIV contrasted 
sharply with HIV treated cells as well as HIV + proNGF. NGF was able to reverse the 
suppression of calcium spiking by HIV. This was consistent with NGFs ability to increase 
spiking in macrophages alone and indicated that the effect of NGF overrode the effects of 
HIV.  However, as calcium spikes have been correlated with phagocytosis [205], it was 
surprising that we saw a reduction in phagocytic activity with co-stimulation of NGF and 
HIV. One possible reason for this is that phagocytosis is also correlated to membrane ruffling 
and we did not see an increase in membrane ruffling with NGF+HIV co-stimulation. NGF 
decreased podosome expression in response to HIV and increased the number of cells in 
culture that lacked both podosomes and ruffles which may represent a “transitional” 
phenotype.  In concert with these observations, co-stimulation of hMDMs with NGF and 
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HIV partially suppressed HIV induced neurotoxicity indicating that NGF may have the 
potential to interfere with HIV signaling and suppress the development of the toxic 
macrophage phenotype.  
 
Neurotophin regulation is mediated through interactions with CXCR4 
The strong relationship between the effects of HIV and proNGF, the ability of NGF 
to reverse many of the changes induced by HIV and the co-localization of all receptors in 
similar domains all supported the possibility of interactions between these receptors.  In an 
effort to understand how NGF may be interfering with HIV signaling we investigated 
potential direct interactions with the HIV co-receptor, CXCR4. We chose this co-receptor 
instead of CCR5 because our data showed that CXCR4 and not CCR5 were involved in 
neurotoxin production and the formation of podosomes. Also, conflicting literature has 
suggested that NGF sustains macrophage viability and HIV replication in macrophages [174] 
while others suggested that it inhibits HIV replication while enhancing CXCR4 but not 
CCR5 expression [171]. NGF has also been shown to increase chemotaxis mediated by it’s 
the CXCR4 ligand SDF-1 in part due to an increase in receptor expression in both untreated 
and HIV infected hMDM [175,176]. However these studies did not explain how NGF may be 
mediating CXCR4 expression and activity. Moses Chao’s group introduced the idea that Trk 
receptors can be transactivated by GPCRs [276-280], and transactivation of CXCR4 by the 
insulin-like growth factor-1 receptor has also been reported in human breast cancer cells 
[281]. Also, transcriptional regulation of CXCR4 has been cited by a number of signaling 
molecules including growth factors TGF-1β[307], basic fibroblast growth factor[308,309], 
vascular endothelial growth factor[309] and epidermal growth factor[286] while 
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inflammatory markers tumor necrosis factor-[310] interferon-[310] and IL-1[310] has 
been shown to negatively regulate CXCR4 expression.  These studies set precedence for 
possible regulation of CXCR4 by a variety of factors, but the nature of these interactions was 
not determined. In our studies we did not see an increase in total CXCR4 with HIV or 
neurotrophin signaling. This discrepancy with previous studies that have shown increased 
CXCR4 expression in the cell surface of hMDMs may be attributed to the whole cell versus 
cell membrane expression of the receptor. In our studies we saw that total CXCR4 is 
diffusely expressed in hMDMs but once activated, phosphorylated CXCR4 is sequestered in 
the outer extremities of the cell. Though we did not address membrane versus cytosolic 
CXCR4 our studies, it is possible that NGF stimulation increases CXCR4 receptor 
expression on the cellular membrane without altering total CXCR4 cellular expression.   
Many studies have shown that CXCR4 engagement with its natural ligand causes 
phosphorylation of the receptor [284]; however, it is unclear in the literature if 
phosphorylation of CXCR4 occurs after engagement with HIV and no study has looked at the 
ability of neurotrophins to stimulate phosphorylation of CXCR4. In our study we showed that 
HIV induced a small increase in CXCR4 phosphorylation. This small increase in 
phosphorylation by HIV suggested that phosphorylation of CXCR4 is not necessary for toxin 
production. In preliminary observations, the toxicity of conditioned medium correlated with 
reduced CXCR4 phosphorylation. Consistent with this, co-stimulation with NGF but not 
proNGF increased this phosphorylation in a TrkA dependent manner. These data suggest that 
neurotrophin signaling may be able to regulate CXCR4 activation states. The likelihood of 
direct regulation of CXCR4 by the neurotrophin receptors was demonstrated in Chapter 3 by 
co-immunoprecipitation of the receptors.  Both TrkA and p75NTR were found in complexes 
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with CXCR4. Consistent with the inability of HIV and the neurotrophins to alter total 
CXCR4 expression, HIV had no effect on TrkA and p75NTR complexes with total CXCR4. 
However, as stated earlier, pCXCR4 expression was sequestered in the outer extremities of 
hMDM in similar domains as neurotrophin receptors. Phospho-CXCR4 often overlapped 
with both TrkA and p75NTR. HIV reduced the regional overlap between pCXCR4 and the 
neurotrophin receptors. While co-stimulation had no effect on pCXCR4/TrkA overlap, 
proNGF decreased pCXCR4/ p75NTR foci in a synergistic manner with HIV. In contrast, 
NGF co-stimulation with HIV restored pCXCR4/p75 overlap to control levels and partially 
increased pCXCR4/TrkA overlap. These data suggested an important role in pCXCR4 and 
neurotrophin interactions during NGF stimulation. However, the partial increase in pCXCR4 
and TrkA may explain why we only see partial suppression of neurotoxicity by NGF in our 
studies. 
The G protein-coupled receptor kinase (GRK) family has been implicated in the 
phosphorylation of CXCR4. The exact family member mediating CXCR4 phosphorylation is 
unknown and currently there are no good specific inhibitors to identify the exact member.  
Nevertheless, GRK2 has been suggested since its overexpression increased SDF-1 mediated 
internalization of CXCR4, a step in CXCR4 activation immediately following 
phosphorylation [284]. To understand GRK2 involvement in our studies we showed that 
GRK2 formed complexes with CXCR4. HIV reduced the amount of GRK2/CXCR4 
complexes whereas NGF co-stimulation increased GRK2 interaction with CXCR4. This 
supported the hypothesis that GRK2 may be the kinase responsible for phosphorylation of 
CXCR4 during NGF signaling. The ability of NGF to alter the HIV-associated phenotype 
may be through increased phosphorylation of CXCR4 whereas proNGF may be acting 
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through pathways common to HIV activation to create synergistic effects on macrophage 
neurotoxin phenotypes.     
 
What is the neurotoxin?  
The hunt for the neurotoxin has been ongoing since the early 90’s when Dana Giulian 
and Lynn Pulliam showed that neuronal damage was caused by factors secreted from HIV 
infected macrophages [18,276]. Since then many studies have tried to identify the neurotoxin 
and factors such as quinolinic acid, arachidonic acid, nitric oxide, viral proteins and 
inflammatory cytokines have been suggested[85]. However, none of these factors have been 
shown to directly induce neuronal damage that recapitulates the effects of macrophage 
conditioned medium when assessed in vitro. In this study we provided the first 
comprehensive evaluation of cytokines and growth factors in the macrophage secretome as 
well as changes in response to HIVADA, proNGF and NGF. Overall, the pattern was similar to 
what we saw in our above experiments, with proNGF sharing many similarities with HIV 
and NGF stimulating a very different secretory profile that counteracted many of the effects 
of HIV. This was evident in that co-stimulation of macrophages with NGF in the presence of 
HIV normalized the expression of 58 out of 67 proteins (increased or decreased) secreted in 
response to HIV with a synergistic effect seen in only 2 proteins. In contrast, proNGF 
reversed changes in 24 out of 67 proteins but showed 11 synergistic effects with HIV.   Thus, 
effects on protein secretion recapitulated the morphological and functional effects of proNGF 
and NGF alone and in combination with HIV.   
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To provide a better interpretation of macrophage functional phenotype, we used a 
bioinformatics tool (DAVID) to analyze the protein changes in the secretome during HIV 
exposure and other conditions. Six functional groups were identified: immune response, 
inflammatory response, defense response, chemotaxis, response to wounding and regulation 
of cell proliferation. Similar groupings were identified by DAVID when analyzing protein 
profiles from NGF or proNGF with or without HIV. These functional groups assigned by 
DAVID were consistent with the known functions of macrophages; however, they did not 
give the full picture of how vastly different the secretory profiles were in the various 
conditions.  In a more thorough analysis of the secretome we grouped the significantly 
changed proteins into five families based on the DAVID analysis:  growth factors, cytokines, 
chemokines, adhesion/MMP and other proteins. To improve the functional relevance of the 
protein array studies, the protein changes were correlated with the average level of  calcium 
dysregulation seen under each stimulation condition.  This helped to identify proteins whose 
changes could predict the neurotoxic outcome. Proteins that emerged as most relevant 
included proteins belonging to the angiogenesis family, the TGF beta family, select cytokines 
and the MMP family. These are discussed below.  
 
Angiogenesis: Proteins regulating angiogenesis were most affected by proNGF, 
proNGF+HIV and HIV alone. We did not see changes in the angiogenesis family during 
NGF stimulation although studies have reported its positive role in angiogenesis [216].  The 
role of proNGF and HIV in angiogenesis is not well understood. P75NTR expression was 
upregulated in endothelial cells of type one diabetic mice and was involved in inhibiting 
neovascularization [253]. Although little is known about the significance of angiogenesis in 
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HIV infection, work on angiogenesis has been done in the context of Kaposi sarcoma, an 
angioproliferative mesenchymal cancer often seen in AIDS and other immune deficient 
patients. HIV Tat and nef have been shown to promote Kaposi sarcoma induced 
angiogenesis[250,251].  The anti-angiogenic factor thromposondin-1 inhibits HIV-Kaposi 
sarcoma induced angiogenic activity[252]. In our studies, thrombospondin and 
thrombospondin -1 were increased with HIV and angiostatin was reduced by HIV. ProNGF 
stimulation of macrophages increased the secretion of thrombospondin, thrombospondin-1, 
and angiostatin; however, during co-stimulation of proNGF and HIV, proNGF was able to 
restore the secretion of angiostatin. Co-stimulation with NGF and HIV reduced 
thrombospondin and thrombospondin-1, validating its role in angiogenesis. This suggested 
that HIV may have a potential role in providing factors to halt angiogenesis but combined 
therapies with neurotrophins during cancers such as Kaposi sarcoma might be fruitful. 
Differentiation of specific macrophage phenotypes have been implicated as a key event in the 
stimulation of angiogenesis and related tumor growth [311-313], and targeting macrophages 
for cancer therapy has been suggested [314,315]. By inducing suppressive or supportive 
macrophage phenotypes, the neurotrophin receptors may play an unrecognized role in the 
control of angiogenesis, introducing an important new area of investigation with high clinical 
significance for studies of tumorigenesis.    
Other Growth factors: It is notable that growth factor secretion was changed more 
than any other family of proteins.  This single observation greatly strengthens the growing 
recognition that pro-growth and pro-repair functions of macrophages are at least as important 
and perhaps more important than the destructive pro-inflammatory effects that have 
dominated the literature.  In this category, the TGF and FGF families were most highly 
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represented.  The profile of proteins altered by HIV and the neurotrophins introduced new 
proteins that were robustly expressed by macrophages such as the GDF subgroup of the TGF 
family. No studies exist on the role of macrophage-derived GDFs in HIV neuropathogenesis.  
In our study, secretion of many GDFs was changed with HIV or the neurotrophins.  
However, GDF3 was the only member of this family whose increase by HIV correlated 
strongly with toxicity.  Only a few studies have examined these proteins in the context of 
other diseases.  GDF15 is important for postnatal neuron survival in developing and lesioned 
neurons [316] and reduces macrophage accumulation at sites of inflammation [317], possibly 
via regulation of chemotaxis [318].  FGF-2 has been associated with inhibiting the angiotoxic 
effect of gp120 on endothelial cells lining the blood brain barrier [68] and was increased with 
co-stimulation of NGF+HIV in our study. The only FGF family members that correlated with 
neurotoxicity were FGF-9 which was increased with HIV and FGF-16, which was decreased. 
Not much work has been done on either FGF-9 or FGF-16 in macrophages or in the context 
of HIV. FGF-9 has been shown to be secreted from neurons and to support basal forebrain 
cholinergic neurons [254]. However more work needs to be done to understand the 
importance of these factors in the context of HIV neuropathogenesis.  
Cytokines: Cytokines have been more extensively explored in HIV infection than any 
other protein group.  MCP-1, MIP1α, MIP-1β, and MIP-2 upregulation has been reported in 
the CSF of patients with HIV infection or other neurodegenerative disorders [319,320] . Each 
of these proteins, excluding MIP-1α, was increased with HIV.  In the protein array analysis 
MCP-1 was increased.  MCP-1, MIP-1β, and MIP-2 secretory levels were restored to control 
levels or suppressed further with NGF co-stimulation. ProNGF stimulation in the presence or 
absence of HIV increased secretion of MIP-1b and MCP-1. Although proNGF stimulation 
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alone increased MIP-1β it did not have an additive effect on HIV-mediated release. It is also 
worth noting that although MIP1α was not increased by HIV stimulation, co-stimulation with 
NGF reduced its secretion to a level lower than controls. These data show that chemokine 
release is a prominent response to inflammatory challenges and also demonstrate a role for 
NGF in the suppression of chemokine secretion while proNGF exacerbates secretion in 
hMDM during HIV exposure.  However, none of the above proteins correlated with calcium 
dysregulation. This is consistent with contradictions in the literature regarding their 
involvement in protection versus damage during disease. Thus, although these factors are 
increased during HIV exposure there is little evidence from studies in this thesis as well as 
other labs that they are directly involved in neurotoxicity.  
 
MMPs: Few of the results from the protein arrays provided leads that might identify 
the protein(s) responsible for neurotoxicity.  The strongest candidates from these studies 
were proteins within the MMP family. NGF increased MMP-7 and MMP-11 in the presence 
and absence of HIV but suppressed the release of MMP-9 by HIV. Support for the 
importance of the MMPs has come from studies showing their involvement in synaptic 
damage and remodeling.   
MMP-7 was low in the medium of unstimulated cells and largely unaffected by HIV.  
However, it was increased by NGF.  MMP-7 has been shown to be one of the enzymes that 
cleaves proNGF to NGF [255] and has also been implicated in positive synaptic remodeling 
by altering presynaptic terminals without affecting neuronal survival [224]. NGF’s ability to 
increase MMP-7 secretion may be a feedback mechanism to support NGF signaling while 
also aiding in reconstruction of any damage caused to neurons during HIV exposure.  A 
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potential positive influence of MMP-7 was supported by the negative correlation with 
toxicity.  
MMP-11 secretion was also increased by NGF stimulation. Most of the work looking 
at MMP-11 in the central nervous system involves gliomas [256,257]. Its involvement in 
HIV neuropathogenesis is unclear, but the anti-angiogenic phenotypic switch with proNGF 
stimulation in macrophages found in this thesis suggests a potential relationship with MMP-
11 that should be explored further.  
One of the most striking observations from the protein array analysis was the increase 
in MMP-9, and tissue inhibitor of metalloprotease-1 (TIMP-1) in response to HIV.  Both 
proteins were robustly expressed and had positive correlations to calcium dysregulation. The 
increase in both MMP-9 and its endogenous inhibitor TIMP-1 suggested that the hMDM 
constantly provide potentially deleterious and protective proteins at the same time in an effort 
to maintain tissue homeostasis.  The balance between MMP-9 and TIMP-1 may be a crucial 
factor in the regulation of tissue damage and has been seen in other brain injury models 
including ALS [258-261]. Evidence for deleterious effects when the balance is changed was 
seen in the effects of proNGF which primarily decreased the secretion of TIMP-1, a result 
consistent with the increase in neurotoxicity of MCM after stimulation with both HIV and 
proNGF. MMP-9 is involved in activity dependent reorganization of dendritic spine and long 
term potentiation and has been implicated in abnormalities in spine morphology in a fragile 
X syndrome mouse model [223,262,263].  MMP-9 has also been associated with neuronal 
damage, including synapse degeneration and axonal demyelination in HIV infection and 
other neurodegenerative diseases [264-267].  In addition to the role of MMP-9 in the 
remodeling of the synapses during disease, part of MMP-9’s damaging effects may be related 
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to its ability to metabolize NGF [268], creating a favorable environment for a high ratio of 
proNGF to mature NGF.  The partially protective role of NGF could also be explained by its 
effects on MMP-9.  NGF decreased MMP-9 and TIMP-1 in the presence of HIV suggesting 
its role in suppressing MMP-9 toxicity. MMP-9 was also increased with proNGF stimulation 
alone but had no effect on TIMP-1 secretion from macrophages. This increase in MMP-9 
secretion may explain why conditioned medium from proNGF stimulated macrophages in the 
absence of HIV is neurotoxic. Finally, studies of macrophage invasion have demonstrated a 
strong relationship between podosomes and MMP-9 secretions, providing a link between the 
MDM phenotype and toxic activity [269,270].  The consistency of these observations makes 
MMP-9 a putative candidate for the neurotoxin.  Indeed, preliminary results indicate that 
MMP-9 induces a gradual accumulation of calcium in neurons and MMP inhibitors reduce 
toxicity.  Much work is needed to understand how MMP-9 may be involved in 
neuropathogenesis but it may serve as a potential biomarker or early indicator for disease 
prognosis.  Consistent with this notion in Alzheimer and traumatic brain injury [267,321], 
neurotrophin intervention may be a way to control this aspect of macrophage activation.  
Conclusion  
This Dissertation has identified a neurotoxic phenotype in macrophages that include 
changes in actin structures, calcium activation and secretion of proteins that correlate with 
calcium dysregulation in neurons. Neurotrophin signaling strongly influence the phenotype 
in macrophages under normal conditions and in the presence of HIV. NGF drives a non-
neurotoxic phenotype that increases calcium spiking and induces ruffles while reducing 
neurotoxin production in a TrkA manner. Its signaling through TrkA also increases 
phosphorylation of CXCR4 and fosters interactions between p75NTR, TrkA and 
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phosphorylated CXCR4. These interactions lead to increased phosphorylation of CXCR4 
which may be mediated through interactions with the G-protein kinase receptor GRK2.  
HIV and proNGF both create a neurotoxic phenotype in macrophages consisting of 
suppression in calcium spiking and the formation of polarized podosomes. The increased 
secretion of neurotoxins was p75NTR and CXCR4 dependent. Unlike NGF, proNGF and HIV 
had little effects on phosphorylation of CXCR4 and suppressed TrkA and p75NTR interactions 
with phosphorylated CXCR4, indicating that phosphorylation of the CXCR4 receptor is not 
necessary for neurotoxin production but instead suppresses HIV induced neurotoxicity. Of 
the proteins secreted from macrophages stimulated with HIV and/or proNGF, anti-
angiogenic factors and MMPs were prominent.  These profiles identify unique responses as 
well as potential sources of the neurotoxic activity.  Novel interactions between the 
neurotrophin receptors and the HIV co-receptor CXCR4 were identified and open new 
therapeutic avenues for the regulation of macrophage function during HIV neuropathogenesis 
and other neurodegenerative diseases.  
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